Investigating alterations in autophagy in Alzheimer’s disease using human brain tissue and skin-derived fibroblasts by Stan, D-M
  
Investigating alterations in autophagy in 
Alzheimer’s disease using human brain tissue 
and skin-derived fibroblasts 
 
Diana-Madalina Stan 
 
 
 
 
School of Environment and Life Sciences  
University of Salford 
 
University of Salford, UK 
Submitted in partial fulfilment of the requirements of the 
Degree of Doctor of Philosophy, 2018 
 
2 
 
 
Table of Contents 
List of Figures .......................................................................................... 5 
ACKNOWLEDGMENTS .......................................................................... 10 
ABBREVIATIONS ................................................................................... 11 
ABSTRACT                                                                                               14 
Chapter 1 INTRODUCTION .................................................................. 16 
1.1 Alzheimer’s disease: a tremendous impact on society ................. 16 
1.1.1 Dementia prevalence ............................................................................ 17 
1.1.2 Symptoms of Alzheimer’s disease ...................................................... 17 
1.1.3 Historical background ............................................................................ 18 
1.1.4 Molecular biology of Alzheimer’s disease .......................................... 26 
1.1.5 Environmental risk factors .................................................................... 27 
1.1.6 Genetic risk factors ................................................................................ 32 
1.1.7 Historical hypotheses of Alzheimer’s disease ................................... 54 
1.1.7 Drug treatment ....................................................................................... 62 
1.1.8 Alternative treatment approaches ....................................................... 64 
1.2 Neuropathology ................................................................................. 69 
1.3 Autophagy pathways ........................................................................ 71 
1.3.1 Macroautophagy .................................................................................... 72 
1.3.2 Chaperone-mediated autophagy ......................................................... 74 
1.3.3 Microautophagy ...................................................................................... 76 
1.4 Autophagy in neurodegenerative disorders ................................... 79 
1.5 Models of Alzheimer’s disease ........................................................ 80 
1.5.1 Drosophila and C. elegans ................................................................... 84 
1.5.2 Zebrafish models ................................................................................... 85 
1.5.3 Mouse models ........................................................................................ 92 
1.5.4 Cell models ............................................................................................. 92 
1.5.5 Skin-derived fibroblasts ......................................................................... 93 
1.6 Aims and objectives .......................................................................... 95 
1.7 Hypothesis ......................................................................................... 99 
Chapter 2 MATERIALS AND METHODS ........................................... 100 
2.1 Human brain tissue ......................................................................... 102 
3 
 
2.1.1 Post-mortem human brain tissue ...................................................... 103 
2.1.2 Patient demographics ......................................................................... 104 
2.1.3 Tissue processing ................................................................................ 104 
2.2 Immunohistochemistry ................................................................... 105 
2.2.1 Antibodies ............................................................................................. 106 
2.2.2 Immunohistochemistry ........................................................................ 106 
2.2.3 Microscopy analysis ............................................................................ 106 
2.3 Double labelling immunofluorescence staining ........................... 108 
2.4 Statistical analysis .......................................................................... 111 
2.5 Human skin-derived fibroblasts ..................................................... 117 
2.5.1 Cells ....................................................................................................... 120 
2.5.2 Growth conditions in vitro ................................................................... 121 
2.5.3 Cell trypsinization ................................................................................. 121 
2.5.4 Protein extraction ................................................................................. 122 
2.6 Western blotting .............................................................................. 123 
2.6.1 Bradford assay ..................................................................................... 124 
2.6.2 Homogenates preparation .................................................................. 124 
2.6.3 SDS polyacrylamide gel electrophoresis ......................................... 124 
2.6.4 Wet transfer of the proteins ................................................................ 125 
2.6.5 Immunostaining of autophagy markers ............................................ 126 
2.6.6 Enhanced chemiluminescence .......................................................... 128 
2.6.7 Stripping and reprobing for beta-actin (loading control) ................ 128 
2.6.8 Protein quantification and statistical analysis .................................. 129 
Chapter 3 RESULTS: Autophagy in human brain tissue ................ 130 
3.1 Immunohistochemistry of human brain tissue ............................. 130 
3.1.1 Variation of staining distribution in the hippocampus ..................... 132 
3.1.2 Variation of staining distribution in the frontal cortex ..................... 134 
3.1.3 Variation of staining distribution in the occipital cortex .................. 151 
3.1.4 Comparison of MA and CMA ............................................................. 165 
3.1.5 Regional comparison of autophagy marker distribution across all 
Braak groups ..................................................................................................... 175 
3.1.6 Non-neuronal distribution of autophagy markers ............................ 176 
3.1.7 Distribution of autophagy markers in glial cells ............................... 182 
4 
 
3.1.8 Autophagy markers vs tau and β-amyloid pathology ..................... 191 
3.2 Immunofluorescence double labelling of human brain tissue .... 197 
3.3 Western-blot analysis of skin-derived fibroblasts........................ 200 
3.4 Optimisation .................................................................................... 211 
3.5 Autophagy markers expression in the fibroblasts ....................... 212 
Chapter 4 Discussion ........................................................................ 217 
4.1 General discussion ......................................................................... 223 
4.2 Future work ...................................................................................... 264 
4.3 Conclusions ..................................................................................... 265 
REFERENCES ...................................................................................... 268 
APPENDIX.. ........................................................................................... 302                                                                                             
Error! Bookmark not defined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
List of Figures 
 
Figure 1.1 Alzheimer’s disease pathology ........................................................ 19 
Figure 1.2 ApoE risk factor ............................................................................... 29 
Figure 1.3 ApoE functions. ............................................................................... 30 
Figure 1.4 The amyloid cascade hypothesis. ................................................... 35 
Figure 1.5 APP processing. .............................................................................. 37 
Figure 1.6 Therapeutic strategies. .................................................................... 59 
Figure 1.7 Anatomical structure of the hippocampus ....................................... 64 
Figure 1.8 Tau pathology distribution ............................................................... 68 
Figure 1.9 Autophagy pathway. ........................................................................ 70 
Figure 1.10 LC3 interaction with p62. ............................................................... 76 
Figure 1.11 Autophagosome formation in macroautophagy. ............................ 78 
Figure 1.12 Chaperone-mediated autophagy. .................................................. 82 
Figure 1.13 Invertebrate and vertebrate models in AD ..................................... 95 
Figure 2.1 Scoring scheme of immunohistochemistry .................................... 113 
Figure 2.2 Immunohistochemical scores areas. ............................................. 114 
Figure 2.3 Glial cells morphologies ................................................................ 116 
Figure 2.4 Fibroblasts confluency ................................................................... 123 
Figure 3.1 Chaperone-mediated autophagy markers across the hippocampal 
subregions (number of cells) .......................................................................... 136 
Figure 3.2 Macroautophagy markers across the hippocampal subregions 
(number of cells) ............................................................................................. 137 
Figure 3.3 Chaperone-mediated autophagy markers in the hippocampal 
subregions across all Braak stages (number of cells) .................................... 140 
Figure 3.4 Macroautophagy markers in the hippocampal subregions across all 
Braak stages (number of cells). ...................................................................... 141 
Figure 3.5 Chaperone-mediated autophagy markers across the hippocampal 
subregions (intensity) ..................................................................................... 143 
Figure 3.6 Macroautophagy markers across the hippocampal subregions 
(intensity) ........................................................................................................ 144 
Figure 3.7 Chaperone mediated autophagy markers in the hippocampal 
subregions across all Braak stages (intensity) ............................................... 147 
6 
 
Figure 3.8 Macroautophagy autophagy markers in the hippocampal subregions 
across all Braak stages (intensity). ................................................................. 148 
Figure 3.9 Autophagy markers across all Braak stages in the hippocampus . 149 
Figure 3.10 Immunohistochemstry of all autophagy markers distribution across 
all Braak stages in the hippocampus .............................................................. 150 
Figure 3.11 Macroautophagy and chaperone-mediated autophagy markers 
staining across the frontal cortex layers. ........................................................ 152 
Figure 3.12 Chaperone-mediated autophagy markers in the frontal cortex 
across all Braak stages (number of cells) ....................................................... 157 
Figure 3.13 Macroautophagy markers in the frontal cortex subcortical layers 
across all Braak stages (number of cells) ....................................................... 158 
Figure 3.14 Chaperone-mediated autophagy markers in the frontal cortex 
across all Braak stages (intensity) .................................................................. 160 
Figure 3.15 Macroautophagy markers in the frontal cortex subcortical layers 
across all Braak stages (intensity). ................................................................. 161 
Figure 3.16 Autophagy markers across all Braak stages in the frontal cortex 163 
Figure 3.17 Immunohistochemistryn of all autophagy markers distribution 
across all Braak stages in the frontal cortex ................................................... 164 
Figure 3.18 Macroautophagy and chaperone-mediated autophagy markers 
staining across the occipital cortex layers ...................................................... 166 
Figure 3.19  Chaperone-mediated autophagy markers in the occipital cortex 
subcortical layers across all Braak stages (number of cells) .......................... 168 
Figure 3.20 Macroautophagy markers in the occipital cortex subcortical layers 
across all Braak stages (number of cells). ...................................................... 169 
Figure 3.21 Chaperone-mediated autophagy markers in the occipital cortex 
subcortical layers across all Braak stages (intensity) ..................................... 171 
Figure 3.22 Macroautophagy markers in the occipital cortex subcortical layers 
across all Braak stages. ................................................................................. 172 
Figure 3.23 Autophagy markers across all Braak stages in the occipital cortex
 ....................................................................................................................... 173 
Figure 3.24 Immunohistochemistry of all autophagy markers distribution across 
all Braak stages in the occipital cortex ........................................................... 174 
7 
 
Figure 3.25 Comparison between macroautophagy and chaperone-mediated 
autophagy....................................................................................................... 176 
Figure 3.26 Comparison of autophagy markers distribution across the three 
brain regions in each Braak group . ................................................................ 179 
Figure 3.27 Autophagy marker distribution across the Braak groups ............. 181 
Figure 3.28 Immunohistochemistry of non-neuronal distribution of autophagy 
markers in the hippocampus .......................................................................... 183 
Figure 3.29 Non-neuronal distribution of autophagy markers in the hippocampus
 ....................................................................................................................... 186 
Figure 3.30 Non-neuronal distribution of autophagy markers in the frontal cortex
 ....................................................................................................................... 188 
Figure 3.31 Immunohistochemistry of diffuse and granular cellular staining of 
the autophagy markers in the hippocampus ................................................... 189 
Figure 3.32 Diffuse and granular staining in the hippocampus and the frontal 
cortex ............................................................................................................. 190 
Figure 3.33 Immunohistochemistry of glial cells ............................................. 191 
Figure 3.34 Glial cells across the Braak groups in the hippocampus  ............ 193 
Figure 3.35 Glial cells across the Braak groups in the frontal cortex .............. 194 
Figure 3.36 Glial cells across the Braak groups in the occipital cortex ........... 196 
Figure 3.37 Immunohistochemical staining of all autophagy markers in 
hippocampal subregions CA4 and CA1 .......................................................... 200 
Figure 3.38 Autophagy protein levels in CA4 and CA1 .................................. 203 
Figure 3.39 Optimisation of double-labelling technique .................................. 205 
Figure 3.40 Co-localisation of autophagy markers LAMP2A/LC3 with AT8 in 
individual neurons of hippocampal subregions CA4 and CA1 ........................ 207 
Figure 3.41 Double-immunofluorescent labelling of hippocampal CA4 and CA1 
with LAMP2A and AT8 in a Braak 0-II case.................................................... 208 
Figure 3.42 Double-immunofluorescent labelling of hippocampal CA4 and CA1 
with LAMP2A and AT8 in a Braak III-IV case. ................................................ 209 
Figure 3.43 Double-immunofluorescent labelling of hippocampal CA4 and CA1 
with LAMP2A and AT8 in a Braak V-VI case .................................................. 209 
Figure 3.44 Double-immunofluorescent labelling of hippocampal CA4 and CA1 
with LC3 and AT8 in a Braak 0-II case ........................................................... 210 
8 
 
Figure 3.45  Double-immunofluorescent labelling of hippocampal CA4 and CA1 
with LC3 and AT8 in a Braak III-IV case. ........................................................ 210 
Figure 3.46 Double-immunofluorescent labelling of hippocampal CA4 and CA1 
with LC3 and AT8 in a Braak V-VI case ......................................................... 212 
Figure 3.51 Optimisation of gel percentages .................................................. 212 
Figure 3.52 Optimisation of protein concentrations ........................................ 213 
Figure 3.53 Blocking optimisation ................................................................... 214 
Figure 3.54 Optimisation to reduce non-specific bands .................................. 214 
Figure 3.55 Antibody dilution optimisation. ..................................................... 215 
Figure 3.56 Optimisation of temperature control. ........................................... 216 
Figure 3.57 Exposure time optimisation ......................................................... 217 
Figure 3.58 LAMP2A relative expression in the fibroblasts ............................ 218 
Figure 3.59 Hsp70 relative expression in the fibroblasts ................................ 219 
Figure 3.60 LC3 relative expression in the fibroblasts .................................... 220 
Figure 3.61 Beclin-1 relative expression in the fibroblasts.   .......................... 221 
Figure 3.62 Autophagy markers expression in each case of the 3 groups ..... 222 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
List of Tables 
 
 
Table 1.2 Ongoing AD clinical trials in 2017. ....................................................... 4 
Table 2.1 Patients demographic ............................................................................ 63 
Table 2.2 Antibodies for immunohistochemistry .............................................. 66 
Table 2.3 Skin-derived fibroblasts used in this study ..................................... 80 
Table 2.4 Optimal conditions of Western blotting experiments.. ................. 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
ACKNOWLEDGMENTS 
 
Firstly I would like to thank my supervisor without which this PhD would not 
have been possible and for the countless outstanding opportunities that she has 
offered me regarding both research and scientific communications such as 
conferences and science festivals. I would like to thank Dr. Gemma Lace-
Costigan for without her help, support and encouragement through really 
difficult times I would not have gained so many skills and have completed my 
PhD.  
I would additionally like to thank all the technical staff for their help in the 
laboratory, providing reagents and guidance on how to use different laboratory 
equipment as well as academics who have supported me such as Dr Niroshini 
Nirmalan, Dr Lucy Smith, Dr Athar Aziz, Dr Geoff Hide and Dr Sarah Withers. 
Thanks to all PhD students from Salford University who helped and supported 
me including Ross Gordon and Emyr Bakker and everyone in the laboratory 
who helped me with different techniques and obtaining results. I would also like 
to thank my laboratory partners for their support and friendship including 
Richard Heale, Luisa Barbato and Neha Tomar.  
I would also like to thank Dominic Mosses from University of Manchester for his 
outstanding support on helping me complete my fluorescent studies and Dr Alex 
Mastin for supporting me with analysing my data.  
I would also like to thank Dr Andrew Robinson, who has processed all the 
human brain tissue samples for my research project and his wonderful team 
and Salford Royal Hospital, including Yvonne Davidson, who has offered me 
extensive training on immunohistochemistry and Prof David Mann for accepting 
to provide the human brain tissue sections which my entire work was mainly 
based on.  
I would like to thank all donors and their families for donating the brain tissue 
and the skin cells for research, without which this project would not have been 
possible. 
I would additionally like to thank all my friends and family for all the support 
through tough times but most importantly to my parents, Paula and Giancarlo 
Florianny Stan, who have offered me unconditional mental, emotional and 
financial support, motivating me to never give up and get to where I am today. 
 
11 
 
ABBREVIATIONS 
Ach= Acetylcholine 
AchE=Acetylcholinesterase 
AD= Alzheimer’s disease 
AICD= amyloid intracellular domain 
Ala= alanine 
AMP= adenosine monophosphate 
AMPK= adenosine monophosphate-activated protein kinase 
ApoE= Apolipoprotein E 
APP= Amyloid precursor protein 
APS= ammonium persulfate 
ATG= Autophagy-related genes 
Bcl= B-cell lymphoma 
BSA= bovine serum albumin 
CA=Cornu Ammonis 
CAA= cerebral amyloid angiopathy 
ChAT= Choline acetyltransferase 
CMA= Chaperone-mediated autophagy 
CoA= Coenzyme A 
CTF= C-terminus fragment 
DAB= diaminobenzidine 
DMSO=Dimethyl sulfoxide 
EC= entorhinal cortex 
12 
 
ECL= electrochemiluminescence 
EDTA= ethylenediaminetetraacetic acid 
FAD=familial Alzheimer’s disease 
Glu= glutamine 
GrDG= granular layer of dentate gyrus 
H202= hydrogen peroxide 
HRP= horseradish peroxidase 
Hsc70=Heat shock cognate 70 
Hsp70= Heat shock protein 70 
LAMP2A= Lysosomal-associated membrane protein 2A 
LC3= microtubule-associated protein 1A/1B light chain 3 
LEC= lateral entorhinal cortex 
LIR=LC3-interacting region 
MA= Macroautophagy 
MEC= medial entorhinal cortex 
MoDG= molecular layer of dentate gyrus 
mTOR= mammalian target of Rapamycin 
NFT= Neurofibrillary tangles 
NMDA- N-methyl-D-aspartate 
PAS= phagofore assembly site 
PD= Parkinson’s disease 
PE= phosphoethanolamine 
PoDG= polymorphic layer of dentate gyrus 
13 
 
PSC=pluripotent stem cells 
PSEN= presenilin 
PtdIns3K= phosphatidylinositol 3-kinase complex 
RIPA= radioimmunoprecipitation assay  
SB= sample buffer 
SDS= sodium dodecyl sulphate 
SN= substantia nigra 
TBS= tris-buffered saline 
TC= temporal cortex 
TEMED= tetramethylethylenediamine 
ULK1= Unc-51like kinase 1 
ULK2= Unc-51like kinase 2 
Vps= vacuolar protein sorting 
WM= white matter 
 
 
  
14 
 
ABSTRACT 
 
Alzheimer’s disease (AD) is the main cause of dementia, affecting 500,000 
people in the UK. Pathology of AD is characterised by the accumulation of 
abnormally phosphorylated tau protein within neurofibrillary tangles and 
plaques containing amyloid-β (Aβ). Autophagy is a normal intracellular 
mechanism that functions to degrade damaged cellular proteins. Studies 
have shown that there is an association between the dysfunction of the two 
main autophagy pathways-macroautophagy (MA) and chaperone-mediated 
autophagy (CMA) - and AD. However, it is unclear how the autophagic 
pathway activity changes during disease progression and how this relates 
to the accumulation of abnormal protein deposits in the brain. 
This study aimed to explore alterations in different autophagy pathway 
linked proteins with AD progression and find the relationship between MA 
and CMA. Immunohistochemical/double labelling techniques were 
performed on post-mortem human brain tissue from 45 cases. Three brain 
regions were used including the hippocampus, the frontal cortex and the 
occipital cortex. Autophagy was investigated via the assessment of cellular 
distribution of LC3, Beclin-1 (markers of MA) and LAMP2A, Hsp70 (markers 
of CMA). Neurofibrillary tangles and amyloid plaques were also assessed 
via immunohistochemistry. Skin-derived fibroblasts from AD patients were 
also used to test the cells potency to become eventual markers in the 
assessment of autophagy impairment in living patients with AD via Western 
blotting. 
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The results showed that the autophagy levels decline with increasing Braak, 
suggesting impairments in both MA and CMA. Also, the results showed that 
CMA markers were significantly lower in the hippocampus while MA 
changes were most prevalent in the frontal cortex. The hippocampal region 
CA1 had increased tau/amyloid-β deposition and decreased autophagy 
markers, while region CA4 had decreased tau/amyloid-β and increased 
autophagy markers. Western blotting revealed significant differences in 
LAMP2A and Beclin-1 expression between the control cells and the AD 
mutated cells. 
Identifying cell models such as skin-derived fibroblasts from patients with 
AD and targeting the autophagy pathays dysregulated at particular disease 
stages could offer potential for novel therapeutic strategies to prevent AD 
pathogenesis. 
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Chapter 1 INTRODUCTION 
 
 
1.1 Alzheimer’s disease: a tremendous impact on society 
 
 
1.1.1 Dementia prevalence 
 
Dementia is a set of symptoms, caused by brain disease or injury and it is 
generally described as a slow, progressive decline in memory and cognition 
(Dobranici, 2010). Alzheimer’s disease (AD) is the most common cause of 
dementia; it accounts for approximately two-thirds of all the cases of 
dementia worldwide (Karantzoulis, 2011). In 2015, AD International 
reported that there were 46.8 million people suffering from dementia with 
the number increasing to 50 million at present, according to Alzheimer’s 
Research UK. The global number will increase to 152 million in 2050, a 
204% increase (dementiastatistics.org).   In the UK, Alzheimer’s Society 
outlines an estimation of 800,000 with dementia, of which 500,000 people 
suffering of AD, a number which is expected to increase to 1 million by 2025 
and 2 million by 2051 (Thies and Bleiler, 2012). Alzheimer’s Research UK 
also reports that the economic impact of dementia is greater than cancer 
and heart disease combined, currently costing the NHS £26 billion. 
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1.1.2 Symptoms of Alzheimer’s disease 
 
AD is characterized by symptoms that relate to impaired cognition leading 
to functional impairment in advanced stages. In early stages, the first signs 
are short term memory loss, difficulty in planning, solving problems, 
depression and apathy (Bäckman, 2004). Later on, in moderate stages of 
AD, patients experience long-term memory loss, irritability, aphasia, 
disorientation (DeFina, 2013). In advanced stages, the AD patients lose 
their ability to move independently and to communicate.  
 
 
1.1.3 Historical background 
 
AD was named after Bavarian psychiatrist Aloysius (Alois) Alzheimer (A.A.), 
one of the founders of the field of neuropathology and the doctor who first 
described the disorder.        
 In 1906, Alzheimer became famous by giving a lecture on his new 
discoveries which related to what was thought to be an uncommon disease 
of the cerebral cortex affecting a middle-age woman, Auguste Deter. She 
presented memory loss, hallucinations, disorientation and died at the age of 
55. The post-mortem studies showed various abnormalities of the brain, 
where A.A. used the reduced silver staining method, described by Max 
Bielschowsky (Bielschowsky, 1902) to show abnormal protein aggregates 
such as senile plaques and neurofibrillary tangles which were evident in the 
shrunken cerebral cortex (see figure 1.1) (Goedert and Ghetti, 2007).  Later 
on, Emil Kraepelin decided to name this unusual disease, Alzheimer’s 
18 
 
disease as A.A.’s case was the first one to describe these unusual features 
associated with senile plaques and tangles, which opened a new area of 
neurodegeneration research (Swerdlow, 2007).  
 
 
1.1.4 Molecular biology of Alzheimer’s disease 
 
From the early 1900s until present, the neuropathology of AD has been 
described by the presence of various microscopic lesions including 
neurofibrillary tangles, senile/amyloid plaques, granulovacuoles and 
eosinophilic rod like inclusions (Hirano bodies), cerebral amyloid angiopathy 
and glial responses (Serrano-Pozo, 2011). However, the two main physical 
hallmarks of AD are the amyloid plaques and the neurofibrillary tangles, by 
which a conclusive diagnosis is made (Perl, 2010; Tanghe, 2010) (see 
figure 1.1). 
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Figure 1.1 Alzheimer’s disease pathology 
Immunohistochemistry of an AD post-mortem brain section presenting 
neurofibrillary tangles (arrowheads), senile plaques (asterisk) and neuropil 
threads (arrows) (Kanaan, 2012). 
 
At a structural level, abnormal intracellular neurofibrillary tangles consist of 
pairs of fibrils (paired helical filaments-PHF) made of hyperphosphorylated 
microtubule-associated protein tau. Formation of neurofibrillary tangles is 
proposed to result in extensive neuronal loss and impaired cognitive and 
memory functions (Nelson, 2012; Di, 2016). They are not specifically 
associated with AD but occur in numerous other neurodegenerative 
disorders called tauopathies which include fronto-temporal dementia with 
tau mutation on chromosome 17, Pick’s disease, progressive supranuclear 
palsy and corticobasal degeneration (Wang, 2016; Wolfe, 2012).  
The adult human brain expresses tau protein in 6 different isoforms 
depending on their number of binding domains, due to the 
inclusion/exclusion of the repeat region coded for by exon 10 and they are 
either three 3R or three 4R repeat domains (Goedert et al. 1989; Himmler et 
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al. 1989). Researchers have widely investigated tauopathies, including 
exploring the most predominant aggregation of the isoforms, either the 4R 
tau or 3R tau (Chen, 2010). Studies suggest structural and functional 
differences between the two tau splicing isoforms. There are similar 
expressed levels of 3R tau and 4R tau in the normal adult human brain 
however, the 3R/4R ratio is altered in the brains affected by tauopathies, 
suggesting that the tau aggregates can be either 3R or 4R specific (Liu, 
2008). A study from 2014, relates how the two isoforms dominance relates 
to different neurodegenerative disorders (Sanders, 2014). They describe 3R 
to be specific to Pick bodies in Pick’s disease, 4R to be associated to tau 
lesions in argyrophilic grain disease, progressive supranuclear palsy and 
corticobasal degeneration, while neurofibrillary tangles in AD have similar 
levels of 3R and 4R tau (Sanders, 2014). 
Regarding structural differences, there is one study on human 
neuroblastoma SH-SY5Y cell lines overexpressing either human 4R tau or 
3R tau which reported structural differences at 2N inclusion of tau isoforms 
(Chen, 2010). The most recent studies emphasize the functional difference 
of tau isoforms as they quantified and compared the ratio of 3R and 4R tau 
in mutant mice models and conclude that 4R overexpression leads to 
tauopathy pathology resulting in behaviour changes in MAPT N296H tau 
mouse model (Kathleen, 2016; Wobst, 2017).  
Apart from conformational changes of tau and its truncation, the most well 
founded cause of defective tau in neurodegenerative disorders is the 
hyperphosphorylation of this microtubule protein which has been 
extensively explored over the past 3 decades (Alonso, 1994; Grundke-Iqbal, 
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1986). Aggregated tau protein, which undergoes hyperphosphorylation, 
changes the microtubule stability, the primary function of this protein. As a 
consequence, the cellular integrity as well as the cytoskeletal maintenance 
is altered and tau dysfunction could contribute to toxicity through various 
mechanisms such as axonal transport defects or synaptic damage (Jadhav, 
2015). The altered microtubule stability due to tau hyperphosphorylation, as 
a result of kinase and phosphatase imbalances (Boutajangout, 2011), 
causes tau to dissociate from the microtubules which result in formation of 
insoluble oligomeric forms, altering the microtubule stability (Mietelska-
Porowska, 2014). Neurotoxicity has been reported to arise from the direct 
toxic effect of free tau oligomers as evidence suggests an alternation of the 
mitochondrial membrane, minimization in complex I levels, and activation of 
the apoptotic-related caspase-9, resulting in toxicity (Churcher, 2006). 
Hyperphosphorylation and abnormal tau aggregation leads to neurofibrillary 
degeneration through cellular cytoskeletal changes as a consequence of 
abnornal tau which depolymerize the microtubule and leads to insoluble 
PHF formation  (Šimić, 2016). Hyperphosphorylation has been explained to 
be an early and crucial event in the AD pathogenesis (Šimić, 2002), being 
clearly described by Braak as the neurofibrillary lesions develop across 
different brain regions at different stages of the disease.   
Cytotoxicity of hyperphosphorylated tau could be explained as it has been 
shown to sequester normal tau into abnormal tangles of filaments 
stimulating microtubule alteration (Alonso, 1996). Moreover, an example of 
studies exploring conformational changes and abnormal aggregation of 
aberrant proteins is prion disease focused studies where structural changes 
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are explained through polymerization of a functional protein into an aberrant 
structured protein that is highly likely to have cytotoxic effects which could 
explain cytotoxicity of abnormal tau aggregates (Avila, 2006).  
Existing tau species including oligomeric tau and soluble tau are known to 
be cytotoxic to the neurons and to the synapses in AD, with the oligomeric 
tau form being extensively investigated and proposed as a potential 
diagnostic biomarker for early detection of AD (Cárdenas-Aguayo, 2014; 
Guerrero-Muñoz, 2015; Sengupta, 2017). In 2009, an in vivo study on AD 
like tauopathy transgenic mouse model suggested an increase of insoluble 
tau fractions with ageing, in contrast to reduced soluble tau fractions and 
lower levels of hyperphosphorylation (Hirata-Fukae, 2009). Despite these 
findings, recent studies demonstrate that soluble tau species are highly 
toxic to the neurons and to the synapses in AD brains as injection of human 
soluble tau into the dentate gyrus of mice hippocampus showed reduction 
of synapses and synaptic vesicles, affecting the morphology and the 
connectivity of granule cells (Kopeikina, 2012; Bolós, 2017; Stern, 2018). 
Since over two decades ago, it has been described that neurofibrillary 
tangles are a sign of cell death that results in neurodegeneration and 
directly correlates with the dementia status in AD in contrast to the plaque 
deposition (Bierer, 1995; Nelson, 2012; Di, 2016). The abnormal 
accumulation of tau is highly damaging to the brain and therefore a rapidly 
developing area of research is trying to find a way to clear defective 
proteins before cell death is initiated (Kayed, 2010; Herrmann, 2014; Funk, 
2015). Phospho-tau AT8 monoclonal antibody is widely used to visualize 
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the abnormal hyperphosphorylation, targeting PHF-tau (Ser202/Thr205) 
and enables researchers to assess the severity in AD (Goedert et al, 1995). 
At first instance, in AD, neurofibrillary tangles seem to occur in regions such 
as hippocampus, limbic structures and the basal nucleus of Meynert and 
then spread to the parietal cortex, the frontal and the occipital cortex (Lace, 
2009).  
The other lesions, found in AD post-mortem brain tissue, are the 
senile/neuritic plaques, located extracellularly between the neurons. These 
are abnormal accumulations of insoluble misfolded amyloid proteins that 
result in a toxic amyloid form called beta amyloid (Aβ) (Perl, 2010). Over the 
past 25 years, there have been numerous clinical and genetic studies 
describing the role of Aβ and the accumulation of the toxic plaques in AD 
(Kirkitadze and Kowalska, 2005). Aβ peptide is a 4kDa protein, which 
results form the proteolytic processing of amyloid precursor protein (APP), 
and is the main component of the amyloid plaques in AD (Murphy and 
LeVine, 2010). APP is highly expressed in the brain and it is cleaved by 
enzymes called α- and γ-secretases, resulting in toxic Aβ fragments such 
as C99 and APPβ (O’Brien, 2011).  A more in-depth description of APP 
processing to Aβ is described in section 1.1.7. After formation of Aβ 
fragments, a complex process takes place and through fibrillization of Aβ 
fragments, senile plaques are formed (Walsh et al, 2010). Aβ fragments can 
be found bound to proteins such as apolipoprotein E albumin or 
complement proteins (Ma et al, 2011), but it can also be present as soluble 
dimers, which were detected in brain homogenates and cell culture media 
(Enya et al, 1999). In young and healthy brains, Aβ is fully catabolised after 
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it is secreted with no deposition taking place, however, in the ageing brain, 
Aβ production is enhanced, leading to deposition and reduced clearance 
(Kirkitadze and Kowalska, 2005). Studies have identified three types of Aβ 
oligomers such as very short oligomers (dimers to hexamers), small 
oligomers between 17kDa and 42 kDa, called Aβ-derived diffusible ligands, 
and protofibrils between 8nm and 150nm (Kirkitadze and Kowalska, 2005). 
Another study identified a stronger relationship between oligomers and 
altered neuronal viability, compared with the fibrils, emphasizing the 
importance of the regulation of oligomers and protofibrils formation in AD 
(Dahlgren et al, 2002). 
Aβ40 and Aβ42 are the main Aβ isoforms, present in AD pathology and 
have been found to have different oligomerization pathways, as Aβ42 forms 
fibrils faster than Aβ40 and is more neurotoxic due to an extra Asp23-Lys28 
salt-bridge in its structure (Kirkitadze et al, 2002; Ahmed, 2010). Presenilin 
proteins, PSEN1 and PSEN2, are known to regulate γ-secretase proteoytic 
function, therefore mutations in the presenilins can affect the enzyme 
funtional rate and lead to an increase production of Aβ (Ridge et al, 2013). 
Besides neurotoxicity, Aβ in high concentrations can also alter the blood 
flow, resulting in neuronal dysfunction due to Aβ accumulation in the 
cerebral blood vessels, known as cerebral amyloid angiopathy and 
considered a hallmarks of AD (Attems, 2010). Vascular accumulation of Aβ 
can cause vasoconstriction and impairment of the vascular tone, causing 
alteration of neuronal projections (Harkany, 2010). 
Considering all AD hallmarks, it has been very challenging to develop the 
perfect transgenic animal model – in particular, a mouse model – due to the 
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complexity of the disease and replicating all pathological characteristics 
(Saraceno, 2013). Most of the transgenic models that have been developed 
exhibit some of the AD hallmarks, including Aβ plaques (Platt, 2013). 
Researchers have mainly focused on the amyloid cascade hypothesis – 
which is described in detail in Section 1.1.7 – based on which amyloid 
deposition is the key contributor to pathogenesis and neurodegeneration. 
One of the first AD transgenic model was reported in 1995 and expressed 
high levels of mutant APP that could generate extracelular neurotoxic Aβ 
(Spires, 2005).  Different types of mutations determine the nature of the 
neurotoxic fragments. For example, mutations at the N terminus of Aβ 
results in mutant Aβ40 and Aβ42, however, mutations at the C terminus 
lead to Aβ1-42 isoform (Xu, 2016). There are numerous AD studies, 
decribing such models that focus on amyloid deposition and these models 
are further described in Section 1.5.  
In 1986, the Consortium to Establish a Registry for Alzheimer’s disease 
(CERAD) was funded by the National Institute on Aging (NIA) (Fillenbaum, 
2008) due to a need of standardized and reliable diagnostic criteria for AD 
and it has been used in neuropathological clinical studies to evaluate the 
presence of tau tangles or neuritic plaques (NP) and determine the stage of 
the disease (Murayama, 2004). Based on CERAD criteria, the cortical 
density of beta-amyloid plaques is measured from 0 (none) to C (abundant) 
(Mirra, 1991) (see Section 1.2).            
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1.1.5 Environmental risk factors 
 
Age is one of the major factors of AD (Guerreiro, 2015) in both males and 
females (Ruitenberg, 2001). The prevalence of the neurodegenerative 
disorder doubles every 5 years after the age of 65. It is known to occur in 1 
in 10 individuals aged 65+ and in 1 in 3 people aged 85+ in developed 
countries (Qiu et al., 2009).  
Cardiovascular disease is another major AD risk factor with smoking being 
known to increase the chance of cardiovascular diseases. Therefore, 
smokers have 45% greater risk of developing dementia, in particular AD by 
accelerating the brain ageing and its cortical reduction (Cataldo, 2010; 
Durazzo, 2014). Smoking is also known to be a high risk of developing 
atherosclerosis, mainly affecting the endothelial cells and resulting in tissue 
remodelling and activation of inflammatory responses (Messner, 2014). This 
leads to changes in the vessel walls resulting in cerebral small vessel 
disease which interconnects with AD (Fitzgerald, 2014). Moreover, tobacco, 
the main component of smoking cigarettes contains several neurotoxins 
such as nicotine alkaloids and acetylaldehydes, which directly damage the 
neuronal cells, event seen in AD (Treweek, 2009). 
It is well known that obesity has negative effects on the cardiovascular 
system, leading to insulin resistance, hypertension and type 2 diabetes (Pi-
Sunyer, 2009). There is a lot of research evidence that links obesity and 
diabetes as risk factors of AD (Alford, 2018), as resistance to insulin 
overstimulates the pancreas to produce insulin, accelerating its failure (Cerf, 
2013). Excessive insulin levels in the blood are also reported to interfere 
with the brain glucose levels by passing the blood brain barrier and binding 
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to insulin receptors on neurons and glial cells, resulting in impaired 
cognition and memory loss (Banks, 2012; Gray, 2014) 
 
1.1.6 Genetic risk factors 
 
Familial AD (FAD) or early onset AD (EOAD refers to the disease starting at 
earlier ages than usual, between 30-65 years old and it accounts for 1-2% 
of all AD cases, arising from one of the three mutations in either APP gene, 
Presenilin 1 (PSEN 1) or Presenilin 2 (PSEN 2) genes, components of the 
γ–secretase enzyme, responsible in cleavage of beta-amyloid (Zhu, 2015). 
EOAD cases with APP mutations account for 10-15% of all EOAD cases, 
while PSEN1 mutations are more common, being found in 18-50% of EOAD 
cases (Bekris, 2010). Bekris’s review from 2010, also reported that PSEN2 
mutations in FAD, found in only 6 families, by that time, were much rarer 
than PSEN1 mutations seen in 390 families (Bekris, 2010). The 
mechanisms by which APP mutations lead to neurodegeneration are 
explained through the amyloid hypothesis which is described in detail in the 
next subsection 1.1.6. FAD is strongly linked to the family history of 
neurodegeneration, diabetes status, vascular diseases and ApoE4 variant, 
the largest genetic risk factor in late-onset sporadic AD (Blennow, 2006; 
Harold, 2009).  
Apolipoprotein E (ApoE) is a lipid transport protein, carrying cholesterol and 
phospholipids, being encoded by genes located on chromosome 19 and is 
known to supports injury repair in the brain (Liu, 2013). ApoE is polymorphic 
with different allelic variants such as ε2, ε3 and ε4 (Figure 1.2) 
(Ghebranious, 2005). It has been shown that  individuals carrying the ε4 
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allele have a higher risk of developing AD compared with those carrying ε3 
allele, found more frequently (Farrer, 1997), whilst ε2 allele  is shown in 
population based studies to decrease the risk of AD (Figure 1.3) (Farrer, 
1997; Verghese, 2012; Liu, 2013).  
ApoE4 genotype together with atherosclerosis, diabetes and peripheral 
vascular disease contribute to a high risk of AD (Haan, 1999). ApoE4 allele 
and cerebrovascular disease also contribute to cognitive decline in patients 
with AD (Liu, 2013). Diabetes plays a crucial role amongst risk factors with 
a strong link of people carrying the ApoE4 allele with diabetes and AD (Irie, 
2008; Matsuzaki, 2010). AD pathogenesis is worsen by diabetes 
complications such as neuropathy and vascular damage (Yagihashi, 2011). 
Studies have shown that carriers of ApoE4 that suffer from diabetes can 
present AD pathology including neurofibrillary tangles, amyloid plaques and 
cerebral amyloid angiopathy (CAA) (Peila, 2002).  Neuritic plaque 
deposition is promoted by ApoE4 allele and diabetes factors such as 
hyperglycaemia, insulin resistance and hyperinsulinaemia (Matsuzaki, 
2010). Other studies demonstrated that ApoE4 can trigger inflammation 
related events, independently from Aβ, leading to neuronal damage, 
neurovascular dysfunction, reduction in the length of small vessels, blood 
brain barrier breakdown resulting in leakage of toxic proteins into the brain 
(Bell, 2012).  
ApoE4 has also been linked to prevalence of coronary artery disease and 
cerebrovascular ischemia with increased risk of cerebral amyloid 
angiopathy (a condition in which amyloid spreads and deposits the blood 
vessels),   which are all significant risk factors in AD (Eichner, 2002). ApoE3 
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could also relate to the amyloid cascade hypothesis as previous, 
biochemical assays confirmed interaction between ApoE3 and Aβ, as 
ApoE3 is thought to mediated the clearance of Aβ (Carter, 2005; Kanekiyo, 
2014), however it is not associated with increased AD risk. ApoE3 was also 
shown to protect the neuronal cells from the toxic effects and oxidation by 
the presence of Aβ (Parihar and Hemnani, 2004). 
Some researchers are describing the post-traumatic brain injury to be linked 
to ApoE4, thus a risk factor in AD (Fleminger, 2003; Verghese, 2011). 
There is a study suggesting that AD pathology increases by 35% in ApoE4 
allele carrier patients as a results of traumatic brain damage, 6 months post 
head injury, resulting in post-mortem abundant Aβ plaque deposition (Nicoll, 
1995). On the other hand, only 10% of ApoE4 noncarriers with brain injury 
presented Aβ pathology (Nicoll, 1995), suggesting that ApoE4 allele is 
linked to increased risk of AD after head injury.  The post injury outcomes 
are thought to be declined due to reduced repair ability of the nervous 
tissue and post-trauma reduced synapse remodelling (Bu, 2009).  
 
 
 
 
 
 
 
Figure 1.2 ApoE risk factor. Percentage of lifetime risk of 
developing Alzheimer’s disease based on ApoE genotype 
comprising of the three alleles. 
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There is also evidence of education playing an important role in the risk 
factors of AD as a recent paper, based on an American study, the 
Framingham Heart Study which is a longitudinal cohort, community based 
initiative, comprising of over 5000 people from Framingham, Massachutes, 
states that there is a decline in the risk of developing dementia in the higher 
educated people (Satizabal et al, 2016). Persons who had at least a high 
school diploma shown a temporal decline over three decades with an 
improvement in the cardiovascular health suggesting that higher education 
levels could have contributed to the onset delay which was observed in the 
study (Satizabal et al, 2016). 
Figure 1.3 ApoE functions. Apolipoprotein E4 roles in Alzheimer 
disease pathogenesis. ApoE4 confers toxic gain of function, loss of 
neuroprotective function or both in the pathogenesis of Alzheimer 
disease. 
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The Framingham Heart study which has had patients under dementia 
surveillance since 1975 offered data which has been considered to be 
reliable by the Alzheimer’s Association using them for educational purposes 
(Seshadri, 2007). However, the study had some limitations as worldwide 
there are millions of people suffering from AD and the study has only used 
5000 participants which are of European ancestry. Therefore, it is unclear 
whether the study can be replicated within groups of participants belonging 
to other ethnic background and races (Satizabal et al, 2016). Despite these 
findings of declining dementia incidence, the worldwide dementia number 
will continue to increase rapidly as estimations suggest, especially in the 
economically vulnerable and developing countries, where life expectancy 
and higher education rate are lower (Wu, 2015; Chan, 2013; George-Carey, 
2012). There is also a European study, from Switzerland emphasizing how 
lifestyle and higher education amongst people can reduce the burden of AD 
pathology, in particular the amyloid plaques found in the diseased brains, 
which declined over a time of three decades (1972-2006) (Kövari, 2014). 
Similarly to Framingham Heart Study, the findings might relate to changes 
in lifestyle, diet, physical activity and high education as Switzerland is a 
highly developed country.  
These studies are thought to have a crucial role in explaining and 
understanding the importance of risk factors and how they impact on the 
prevention and the disease delay, despite the small number of participants 
in the studies, compared to the millions of AD sufferers worldwide and 
considering the increasing number projections over the next decades 
(Prince, 2013). 
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1.1.7 Historical hypotheses of Alzheimer’s disease 
 
There are two main historical hypotheses which describe the molecular 
events that may lead to AD and attempt to explain the comprehensive 
pathogenesis of this disorder: the cholinergic hypothesis and the amyloid 
cascade hypothesis (Parihar and Hemnani, 2004). Though neither offer a 
full explanation of the disease pathogenesis, both offer same insight to the 
disease process and are useful for highlighting the key early research 
findings in this field. 
 
The cholinergic hypothesis 
 
The cholinergic hypothesis suggests that a defective cholinergic system and 
loss of cholinergic neurons in the basal forebrain is linked to memory loss 
and neurodegeneration (Mufson, 2008). Importantly, this hypothesis 
suggests that cholinergic cells are characterized by selective vulnerability in 
the AD pathogenesis (Mufson, 2008). However, more recent studies argue 
that pathogenesis spread is impacting a variety of cells including the CNS 
immune cells: astrocytes, microglia and others (Kurosinky, 2002; Serrano-
Pozo, 2011; Van Eldik, 2016). Cholinergic neurons are specialized nerve 
cells that produce the neurotransmitter acetylcholine and are involved in the 
cortical activation of the brain during wakefulness but also during the sleep 
state (Deurveilher, 2011). Impairment in the acetylcholine-based pathway 
(Ach) was suggested to occur as a result of reduction in both the 
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synthesizing enzyme choline acetyltransferase (ChAT) and the metabolizing 
enzyme acetyl cholinesterase (AchE which converts Ach into inactive 
choline and acetate). This was proposed to lead to a cascade of molecular 
events including depletion of Ach neurotransmitter, essential in sending 
signals between the neurons of the parasympathetic nervous system 
(Parihar and Hemnani, 2004).  
In the early 1970s, researchers initiated a biochemical investigation of post-
mortem AD brains, hoping that they would identify a neurochemical 
imbalance that could be to treat AD (Francis, 1999). In the following years, 
studies have identified deficits of ChAT enzyme in the neocortex and 
reduced levels of Ach, confirming a cholinergic impairment (Bowen, 1976; 
Davies, 1976; Perry, 1977).  
Ever since then, researchers took the theory into consideration for a 
potential therapeutic approach to target and correct the neurochemical 
alterations found in the samples (Contestabile, 2011). Current drugs such 
as cholinesterase inhibitors that aim to enhance the cholinergic 
neurotransmission already exist such as donepezil, rivastigmine, 
galantamine and tacrine (described later on in section 1.1.4). They 
ameliorate the symptoms, but cannot repair or reverse the 
neurodegenerative mechanisms, lacking efficacy once the cells die. 
Currently, the main treatment of AD, works by aiming to enhance the 
cholinergic transmission, however it does not cure or slow AD progression, 
demonstrating that the hypothesis has limitations as it does not explain the 
underlying cell death or formation of abnormal protein aggregates. 
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The amyloid cascade hypothesis 
 
Another theory of AD pathogenesis, which was proposed by John Hardy in 
1992, the amyloid cascade hypothesis, is based on explaining 
neurodegeneration as a result of excessive production and accumulation of 
extracellular β-amyloid (Aβ) plaques (Figure 1.1) which eventually leads to 
deposition of intracellular neurofibrillary tangles (NFT) (see figure 1.4) 
(Hardy and Higgins, 1992; Reitz, 2012).  
The β-amyloid protein occurs as a result of proteolytic processing of its 
parent protein, APP, which lies on chromosome 21 (Selkoe, 1988; 
Korenberg, 1989). Its importance has not been clearly emphasized, 
however it is thought to be essential for neuronal growth, thus cerebral 
development (Swerdlow, 2007; O’Brien, 2011; Müller, 2012). More recent 
papers support that APP controls cholesterol homeostasis, promotes the 
cell survival and the formation of the synapses between neurons as well as 
being involved in neurons maturation as a result of APP being expressed at 
early stages of nervous system development (Dawkins, 2014; Kant, 2015). 
One of the most recent papers reviews the findings on in vivo APP knockout 
mouse studies, focusing on the function of the APP protein and the APP 
fragments in the development of the nervous system, synaptogenesis, 
neuroprotection, brain injury and ageing (Müller, 2017).  
Amyloid precursor protein is a transmembrane protein which consists of 770 
amino acid residues (Matsui, 2007). Its amino-terminal domain is 
hydrophilic and it is situated extracellularly. The transmembrane domain is 
hydrophobic continuing with a small carboxyl-terminal cytoplasmic domain 
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(Parihar and Hemnani, 2004) (see figure 1.5). Secretases α, β and γ are 
essential enzymes involved in the production of Aβ from APP parent 
molecule (Hartmann, 2013) (see figure 1.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The amyloid cascade hypothesis. This hypothesis 
describes the events that lead to dementia pathology showing that the 
hypotheses can coexist with abnormal accumulation of plaques, 
hyperphosporylation of tau and reduction of neurotransmitters in the 
brain. 
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Secretases α, β and γ cleave the APP molecule at different positions, 
respectively at residue 687 by α-secretase and at residue 671 by β-
secretase, resulting in large soluble N-terminus fragments, sAPPα and 
sAPPβ (see figure 1.5). In addition, smaller C-terminus fragments are 
released: C83 and C99, which are further cleaved by γ-secretase. Cleavage 
of C83 results into Aβ40 and Aβ42 whereas C99 peptide fragment results 
into Aβ40 (more common and soluble form) and Aβ42, having two more 
amino acids on the tail end of the peptide (see figure 1.5). One of these, 
amino acid 42 is represented by alanine, which extends, resulting in a salt 
bridge with amino acid 35, and methionine. This makes Aβ42 less soluble 
and more toxic (Kowalska, 2004; Kazuhiro, 2005). 
In this hypothesis, the Aβ plaque accumulation is proposed to act as a 
pathological trigger for a cascade of neurotoxic events such as free radicals 
release, inflammatory responses in the neurons within the brain, neuritic 
injury, disruption of Ca2+ channels (Kowalska, 2004), all leading to 
irreversible neuronal damage, cell death and shrinkage of the brain (Figure 
1.4) (Parihar and Hemnani, 2004). 
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This hypothesis was supported by human genetic studies (Goate et al, 
1991). In the early 1990s, the amyloid cascade hypothesis was formulated 
after a case of APP gene mutation was discovered in a family with 
autosomal dominant, early onset AD. At this point, the hypothesis was only 
sustained by the idea that the mutation in the APP gene causes alteration in 
the β-amyloid production, giving rise to senile plaques formation and 
dementia related symptoms (Goate et al., 1991). Later on, further research 
studies failed to prove that this was the only cause of AD but researchers 
Figure 1.5 APP processing. Diagram describing the processing of 
amyloid precursor protein (APP) via the non-amyloidogenic and the 
amyloidogenic pathways leading to Aβ plaques formation that trigger AD 
pathology. APP molecule is cleaved by α-secretase (α-sec) resulting in 
sAPPα fragment and a C-terminus fragment (CTFα or C83), which is 
further cleaved by γ-secretase to P3 peptide and AICD (amyloid 
intracellular domain) which are non-plaque fragments. The amyloidogenic 
pathway starts with APP being cleaved by β-secretase releasing sAPPβ 
and CTFβ or C99 which is then cleaved by γ-secretase, resulting in 
monomers of Aβ38-42 which fold into the toxic plaques.  
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continued the genetic analysis finding results that contributed to the 
consolidation of the hypothesis (Swerdlow, 2007). 
Two important gene mutations were found on chromosome 14 in presenilin 
1 gene and on chromosome 1, in gene presenilin 2. These were shown to 
cause early onset of autosomal dominant hereditary AD (Levy-Lehad et al., 
1995). Understanding of presenilin proteins functions was poor; however it 
was found that the mutations increased the production of a long 42 amino 
acid APP C-terminal product Aβ42. This product manifests toxicity to cells 
grown in culture and it is found within the plaques specific to AD pathology, 
due to its aggregation properties (Scheuner et al., 1996). However, as more 
studies were done on the key AD protein, tau, researchers, began to argue 
the compentence of this protein as well as β-amyloid. This was particularly 
after tau mutations were found to underlie FTDP-17 (Gpedert, 1999).  
Additionally, amyloidocentric drugs were not proven successful in clinical 
trials (Tarenflurbil, Bapineuzumab, etc.-see Table 1.1) suggesting that β-
amyloid build-up alone, might not fully underlie AD pathogenesis (Karran, 
2016). The amyloidocentric drugs have been described through programs 
that involved patients with mild to moderate AD, reaching Phase II and III 
clinical trials, however most of them were terminated or discontinued (see 
Table 1.1) (Morris, 2014).  
A review paper from 2009 describes the missing gaps in the amyloid 
cascade hypothesis supporting research (Hardy, 2009). The paper debates 
animal studies on Aβ toxicity, one of the main hypothesis events, 
suggesting that although there is evidence on behavioural improvements 
such as enhancing memory and learning after passive immunization with 
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anti β-amyloid monoclonal antibody, there is no convincing evidence to 
reduce the massive cell loss seen in AD brains, thus slow the disease 
progression (Morgan et al, 2000; Dodart et al, 2002). A second aspect 
debated in the paper is based on tau pathology developing as a secondary 
effect in the amyloid cascade events. Cell studies suggest that tau 
pathology can modulate β-amyloid toxicity (Roberson et al, 2007), however 
the actual relationship between β-amyloid and tau protein has been 
described to be very complex in human studies (Mudher and Lovestone, 
2005). Although β-amyloid deposition is thought to occur prior to the 
neurofibrillary tangles, tau pathology has been described to be more related 
to cellular death and neuronal loss (Hanger et al, 2009). Numerous papers 
review experimental evidence from AD patients’ studies or from in vivo and 
in vitro animal studies, suggesting that the two AD pathological hallmarks, 
tau and β-amyloid interact with each other, as β-amyloid expresses its 
toxicity via tau (Wray, 2009; Nisbet, 2014; Stancu, 2014). Some papers 
suggest that β-amyloid plaques form in neocortical areas that receive 
afferent projections from NFT containing neurons, which could indicate a 
link between the presynaptic NFT and the postsynaptic plaques (Ittner, 
2011; Musiek, 2015).  In the most recent study, aiming to explore the 
relationship between tau and β-amyloid in AD, researchers performed in 
vivo PET scans on β-amyloid positive and negative AD patients. Results 
suggested that tau accumulation was locally associated to plaque burden in 
the frontal, cortex and the occipital cortices (Iaccarino, 2018).  
There is plenty of evidence that both tau and β-amyloid have neurotoxic 
effects in AD brains and as a result, a successful treatment approach would 
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be to establish new ways of clearing both abnormal protein aggregates 
(Bloom, 2014; Lansdall, 2014; Lloret, 2015; Nisbet, 2015).  
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Table 1.1 AD clinical trials in 2014. Amyloid hypothesis-based trials that 
tested different amyloidocentric drugs that reached phases II and III, however 
most of them were discontinued or terminated (adapted from Morris, 2014). 
 
Mechanism 
of action 
 
Drug name 
 
Clinical 
Phase 
 
Key results from each trial 
 
Current status 
(August 2014) 
 
Active 
immunisation 
with Aβ 
 
AN1792 
 
2 Plaque cleared. NFT reduced in neuronal 
processes, but not cell bodies. Very few 
antibody responders (25/239). Reports of 
encephalitis 
 
Discontinued 
 
 CAD106 
 
2 Favourable safety profile. Prolonged antibody 
titre in responders. 
 
Ongoing 
 
 ACC001 
 
2 Co-administration of adjuvant required for 
strong antibody response. Generally safe and 
well-tolerated, no adverse-related events. 
 
Discontinued 
 
 AD02 
 
2 Favourable safety and tolerability profile. Did 
not reach primary or secondary outcomes 
measures in phase 2. 
 
Ongoing 
 
Passive 
immunisation 
with Aβ 
 
Solanezumab 
 
3 Worsening cognition compared to placebo, 
multiple adverse events. 
 
Terminated 
 
 Babinezmab 
 
3 Engaged target. Reduction in cerebrospinal 
fluid phospho-tau in APOE4 carriers. 
Decreased rate of amyloid accumulation in 
APOE4 carriers. No improvement in clinical 
outcomes in carriers or non-carriers of 
APOE4. Negative amyloid scans in 36% of 
non-carriers. 
Discontinued 
 
 Gantenerumab 
 
2 and 3 Safe and well-tolerated at phase 1. Focal 
inflammation in areas with amyloid reduction 
a concern. Amyloid reductions compared to 
placebo. 
Recruiting for 
Phase 3 DIAN 
trial 
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 Crenezumab 
 
2 Did not meet co-primary endpoints. Trend of 
improved cognition in people with mild 
disease. 
Ongoing 
 
 Ponezumab 
 
2 Safe and well-tolerated at phase 1. Plasma 
Aβ40 increased at phase 2. No effect on 
primary endpoints in phase 2.  
 
Recruiting for 
further Phase 
2 trials 
 
γ-Secretase 
inhibitors 
 
Avagacestat 
 
2 Gastrointestinal and dermatological side 
effects at phase 1. Also dose-dependent 
pharmacodynamics effects on CSF biomarkers 
in some patients. Trend towards worsening 
cognition at higher doses compared to 
placebo. Amyloid related imaging 
abnormalities. 
Discontinued 
 
 Semagestat 
 
3 Dose-dependent reduction in Aβ synthesis at 
phase 1. Reduced plasma Aβ at Phase 2, but 
no differences in cognition. No improvement 
in cognition and worsening cognition at 
higher doses compared to controls at Phase 
3. 
 
Discontinued 
 
γ-Secretase 
modulators 
 
CHF5074 
 
2 Anti-inflammatory at Phase 2. Trend towards 
improved function in APE4 carrier. 
Ongoing 
 
 EVP-0962 
 
2 Does not inhibit cleavage of γ-secretase 
substrate other than APP. 
Ongoing 
 
 Tarenflurbil 
 
3 Small functional benefit at higher doses in 
mild AD but no cognitive benefit at Phase 2. 
No changes in CSF Aβ42. Failed to meet 
primary and secondary endpoits at phase 3.  
Discontinued 
 
β-Secretase 
modulatos 
 
MK-8931 
 
3 Reduced CSF Aβ compared to controls. Safe 
and tolerable at Phase 2. 
Recruiting for 
Phase 3 
 
 CTS-21166 
 
1 Dose dependent reduction in plasma Aβ. Completed 
 
According to Karran and Hardy, most of the drugs tested failed to replicate 
their benefits which were previously proved in the research laboratories, 
into the clinical science on patients (Karran and Hardy, 2014). As an 
example, Solanezumab appeared to improve cognition in Phase II clinical 
trials in mild stages of the disease but failed in phase III revealing multiple 
adverse effects (Siemers et al., 2016).  According to Morris and co-workers, 
there are still many gaps in the research field of amyloid hypothesis, with 
poorly explained Aβ presence in cognitively healthy people, weak 
correlation between how cognition is affected by the plaques and many 
unresolved questions regarding the chemical nature, presence and 
importance of the Aβ oligomeric fragments. Reviewing the existing 
evidence, it was concluded that it is necessary for the AD pathogenesis 
research to go beyond the existing hypothesis including Aβ and tau 
pathology (Morris, 2014).  A more recent paper, from 2016, is reviewing the 
amyloid cascade hypothesis, at 25 years, after it has become one of the 
most important AD related theories, covering the treatment development 
and the latest findings (Selkoe, 2016). It suggests a novel antibody against 
β-amyloid, aducanumab, which has demonstrated slowing effects on 
cognitive decline in 165 patients with mild AD. Selkoe mentions that the 
human monoclonal antibody BIIB-037 (aducanumab) passed Phase 1b trial 
in 2014 and the studies show that it has entered Phase 3 trial in 2015 
(Selkoe, 2016). The limitations of the study described how the antibody was 
binding to the plaques and the oligomers but not to the monomers, despite 
the cognitive improvement in the AD patients. According to the U.S. 
National Library of Medicine, aducanumab was still in Phase III 
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immunotherapy trial in September 2017, targeting Aβ in early and mild to 
moderate AD subjects (Cummings, 2017). 
Selkoe’s paper describes that although there are many contributing factors 
to AD pathogenesis, β-amyloid approach remains the most proven theory 
contributing to the disease progression that could target potential 
therapeutics (Selkoe, 2016). Nevertheless, the amyloid cascade hypothesis 
has been useful to contribute to both academia and industry science and 
the field has established that amyloid deposition occurs many years before 
the first AD symptoms resulting in a preclinical asymptomatic amyloidosis 
phase (Sperling et al., 2011). Many researchers argue that anti-Aβ drugs 
would only be beneficial if given at pre-clinical stages of AD but practically 
this would be very difficult to conduct (Hardy, 2011; Selkoe, 2016). This 
research based on Aβ clearing is still very popular (Ries, 2016; Wood, 
2017; Zuroff, 2017), however neither fully explain AD biochemical and 
histopathological lesions which might explain the limitations in developing 
effective drugs to cure AD (Roy, 2005; Morris, 2014; Selkoe, 2016; 
Harrison, 2016).  
As previously mentioned, abnormal tau and β-amyloid, characterized by 
neurotoxicity, become damaging to the healthy brain cells, disrupting the 
functioning of the synapses and altering the axon transportation.  As a 
result, neuronal injury and cell loss lead to plaque and tangle pathology and 
lastly to neurodegeneration (Bloom, 2014; Lloret, 2015; Nisbet, 2015). All 
these mechanisms have been intensively investigated by researchers and 
one of the main focuses targerted the clearance of the abnormal tau and β-
amyloid aggregates (Lansdall, 2014; Tarasoff-Conway, 2015). More recent 
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studies support defective protein clearance pathways in AD, which could 
lead to abnormal accumulation of tau and β-amyloid (Nixon, 2005; Pickford, 
2008; Son, 2012, Nixon, 2013; Talboom, 2015).  
Nixon was one of the first researchers to explain how electron microscopy 
revealed increased immature autophagic vacuoles within the lysosomes of 
the AD brain cells, as well as finding high autophagic levels in the cell 
bodies of the damaged neurons containing NFT (Nixon et al, 2005).  
Nixon’s study suggested how impaired autophagy, due to incomplete 
development of autophagic vacuoles, altered their transportation to the 
lysosomes enabling a normal autophagy functioning. These findings were 
supported by another study which described how immunolabeling detected 
immature autophagy vacuoles, in the human brain, which were found to be 
abundant in beta-cleaved APP, complete APP or presenilin proteins (Yu et 
al, 2005).  
Restoring the function of protein degradation pathways could potentially 
clear the abnormal protein aggregates found in AD brains, however there 
are still gaps in this relatively new area of research. This will be fully 
explained in Section 1.4. 
In continuation to Table 1.1, the status of the ongoing drugs in Phase II and 
III trials has been updated and the latest data regarding all current clinical 
trials has been published in September 2017 (See Table 1.2). 
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AGENT 
AGENT 
MECHANISM 
CLASS 
MECHANISM OF ACTION STATUS START DATE END DATE 
AC-1204 Methylphenidate Ketogenic agent 
Active, not 
recruiting 
Mar-13 Oct-17 
Aducanumab Anti-amyloid Monocloncal antibody Recruiting Sep-15 Feb-22 
Albumin + 
immunoglobulin  
Anti-amyloif Polyclonal antibody Recruiting Aug-15 Feb-22 
ALZT-OP1a + 
ALZT-OP1b 
Anti-amyloid 
Anti-amyloid 
combination, inhibits 
neuroinflammation 
Recruiting Mar-12 Dec-16 
Aripiprazole 
Neurotransmitter 
based 
Atypical anti-psychotic 
(dopamine partial 
agonist) 
Recruiting Sep-15 Mar-18 
AVP-786 
Neurotransmitter 
based 
Mixed transmitter effect; 
agitation therapy 
Recruiting Jun-14 Jul-17 
AZD3293 
(LY3314814) 
Anti-amyloid BACE1 inhibitor Recruiting Sep-15 Jul-18 
Brexpiprazole 
(OPC-34712) 
Neurotransmitter 
based 
Atypical anti-psychotic 
(dopamine partial 
agonist) 
Recruiting Dec-15 Jul-19 
CAD106 Anti-amyloid Amyloid vaccine Recruiting Sep-14 Aug-19 
CNP520 Anti-amyloid BACE inhibitor Recruiting Jul-16 Apr-21 
Crenezumab Anti-amyloid Monoclonal antibody Recruiting Mar-16 Jul-21 
E2609 Anti-amyloid BACE inhibitor Recruiting Oct-16 Jun-20 
Gantenerumab Anti-amyloid Monoclonal antibody Active, not Mar-14 Nov-19 
Table 1.2 Ongoing AD clinical trials in 2017. (A) Phase I trials; (B) Phase II trials; (C) Phase III 
trials. 
A 
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recruiting 
Idalopirdine  
(Lu AE58054) 
Neurotransmitter 
based 
5-HT6 antagonist 
Recruting, 
extension 
Apr-14 Oct-17 
Insulin (humulin) Metabolic Metabolic agent 
Active, not 
recruiting 
Sep-13 Feb-17 
ITI-007 
Neurotransmitter 
based 
5-HT2A antagonist, 
dopamine receptor 
modulator 
Recruiting Jun-16 Aug-18 
JNJ-54861911  Anti-amyloid BACE inhibitor Recruiting Nov-15 May-23 
Methylphenidate 
Neurotransmitter 
based 
Dopamine reuptake 
inhibitor 
Recruiting Oct-15 Aug-20 
MK-8931 
(verubecestat) 
Anti-amyloid BACE inhibitor 
Active, not 
recruiting 
Nov-13 Mar-21 
MK-4305 
(suvorexant) 
Neurotransmitter 
based 
Dual orexin receptor 
antagonist 
Recruiting May-16 Jul-17 
Nabilone 
Neurotransmitter 
based 
Cannabinoid (receptor 
agent) 
Recruiting Jan-15 Dec-17 
Nilvadipine Anti-amyloid Calcium channel blocker 
Active, not 
recruiting 
Oct-12 Dec-17 
Pioglitazone Metabolic 
PPAR-gamma agonist, 
anti-amyloid effect 
Recruiting, 
extension 
Feb-15 Apr-21 
RVT-101 
(interpirdine) 
Neurotransmitter 
based 
5-HT6 antagonist Recruiting Oct-15 Oct-17 
Sodium Oligo-
mannurarate (GV-
971) 
Anti-amyloid Anti-amyloid agent 
Recruiting, 
extension 
Apr-14 May-17 
Solanezumab Anti-amyloid Monoclonal antibody 
Active, not 
recruiting 
Dec-12 Dec-19 
TRx0237 Anti-tau 
Tau protein aggregation 
inhibitor 
Recruiting, 
extension 
Aug-14 Sept-17 
TTP488 Anti-amyloid Anti-amyloid RAGE Recruiting Apr-15 Jan-19 
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(azeliragon) antagonist 
 
 
 
AGENT 
AGENT 
MECHANISM 
CLASS 
MECHANISM OF ACTION STATUS START DATE END DATE 
AADvac1 Anti-tau Monoclonal antibody Recruiting Dec-15 Feb-19 
ABBV-8E12 Anti-tau Monoclonal antibody Recruiting Oct-16 Mar-21 
ATP Anti-amyloid 
Inhibits amyloid 
misfolding and toxicity 
Activr, but 
not 
recruiting 
Nov-14 Nov-16 
AD-SVF cells Regenerative AD-SVF cell infustion Recruiting Nov-15 Dec-17 
ANAVEX 2-73 Neuroprotective Sigma-1 receptor agonist 
Active, but 
not 
recruiting 
Dec-14 Oct-16 
Atomoxetine Anti-amyloid 
Adrenergic uptale 
inhibitor, SNRI 
Active, but 
not 
recruiting 
Mar-12 Dec-17 
AVP-786 
Neurotransmitter 
based 
Mixed transmitter 
mechanism 
Recruiting Oct-15 Mar-18 
AZD0530 Anti-amyloid Kinade inhibitor 
Active, but 
not 
recruiting 
Dec-14 Dec-17 
BAN2401 Anti-amyloid Monoclonal antibody Recruiting Dec-12 Jul-18 
Benfotiamine Metabolic Antioxidant Recruiting Nov-14 Nov-19 
BI409306 Neuroprotective 
Phosphodiesterase 9A 
inhibitor 
Recruiting Jan-15 Oct-17 
Bryostatin 1 Neuroprotective 
Protein kinase C 
modulator 
Recruiting Jul-15 May-17 
B 
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Candesartan Neuroprotective 
Angiotensis receptor 
blocker 
Active, but 
not 
recruiting 
Jun-16 Sept-21 
CB-AC-02 Regenerative Stem cell therapy 
Not yet 
recruiting 
Sept-16 Jun-18 
Cilostazol Neuroprotective 
Phosphodiesterase 3 
antagonist 
Recruiting Jul-15 Jul-18 
CPC-201 Neuroprotective 
Cholinesterase inhibitor 
+ peripheral cholinergic 
antagonist 
Recruiting Oct-15 Dec-16 
Crenezumab Anti-amyloid Monoclonal antibody Recruiting Dec-13 Sep-20 
CT1812 Anti-amyloid 
Sigma-2 receptor 
modulator 
Recruiting Sep-16 Jun-17 
DAOIB 
Neurotransmitter 
based 
NMDA enhancer Recruiting Feb-14 Sep-17 
Dronabinol 
Neurotransmitter 
based 
CB1 and CB2 
endocannabinoid 
receptor partial agonist 
Not yet 
recruiting 
Aug-14 Dec-20 
E2609 Anti-amyloid BACE inhibitor Recruiting Nov-14 Jan-18 
Formoterol Neuroprotective 
Beta-2 adrenergic 
receptor agonist 
Recruiting Jan-15 Jul-16 
hUCB-MSCs Regenerative Stem cell therapy Recruiting Feb-14 Feb-18 
Insulin detemir 
(intranasal) 
Metabolic 
Increases insulin 
signalling in the brain 
Active, not 
recruiting 
Aug-15 Sep-17 
Insulin glulisine Metabolic 
Increases insulin 
signalling in the brain 
Recruiting Aug-15 Sep-17 
JNJ-54861911 Anti-amyloid BACE inhibitor 
Active, not 
recruiting, 
extension 
Jul-15 Oct-22 
Levetiracetam 
Neurotransmitter 
based 
Anticonvulsant Recruiting Jun-14 Mar-19 
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Liraglutide Metabolic 
Glucagon-like peptide 1 
receptor agonist 
Recruiting Jan-14 Mar-19 
Lithium 
Neurotransmitter 
based 
Ion channel modulator Recruiting Jun-14 Apr-19 
LY3202626 Anti amyloid BACE inhibitor Recruiting Jun-16 Aug-18 
Methylene blue Anti-tau 
Tau inhibitor, neuronal 
stimulant 
Recruiting Jul-15 Jul-18 
NewGam 10% IVIG Anti-amyloid Polyclonal antibody 
Active, not 
recruiting 
Jan-11 Nov-17 
Nicotine 
Neurotransmitter 
based 
Nicotinic acetylcholine 
receptor agonist 
Not yet 
recruiting 
Dec-16 Dec-19 
Nilotinib Anti-tau Tyrosine kinase inhibitor 
Not yet 
recruiting 
Nov-16 Mar-18 
ORM-12741 
Neurotransmitter 
based 
Alpha-2c adrenergic 
receptor 
Recruiting Jun-15 Jul-17 
Pimavanserin 
Neurotransmitter 
based 
5-HT2A inverse agonist 
Active, not 
recruiting 
Nov-16 Jun-19 
Piromelatine 
Neurotransmitter 
based 
Melatonin receptor 
agonist; 5-HT 1A and 1D 
receptor agonist 
Recruiting Nov-15 Mar-18 
Posiphen Anti-amyloid 
Selective inhibitor of APP 
production 
Not yet 
recruiting 
Dec-16 Dec-18 
PQ912 Anti-amyloid 
Glutaminyl-peptide 
cyclotransferase 
inhibitor 
Recruiting Mar-15 Mar-17 
Probucol Neuroprotective Anti-hyperlipidemic 
Not yet 
recruiting 
Apr-16 May-18 
Rasagiline Neuroprotective 
Monoamine oxidase B 
inhibitor 
Recruiting Feb-15 May-17 
Riluzole Neuroprotective 
Glutamate receptor 
anatagonist; glutamate 
Recruiting Apr-13 Nov-18 
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release inhibitor 
RVT-101 
Neurotransmitter 
based 
5-HT6 antagonist Recruiting Oct-16 Sep-17 
S47445 
Neurotransmitter 
based 
AMPA receptor agonist; 
nerge growth factor 
stimulant 
Active, not 
recruiting 
Feb-15 Dec-17 
Sargramostim (GM-
CSF) 
Anti-amyloid 
Granulocyte colony 
stimulator; amyloid 
removal 
Recruiting Mar-11 Jan-17 
Simvastatin +  
L-Arginine + 
Tetrahydrobiopterin 
Neuroprotective 
HMG-CoA reductase 
inhibitor and antioxidant 
Recruiting Nov-11 Dec-16 
STA-1 Neuroprotective 
Antioxidant properties of 
echinascoside 
Not yet 
recruiting 
Dec-15 Dec-18 
SUVN-502 
Neurotransmitter 
based 
5-HT6 antagonist Recruiting Sep-15 Jun-17 
T-817 MA 
Neurotransmitter 
based 
Neurotrophic agent 
Active, not 
recruiting 
Mar-14 Mar-17 
Telmisartan Neuroprotective 
Angiotensin II receptor 
blocker 
Recruiting Mar-14 Aug-18 
UB-311 Anti-amyloid Monoclonal antibody Recruiting Oct-15 Dec-17 
Valacyclovir 
Anti-amyloid, 
anti-tau 
Antiviral agent Recruiting Dec-16 Dec-17 
VX-745 Neuroprotective 
P38 mitogen-activated 
protein kinase inhibitor 
Active, not 
recruiting 
Apr-15 Nov-16 
Xanamema Neuroprotective 
Blocks 11-HSD1 enzyme 
activity, decreasing 
cortisol in the brain 
Not yet 
recruiting 
Apr-15 Sep-16 
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AGENT 
AGENT 
MECHANISM 
CLASS 
MECHANISM OF ACTION STATUS START DATE END DATE 
AADvac1 Anti-tau Monoclonal antibody 
Active, not 
recruiting 
Jan-14 Dec-16 
Aducanumab Anti-amyloid Monocloncal antibody 
Active, not 
recruiting 
Oct-12 Oct-19 
Allopregnanolone Regenerative 
GABA receptor 
modulator 
Active, not 
recruiting 
May-15 Dec-16 
BI409306 
Neurotransmitter 
based 
Phosphodiesterase 9A 
inhibitor 
Active, not 
recruiting 
Apr-15 May-17 
Bisnorcymserine  
Neurtransmitter 
based 
Butyrylycholinesterase 
inhibitor 
Recruiting Nov-12 Jul-17 
BPN14770 Neuroprotective 
Negative allosteric 
modulator of 
phosphodiesterase 4D 
Recruiting Jun-16 Dec-16 
Crenezumab Anti-amyloid Monoclonal antibody Recruiting Feb-15 May-17 
E2609 Anti-amyloid BACE inhibitor 
Not yet 
recruiting 
Aug-16 Jan-17 
HTL0009936 
Neurotransmitter 
based 
Muscarinic M1 receptor 
agonist 
Recruiting Sep-15 Sep-16 
Insulin Apart 
Intranasal 
Metabolic 
Increases insulin 
signalling in the brain 
Recruiting May-15 Dec-16 
KHK6640 Anti-amyloid 
Amyloid aggregation 
inhibitor 
Active, not 
recruiting 
Jul-14 Apr-17 
HMSCs Regenerative Stem cell therapy Recruiting Jan-16 Oct-19 
Lu AF20513 Anti-amyloid Polyclonal antibody Recruiting Mar-15 May-17 
LY2599666 + 
solanezumab 
Anti-amyloid 
Monoclonal antibody 
combination 
Active, not 
recruiting 
Dec-15 Sep-17 
C 
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LY3002813 Anti-amyloid Monoclonal antibody 
Active, not 
recruiting 
May-13 Jan-17 
LY3303560 Anti-amyloid Monoclonal antibody Recruiting Dec-15 Jun-20 
MK-8931 
(vrubecestat) 
Anti-amyloid BACE inhibitor Recruiting Apr-16 Apr-17 
NGP 555 Anti-amyloid 
Gamma-secretase 
modulator 
Recruiting Oct-16 Apr-17 
Oxaloacetate  Metabolic Mitochondrial enhancer Recruiting Oct-15 Oct-17 
PF-06751979 Anti-amyloid Undisclosed mechanism Recruiting Jun-16 Jan-17 
RGN1016 Undisclosed Undisclosed mechanism Recruiting Jun-16 Feb-17 
RO7105705 Anti-tau Anti-tau antibody Recruiting Jun-16 May-17 
TAK-071 
Neurotransmitter 
based 
Muscarinic M1 receptor 
modulator 
Recruiting May-16 Mar-17 
Telmisartan 
Neuroprotective. 
Anti-
inflammatory 
Angiotensin II receptor 
blocker, PPAR-gamma 
agonist 
Recruiting Apr-15 Mar-18 
TPI-287 Anti-tau 
Microtubule protein 
modulator 
Active, not 
recruiting 
May-14 Nov-17 
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1.1.8 Drug treatment  
 
 
A number of medications are currently prescribed to AD patients to 
temporarily help improve some symptoms and enhance cognitive 
functions. The already approved palliative drugs treat symptoms that affect 
memory, thinking, learning and communication and they are called 
cholinesterase inhibitors (Wilkinson, 2004; Pepeu, 2010). One of the first 
drugs introduced on the marker was donepezil (Aricept) approved in 1996, 
to treat all stages of AD. It is the most common used in patients with AD, 
followed by rivastigmine (Exelon) approved in 2000, to treat mild to 
moderate AD, galantamine (Razadyne) approved in 2001, to treat mild to 
moderate AD and tacrine (Cognex), approved in 1993, to treat mild to 
moderate AD (Birks, 2006). The mechanism by which they work is based 
on the cholinergic hypothesis by preventing the breakdown of 
acetylcholine (Ach), the key neurotransmitter, and essential in sending 
signals between the neurons of the parasympathetic nervous system 
(Čolović, 2013). By keeping continuous and healthy communication 
between the nervous cells, cognitive symptoms may be improved (Birks, 
2006). Donepezil, the leading cholinesterase inhibitor drug, used in the 
treatment of AD, was reported to have the best pharmacological profile 
regarding the cognitive improvement, showing efficacy in 40-58% of 
patients, with only 6-13% side effects (Cacabelos, 2007), whereas other 
studies suggest that rivastigmine exhibit a higher rate of adverse effects 
(Hansen, 2008).  
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In 2003, a drug was approved to treat moderate to severe conditions of 
AD. It is called memantine (Namenda), an NMDA (N-methyl-D-aspartate) 
receptor antagonist, which works by a different molecular mechanism than 
the others (Wang, 2015). It regulates the activity of glutamate, a key 
neurotransmitter in the brain (Nedergaard, 2002). Glutamate attaches to 
specific sites on the nerve cell surfaces called NMDA receptors allowing 
Ca2+ to enter the cell (Korde, 2012). This process is important for cell 
signalling, enhancing learning and memory. Glutamate has excitatory 
functions, being the main excitatory brain neurotransmitter (Petroff, 2002). 
It is present in over 50% of the nervous tissue and it interacts with 
receptors at the surface of a neuron resulting in an action potential 
(Shigetomi, 2004), which is known as an impulse triggered by ion 
molecules crossing the neuron membrane. This impulse passes from the 
cell body down the axon to send information which is crucial in learning 
and memory formation (Barnett, 2007). Therefore, when glutamate binds 
to the NMDA receptors on the neurons, Ca2+ goes in the cell and an action 
potential is fired.  In AD, however, glutamate is excessively released from 
altered cells, leading to calcium overexposure, which enhances cell 
alteration (Danysz, 2012). Memantine drug targets the NMDA receptors, 
blocking them and preventing this destructive series of events by stopping 
the glutamate to bind to the receptors, thus reducing the Ca2+ flow (Wang, 
2015). 
All of these current drugs help ameliorate the AD patients’ symptoms, but 
they do not succeed in treating the actual disease or cannot postpone its 
progression. A perfect, successful drug would be able to treat the 
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fundamental disease by reversing it or by delaying the cellular damage 
and preventing the cell death that leads to pathogenesis.  
One of the most important category of AD drugs, in clinical trials, 
comprises of those that target the amyloid plaques and reduce amyloid 
plaques production or increase their removal from the system. As Aβ is 
produced by secretase enzymes, inhibition agents are used to reduce or 
block the activity of the proteases that cleave the APP molecules and lead 
to the more toxic Aβ fragments. These amyloid drugs such as 
semagacestat, solanezmab, avagacestat, tarenflurbil etc have gone to 
either phase II or phase III clinical trials to assess their effectiveness and 
safety but some have failed due to poor outcome (see table 1.1 and table 
1.2). Enzyme γ-secretase is involved in processing Notch3 protein, 
essential for maintenance and development of the brain (Rusanescu, 
2014; Wang, 2014). Thus, altering the protein balance in this pathway can 
result into dementia and cerebral autosomal dominant arteriopathy 
condition, followed by subcortical infarcts (Panza, 2011; Rutten, 2014). It 
was therefore very important to define the cellular action sites of γ-
secretase for APP processing and Notch3, as γ-secretase is a key target 
for drug development in AD. Previous studies have used small molecule 
approaches, utilizing γ-secretase inhibitors (L-685, 458, MRL505 and 
MRL631) and found that there are at least two cellular sites for γ-
secretase action: one for Notch3, which is blocked by MRL631 and the 
other for APP which is not inhibited by MRL631. Therefore, Notch and 
APP have distinct γ-secretase pathways (Tarassishin, 2004). 
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An example of drug induced side effect would be the phase III clinical trials 
of semagacestat, which failed in mild to moderate AD patients due to 
damaging effects on cognition and brain function (Panza, 2011).  
Immunotherapies that aim to clear amyloid plaques are also under 
evaluation in clinical trials and include aducanumab, CAD106, 
crenezumab, solanezumab and many others (Table 1.2). Passive 
immunization is desired, by using antibodies against Aβ, without triggering 
adverse immune responses that involve inflammation like encephalitis 
(Relkin et al., 2005).  
In addition to drugs targeting Aβ pathology, therapeutic approaches 
towards tau pathology have also evolved as disruption of tau protein 
contributes as well to the neurotoxicity events that lead to neuronal death 
(Mietelska-Porowska, 2014). In a normal healthy brain cell, phosphatase 
and kinase activities regulate the phosphorylation of tau. Imbalances in 
these activities result in hyperphosphorylation of tau that leads to 
microtubule instability and cell homeostasis disruption in AD cells (Martin, 
2013). Research on pharmacological targets that restore kinase and 
phosphatase activities and inhibit tau hyperphosphorylation include drugs 
that target glycogen synthase kinase (GSK-3), MAPK family members 
(extracellular signal-regulated kinsases Erk1 and Erk 2), cyclin-dependant 
kinase-5 (Cdk-5), calcium calmodulin-dependant kinase II (CaMK-II), 
casein kinase, microtubule affinity regulating kinase (MARK) and others 
(Churcher, 2006). Therapeutics also aim to promote microtubule stability 
and most importantly to reduce aggregation of tau and enhance NFT 
clearance by administrating specific drugs of immunotherapies against the 
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tangles. (Boutajangout, 2011). As seen in Table 1.2, there are numerous 
tau therapies in phase II and III clinical trials that work through various 
agents: either monoclonal antibodies targeting pathogenic tau (AADvac1, 
ABBV-8E12, RO7105705), kinase inhibitors that aim to halt 
hyperphosphorylation (Nilotinib) or modulators for microtubule stability 
(TP1-287).  
The most recent tau study, published in October 2017, presents the use of 
Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM), a tau 
aggregation inhibitor used in the treatment of mild AD in a phase III clinical 
trial (Wischik, 2017). An initial phase III clinical trial, from 2016, using 
LMTM, used high doses of the drug (175mg) along with AD cholinesterase 
inhibitors and memantine. The study revealed no benefits when LMTM is 
taken in combination with other drugs however the second phase III 
clinical trial and the most recent study on monotherapy with LMTM, used 
doses of 4mg and 100mg which showed improvements such as slowing 
the cognitive decline in the AD patients, increasing the brain glucose and 
lowering the rate of brain tissue waste (Wischik, 2017). After the two 
phase III clinical trials, they concluded that LMTM is an effective 
monotherapy that needs further investigation. 
Considering all Aβ and tau ongoing clinical trials and their previous 
individual proven benefits, their relationship is still poorly understood in 
how they cause AD. This suggests that an ideal combination therapy 
between amyloid and tau-targeting treatments would be essential, 
especially in moderate and severe stages of AD, were tau and amyloid 
pathology is very abundant in more than one brain region, as well as 
17 
 
treating at the right stage to prevent the build-up of toxic proteins 
(Lansdall, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current drugs ameliorate the symptoms in patients with AD, however they 
cannot slow down, reverse or stop the progression of the disease. 
Therefore, it is very important to prevent the build-up of toxic proteins that 
lead to a cascade of neurotoxic events which result in neuronal death and 
neurodegeneration (see figure 1.4).  
Figure 1.6 Therapeutic strategies and specific drugs in the treatment of 
AD, based on different hallmarks such as neuritic plaques, neurofibrillary 
tangles and neurotransmitters reduction (adapted from Hung, 2017). 
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Thus, drugs that enhance protein degradation in the brain, could have a 
potential as a new treatment for AD by preventing the build-up of abnormal 
proteins. Protein degradation pathways are very complex, characterized 
by numerous steps at which various regulatory proteins participate and 
despite the existing impairment, the location and the nature of these 
defects are still unclear.  
Autophagy is an intracellular degradation mechanism that functions to 
clear abnormal or dysfunctional cellular components such as abnormal 
proteins in order to maintain homeostasis and under stress conditions 
(Glick, 2010) (see chapter 1.3 and 1.4).  In AD brains, the abnormal 
deposits of amyloid and tau fail to be cleared and there has been a lot of 
evidence over the past decade, describing impaired autophagy in AD 
patients (see Chapter 1.4) (Nixon, 2005; Yu, 2005; Wang; 2009; Pickford, 
2008; Son, 2012).  
One example of autophagy related drug is rapamycin which is known to be 
involved in rescuing autophagy and helps reduce AD pathology in both 
human and mice models (Cai, 2013). Rapamycin, a macrolide compound, 
produced by the soil bacterium Streptomyces hygroscopicus has 
beneficial uses in cancer having immunosuppressant  and anti-tumour 
properties, preventing organ rejection after transplant by inhibition of T and 
B cell proliferation (Khanna, 2000; Law, 2005). Rapamycin is also shown 
to have neuroprotective effects in 3xTg-AD mice after enhancing 
autophagy that facilitates the clearance of abnormal proteins tau and 
amyloid, resulting in cognitive improvement (Santos, 2011; Majumder, 
2011). Aβ can be degraded by autophagy-lysosome systems in normal 
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ageing brains, however if autophagy clearance pathways are impaired, Aβ 
seems to abnormally accumulate and the lysosomal systems fail to 
degrade it (Nixon, 2007). A study from 2010, suggests that rapamycin has 
cleared abnormal Aβ in a transgenic mouse model, facilitating the 
autophagy-lysosome systems (Spilman, 2010). Three years later, an in 
vitro study suggested that Rapamycin could enhance autophagy and clear 
abnormal tau after showing potential of reduction in tau 
hyperphosphorylation in human neuroblastoma SH-SY5Y cells (Liu, 2013). 
There are several types of autophagy, including macroautophagy, 
chaperone-mediated autophagy and microautophagy which are fully 
described in section 1.3 (Haidar, 2017). It has not been established how 
these different pathways interact in disease and if there is a shift in 
pathway recruitment to compensate for any deficit. Studies have not yet 
shown how autophagy impairment in AD brains manifests in different brain 
regions and whether the impairment varies across different stages of the 
disease. Levels of significance might differ from mild to moderate to 
severe cases which could influence the necessary amount of drug that 
needs to be administrated to regulate autophagy. The brain is a very 
complex and evolved organ which differs from individual to individual, 
hence some therapeutic drugs might show improvement in one pathway 
and be damaging to the others. Moreover, different types of dementia with 
different abnormal proteins may need drugs to target different autophagy 
pathways. Previous studies on transgenic mouse models (SOD1G93A) 
have suggested that treatment with Rapamycin, a commonly drug used to 
enhance autophagy, can increase the neuropathology in the mice brains 
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while the symptoms worsen (Zhang, 2011). As a result, switching on the 
whole autophagy machinery can have irreversible damaging effects in 
some cases and the most suitable therapeutic intervention would be a 
highly specific drug that could target the defected step within the pathway 
(Zhang, 2011). In order to develop successful autophagy based 
therapeutics, more understanding is needed regarding the exact nature of 
the deficit, how this impacts other protein degradation pathways and how 
this varies across different neurodegenerative diseases. Autophagy 
pathways and their role in neurodegeneration are covered in chapter 1.4. 
Therefore, if there is an impairment in the autophagic process, an ideal 
drug would specifically target the deficit which lies within the pathway and 
restore its function leading to clearance of the abnormal proteins in the AD 
brains (Liu, 2014). As previously mentioned, there is evidence that 
restoring the whole autophagy system may not be beneficial in all 
diseases as it might lead to degradation of normal cellular components. 
 
1.1.9 Alternative treatment approaches 
 
An alternative treatment considered by researchers was antioxidant-based 
and has been tested in AD clinical trials. One example is a study from 
1997, when high doses of ascorbic acid (vitamin C) and α- tocopherol 
(vitamin E) were tested and were reported to have potential in slowing AD 
progression by delaying loss of ability to carry out daily tasks (Evans, 
2014). Nevertheless, study groups showed side effects such as increased 
risk of death in people with coronary artery disease, a risk of AD whilst the 
groups tested with memantine only were not shown to have high risk of 
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death (Evans, 2014). Vitamin E was then thought to be effective in 
combination with other AD drugs and as a result in a study group with 613 
individuals, results showed improvements in patients with moderately 
severe AD however in mild stages, the evidence was limited (Dysken, 
2014). In another study, 341 patients, with moderate AD, were 
administered vitamin E and selegiline, treatment which also demonstrated 
a potential to slow the progression of AD by significantly delaying the time 
to hospitalization (585 days in the vitamin E and selegiline treatment group 
vs 440 days in the placebo group, p=0.049), loss of the ability to perform 
basic activities of daily living or to death (Sano, 1997). A few years later, a 
contradictory study, on 769 patients, demonstrated that vitamin E does not 
change the progression of AD with no benefits to the cognitive decline 
(Petersen, 2005).  
Oestrogen hormone showed its properties to modulate neurotransmission 
and act as a free radical scavenger (Razmara, 2007; Hayes, 2012; Zhu, 
2012). Oestrogen plays a role in cell signalling within the cell and it has 
been suggested to prevent Aβ formation by promoting the non 
amyloidogenic α-secretase processing APP (Parihar and Hemnani, 2004). 
Most studies with oestrogen hormone treatment in the assessment of the 
cognitive function have been performed on female subjects (Asthana, 
2001; Sherwin, 2003; Hampson, 2013), however there are some studies 
on animal models which test both males and females (Razmara, 2007).  
A study from 2001 showed that treatment with high dosage of oestrogen 
may benefit menopausal women with AD by enhancing attention and 
memory (Asthana, 2001). Similarly, a more recent pilot study 
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demonstrated that both oestrogen and progesterone have beneficial 
effects on cognition with respect to visual and verbal functions when 
tested on menopausal women however this needs further investigation as 
they used a small sample size (Berent-Spillson, 2015). 
 
 
1.2 Neuropathology 
 
In Alzheimer’s disease, the hippocampus is one of the first area of the 
brain to suffer damage, causing early symptoms such as short-term 
memory loss and disorientation (Dhikav, 2011). The hippocampus is a 
neural structure of the brain, situated in the medial temporal lobe. It is 
particularly differentiated from other structures by its specific circular 
seahorse shape. It belongs to the limbic system, playing a crucial role in 
spatial navigation, learning and forming short-term memories and long-
term memories (Rajmohan, 2007). The hippocampus subregions exhibit 
histological differences regarding the cell size and morphology (see Figure 
1.7). 
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This figure shows a cross section of the hippocampus, which extends to the 
subiculum (S). The three layers of the dentate gyrus (DG) are the 
polymorphic layer (PoDG), the molecular layer (MoDG) and the granular 
layer (GrDG). Cornu Ammonis 3 (CA3) and Cornu Ammonis 2 (CA2) differ 
from Cornu Ammonis 1 (CA1) by higher density of the pyramidal cells, 
which are more dispersed in CA1. The subiculum is an extension of the DG, 
with two subdivisions: presubiculum (PreS) and parasubiculum (ParaS). 
CA1/S is the border between CA1 and S. Drawing by C. Golgi (1894) 
 
 
Understanding the anatomy of the hippocampus is important as the 
subregions are differentially affected at different stages of AD (Lace, 
2009). The dentate gyrus (DG) is a separate, tightly dense packed layer of 
small granule/polymorphic/pyramidal cells, which surrounds a C-shaped 
structure called the hippocampus proper or Cornu Ammonis (CA). This 
Figure 1.7 Anatomical structure of the hippocampus 
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area extends to the subiculum (S) and finally to the parahippocampal 
gyrus, comprising of the entorhinal cortex (El Falougy, 2008) (Figure 1.7). 
CA divides into 4 subregions, CA4, CA3, CA2 and CA1, due to cell body 
location, size and shape, proximal terminations and afferent/efferent 
projections (Dekeyzer, 2017). The dominant neurons in the hippocampus 
proper and the subiculum are the pyramidal cells which vary in density and 
size depending on the subregion. The CA subregions are made up of 
densely packed pyramidal cells similar to those found in the neocortex (El 
Falougy, 2008).  
The subiculum is the area that lies between CA1 in the hippocampus 
proper and the medial entorhinal cortex. The ending area of the 
hippocampus is the entorhinal cortex (EC), the interconnecting network 
between two major brain areas, the hippocampus and the neocortex. 
The degree of pathology in AD is assessed by pathologists using a 
scheme called Braak staging firstly described in 1991, according to which 
Braak I and II stages represent the presence of neurofibrillary tangles in 
the transentorhinal cortex, Braak III-IV when the hippocampus and other 
limbic structures get involved and Braak V-VI are associated with 
isocortical regions (Braak et al, 1991; Braak et al, 1997). 
AD specific tau deposition follows a spatiotemporal pattern of 
neurofibrillary degeneration that initially appears in the transentorhinal 
cortices, CA1 and EC subregions in stages I-II, then in the limbic cortices 
(subiculum, amygdala, and thalamus) in stages III-IV and lastly in the 
isocortical regions, in stages V-VI (Serrano-Pozo, 2011) (Figure 1.8 A). 
According to Lace, regions such as EC, TEC (transentorhinal cortex) and 
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CA1 are primarily affected by tau pathology in Braak 0-II; CA2 and CA3 in 
Braak III; S in Braak IV and lastly late Braak stages affect DG and CA4 tau 
deposition, resulting in a tau staging system 0-5 (Lace, 2009) (Figure 1.8 
B).  
In 1986, the Consortium to Establish a Registry for Alzheimer’s disease 
(CERAD) was funded by the National Institute on Aging (NIA) (Fillenbaum, 
2008) due to a need of standardized and reliable diagnostic criteria for AD 
and it has been used in neuropathological clinical studies to evaluate the 
presence of tau tangles or neuritic plaques (NP) and determine the stage 
of the disease (Murayama, 2004). Based on CERAD criteria, the cortical 
density of beta-amyloid plaques is measured from 0 (none) to C 
(abundant) (Mirra, 1991).  On the other hand, Braak staging measures the 
density of tau tangles (NFT) characterized by entorhinal spread (Braak I-
II), limbic spread (III-IV) and neocortical spread (V-VI), corresponding to 
normal cognition, impaired cognition and dementia (Braak, 1991; Serrano-
Pozo, 2011). NIA and Ronald and Nancy Reagan Institute of Alzheimer’s 
Association proposed the two scoring systems to merge and result in three 
categories: Braak V-VI and NP C (highly likely AD diagnosis), Braak III-IV 
and NP B (probable AD diagnosis) and Braak I-II and NP A (low AD 
probability) (Boluda, 2014). 
Considering the existing literature on hippocampal subregions differential 
involvement in the disease, CA regions as well as DG, S and EC regions 
were chosen for this study since they capture cells and regions that 
become affected by AD pathology at the earliest stages, as well as the late 
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stages of disease. This allows for an assessment of cells, both burdened 
and cleared of AD pathology, within the same case. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Tau pathology distribution. (A) Neurofibrillary tangles 
distribution pattern in the brain regions with AD progression. The areas of 
darker colour shades represent increased pathological densities; Amyg 
=Amygdala; Cg =Cingulate cortex; Prec = Precuneus; 3-1-2 = Primary 
sensory cortex; 4 = Primary motor cortex; 17 = Primary visual cortex; 18 = 
Associative visual cortex (Serrano-Pozo, 2011); (B) Tau pathology 
distribution in the hippocampus across tau stages 0-5; arrows indicate the 
hippocampus connectivity and their associated areas; red dots represent the 
new areas of involvement in each tau stage and the brown dots show tau 
deposition from previous stage (Lace et al, 2009). 
A 
B 
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1.3 Autophagy pathways 
 
In order for a healthy cell to grow and develop, it is necessary to maintain 
a well-controlled balance between protein/organelle synthesis and 
degradation that takes place in the cell (Rothman, 2010). Autophagy is the 
mechanism that maintains cellular homeostasis and balance, essential in 
cellular development and maintenance under certain environmental stress 
conditions (Glick, 2010). There are three main autophagy pathways: 
macroautophagy, chaperone mediated autophagy (CMA) and 
microautophagy, mediated by specific genes and their associated 
proteins/enzymes described in more detail in the following sections 
including figure 1.9 (Haidar, 2017).  
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Diagram illustrating all three autophagy pathways: MA (I), CMA (II) and 
Figure 1.9 Autophagy pathway. 
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macroautophagy (III); MA steps 1-6 are described in detail starting with the 
induction, nucleation and formation of the phagophore which expands, 
recognizes the substrate that needs to be degraded resulting in a closed 
autophagosome  vesicle. This binds to the lysosome forming the 
autolysosome. Here acidic lysosomal enzymes degrade the proteins in 
amino acids, which are released back in the cytosol to be reused. *Key 
biomarkers of MA and CMA are highlighted within a red circle. 
 
 
1.3.1 Macroautophagy  
 
Macroautophagy, the main pathway of autophagy takes place to eliminate 
damaged cell organelles or protein aggregates. In the 1950s, 
autophagosomes were firstly observed in mammalian cells, a few years 
after autophagy started being investigated. The research began with 
genetic assays in a specific species of yeast: Saccharomyces cerevisiae 
and resulted in a discovery of 31 different autophagy-related genes (ATG).  
The proteins processed from ATG have different functions at different 
stages of autophagy such as cargo recognition, packing of cargo or 
vesicle formation (Klionsky, 2007). 
In eukaryotic cells, the lysosome is the main organelle used for 
degradation through acid hydrolases, enzymes that facilitate degradation 
of various types of macromolecules, such as proteins, lipids, complex 
sugars or nucleic acids (Schneider, 2014). After engulfment of cargo, the 
fusion takes place between the outer-membrane of the autophagosome 
with the membrane of the lysosome (Figure 1.9). Here, the inner vesicle, 
containing the cargo, is degraded (Yorimitsu, 2005). The process involves 
the sequestration of cellular matter by a specialized component, a double-
membrane autophagosome that fuses with the lysosome (Figure 1.9). 
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Here, there are various hydrolases, known as cathepsins, specialized in 
degradation of the autophagy substrates (Lee, 2012). They can be divided 
based on the catalytic residue in the active site such as serine, cysteine 
and aspartic enzymes (Kaminskyy, 2012). 
Extracellular and intracellular stress signals (endoplasmic reticulum stress, 
cell starvation, infections) are both triggers for autophagy upregulation. 
When autophagy is defective, it has been associated with diseases such 
as cancer, neurodegeneration and infectious diseases as a consequence 
of autophagy alteration since clearance of unnecessary or damaged 
components maintains a good functioning of the cell (see Chapter 1.4) 
(Chen, 2011). 
 
1.3.1.1 Induction of macroautophagy 
 
 
Levels of macroautophagy are kept low under normal physiological 
conditions (He, 2009). Under stress or starvation autophagy is induced 
and the levels are amplified in order to provide sufficient nutrients for 
survival and homeostasis under scarcity conditions (Shang, 2011). 
Numerous genetic studies have shown that the yeast ATG1 kinase with its 
essential regulatory component ATG13, have an essential role in 
autophagy induction (Scott, 2007; Cebollero, 2009; Chang, 2009; 
Kamada, 2010; Jung, 2010; Papinski, 2016).  
Phosphatidylinositol 3-phosphate is produced from the 
phosphatidylinositol 3-kinase complex and is important in targeting yeast 
ATG proteins (ATG18, 20, 21, 24) that bind to phosphatidylinositol 3-
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phosphate. This proteins interaction is a mediator in autophagy induction. 
Nevertheless, in mammals, some of these proteins have not been 
identified or are poorly understood (ATG 20, 24) (Stromhaug, 2004; Yang, 
2009; Popelka, 2017). 
Unc-51 like kinase 1 (ULK1) and unc-51 like kinase 2 (ULK2) are 
serine/threonine protein kinases, the homologues of yeast ATG1 and are 
known to regulate the induction of autophagy in human cells (Figure 1.11) 
(Ro, 2013). Autophagy is also enhanced by adenosine monophosphate-
activated protein kinase (AMPK), a key enzyme that regulates the cell 
metabolism to ensure healthy homeostasis (Zhao, 2011). On the other 
hand, the mammalian target of Rapamycin (mTOR), which is a growth 
factor regulator, inhibits autophagy. When mTOR is inhibited by either 
Rapamycin or starvation, ULKs are activated and contribute to a well-
functioning mechanism of autophagy (Figure 1.11) (Hara, 2008). When the 
cells undergo glucose starvation, AMPK kinase activates ULK kinases by 
phosphorylation resulting in activating macroautophagy (Figure 1.11). An 
example is a study on human embryonic kidney cells which demonstrated 
that cell starvation activates signalling mechanisms of regulatory ULK1 
leading to macroautophagy induction (Kim, 2011). Another study from 
2009 describes a binding protein called ATG101 that attaches to ATG13 
interacting with ULK1 and leading to the induction of macroautophagy in 
mammalian cells (Mercer, 2009).  
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1.3.1.2 Recognition and selection of cargo 
 
 
Studies of autophagy relate that clearance of abnormal proteins is 
characterized by selectivity through mediators such as protein p62/ 
sequestrome 1 (SQSTM1) (Hewitt, 2016). Protein p62 was initially 
reported to play a role in signalling and regulatory pathways of cell growth 
and proliferation and later on, it was described to get involved in detecting 
ubiquitinylated proteins in macroautophagy (Moscat, 2009). LC3 
(microtubule-associated protein 1 light chain 3) along with mono and poly-
ubiquitin-associated domain, are shown to bind to protein p62 (figure 1.10) 
and contribute to the cargo being tagged, processed and degraded (He, 
2009). Ubiquitinylated proteins, recognized by p62/SQSMT1, are tagged 
through ubiquitin receptors that have binding domains (Pankiv, 2007). The 
specific structure of p62 allows the binding of key proteins of the pathway, 
such as LC3 through a short LC3-interacting region (LIR) found on p62 as 
well as ubiquitin binding to a binding domain found on the C-terminal of 
p62 (Pankiv, 2007). Studies on knockout mouse models showed that 
deletion of p62 gene, inhibits the formation of ubiquitinylated protein 
aggregated for degradation, thus emphasizing the importance of p62 in 
the autophagic clearance (Komatsu, 2007). Specialized autophagy 
receptors such as p62/SQSTM1, NBR1 and NDP52 selectively tag 
misfolded proteins, damaged mitochondria, intracellular pathogens and 
other substrates, mediating their engulfment into the autophagosome 
(Muhlinen, 2010; Mizushima, 2015; Wang, 2015). Atg8/LC3 protein 
complex is required in mediating macroautophagy via the recruitment of 
33 
 
LIR-containing autophagy receptors that recognize and select cargo 
(Lippai, 2014).  
Once the double membrane is formed and elongated, free cytosolic LC3I 
is recruited and binds to the autophagosome, becoming membrane bound 
LC3II (see figure 1.10). P62, previously attached to the ubiquitin cargo that 
needs to be degraded, will bind to LC3II protein. After the autophagosome 
and the lysosome fuse to form the autolysosome, LC3II dissociates from 
the membrane and is released back into the cytosol. P62 with the cargo 
are degraded by lysosomal acid hydrolases resulting into release of amino 
acids and fatty acids back into the cytosol that are ready to be used later 
on (see figure 1.10). LC3 and p62 proteins are often found in the 
autophagy related research among the most used proteins of 
macroautophagy as they actively participate into numerous steps of the 
protein degradation including the membrane elongation (see figure 1.7), 
the formation of the autophagosome and the autolysosome (see figure 
1.7). Most research investigating MA pathway considers both LC3 and p62 
key markers since p62 binds to LC3 to form a complex which actively 
participate in the recognition and the tagging of the protein to degraded, 
resulting in autophogosome formation. 
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1.3.1.3 Autophagosome formation 
 
The phagophore assembly site (PAS) is known as the initial site where 
autophagy-related proteins are recruited and double-membrane 
autophagosomes are assembled. It is the most complex molecular event 
of the autophagy mechanism, by which vesicles form to sequester material 
for degradation. Numerous ATG proteins are required and recruited to the 
phagophore site to participate in the formation of the autophagosome (see 
figure 1.11).  This step is crucial with respect to very well-balanced 
Figure 1.10 LC3 interaction with p62. This diagram illustrates the 
interaction of p62 to LC3 in macroautophagy, where p62 molecules bind 
to cytosolic LC3I which is then recruited to the autophagosome 
membrane. 
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regulation of all ATG proteins (He, 2009). The process of self-assembly 
and nucleation of the phagophore membrane involves the class III 
phosphatidylinositol 3-kinase complex (PtdIns3K), which comprises of the 
PtdIns3K Vps34 (vacuolar protein sorting 34), a serine/threonine kinase 
Vps15, mATG14 and Beclin-1. Beclin-1 is known to be regulated by an 
antiapoptotic protein called Bcl-2 (B-cell lymphoma-2) which inhibits 
autophagy by binding to Beclin-1. Autophagy is induced if Bcl-2 
dissociates from Beclin-1 (Liang, 1999) (see figure 1.11). Beclin-1 and 
LC3 are commonly used in autophagy related studies as macroautophagy 
proteins, especially in cancer studies (He, 2014). They are involved in the 
most important and complex steps of the pathway, promoting membrane 
nucleation (Beclin-1), membrane elongation (LC3) and autophagosome 
formation (LC3) (He, 2009). 
The ATG proteins in partnership with the phosphatidylinositol 3-kinase 
complex recruit other two ubiquitin-like conjugation systems, ATG5-12-16 
and ATG8- phosphatidylethanolamine (PE), to the phagophore which is 
vital in membrane the regulation of elongation and expansion of the 
forming autophagosome (see figure 1.11). ATG8 is mainly found free in 
the cytosol; after autophagic induction, it can be found in a lipid-
conjugated form, bound to the phagophore.  This protein is important in 
controlling autophagosome size and its membrane shaping. ATG8 
lipidation, LC3 protein, p62, ubiquitin and Beclin-1, are extensively used to 
assess macroautophagy activity (He, 2009). 
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Figure 1.11 Molecular regulation of autophagosome formation in 
macroautophagy. The ULK protein complex comprising ULK1, ATG13, 
FIP200 and ATG101 dissociates from mTORC1 and binds to the membrane 
to initiate autophagosome formation under stress such as starvation. 
Membrane nucleation involves the formation of Beclin-1/PI3K complex, 
coordinated by the interactions between Beclin-1, UVRAG, ATG14, Bcl-2, 
p150, ambra1, endophilin B1 and Vps34. For the membrane elongation, 
ATG3, ATG4, ATG7, ATG10, and an ATG5–ATG12–ATG16L1 complex are 
recruited to conjugate PE to LC3 (cytosolic LC3I), leading to the translocation 
of LC3 from cytoplasm to the autophagosome membrane (bound form LC3II). 
Also, phosphorylation and acetylation of macroautophagy key proteins 
enhance autophagosome formation. 
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1.3.1.4 Vesicle fusion and autophagosome breakdown 
 
Finally, the autophagosome is completely formed and ATG8 protein, which 
lies on the surface of the membrane, is cleaved by ATG4 and released 
back into the cytosol. The same mechanism that regulates the autophagic 
vacuole membrane fusion mediates the fusion between autophagosome 
and lysosome, resulting in autolysosome formation which requires the 
lysosomal membrane protein isoform B (LAMP2B) (Nishino, 2000). This 
has been reported to be used as a biomarker of macroautophagy 
measuring the rate of autolysosome formation as previously described 
(Massey, 2006; Pérez, 2016). After fusion is completed, the inner vesicle 
has to be degraded by numerous lysosomal acid hydrolases such as 
proteinases A and B. This degradation process results in smaller 
compounds, particularly amino acids that are transported back into the 
cellular cytosol for further protein synthesis. This continuous cycle 
maintains vital cellular functions and assures nourishment during cellular 
stress such as starvation (He, 2009). 
Macroautophagy is usually measured by looking at the levels of 
autophagic markers either by immunohistochemical studies using 
antibodies against proteins of interest, by immunofluorescence or by 
immunoblotting, looking at immunoreactive bands for proteins of interest 
(Martinet, 2013). As previously mentioned, the most common used 
markers of macroautophagy are LC3, p62, beclin-1 and ubiquitin proteins 
(Pickford et al, 2008; Spencer et al, 2009; Jaeger et al, 2010; Liu, 2014; 
Guo, 2016; Hewitt, 2016). Macroautophagy stimulation has been shown to 
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enhance clearance of tau and beta-amyloid aggregated in AD, providing 
neuronal protection in cellular and animal models which suggests potential 
therapeutic benefits (Jiang, 2014). However, it is necessary to explore and 
identify at which parts of the macroautophagy pathway, the protein 
degradation is failing. This will allow development of more targeted 
therapeutic strategies. 
 
1.3.2 Chaperone-mediated autophagy 
 
CMA is the most specific autophagy pathway. It differs from the other two 
as it transfers proteins one by one, being highly selective with the 
substrates that pass into the lysosome (Kaushik, 2012). The protein to be 
translocated, requires a chaperone, Hsc70 (heat shock-cognate protein 
70), which is part of Hsp70 family (heat-shock protein70), a group of 
70kDa molecular weight proteins produced by cells when exposed to 
stress, forming the CMA- substrate/chaperone complex. Subsequently, the 
complex will travel to the lysosome where it will bind with the CMA 
receptor, LAMP2A, allowing entrance in the lysosome (figure 1.12).  Due 
to recognition, the substrate protein becomes unfolded and it is transferred 
across the lysosome membrane with the aid of the hsc70 chaperone (Lee, 
2012). It has been stated that the CMA rate is regulated by the rate of 
assembly and disassembly of the translocation complex (Cuervo, 1996).  
CMA does not require vesicles for engulfment, thus substrates are 
recognized in the cytosol and directly enter the lysosome by crossing the 
membrane. The substrate selectivity is highly specific, removing certain 
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proteins without interference with other healthy ones. Chaperones are 
indispensable in this cellular pathway and in 2000, their dependence led to 
the name of the autophagic pathway (Cuervo, 2000).  
CMA is a complex process with four main cellular steps: protein/substrate 
recognition and lysosomal targeting; substrate binding followed by its 
unfolding; substrate translocation and substrate degradation in the lumen 
of the lysosome (Cuervo, 2014). The first step takes place in the cytosol 
when a specific chaperone, hsc70, binds to a motif made of five peptides, 
present in the amino acid sequence of all CMA substrates (see Figure 
1.12a). This motif (e.g. KFERQ) consists of a glutamine residue (Q) either 
at the beginning or at the end of the sequence, one of the two positively 
charged amino acids, lysine (K) or arginine (R), one of the non-polar 
hydrophobic amino acids, phenylalanine (F), leucine, isoleucine and valine 
and lastly, one negatively charged amino acids, either glutamic acid (E) or 
aspartic acid (Jackson, 2016). The second step takes places after the 
chaperone-substrate binding, when the complex is targeted to the 
lysosome (Figure 1.12). Here, the substrate interacts with the membrane 
through the cytosolic tail of a specific transmembrane protein called 
lysosome-associated membrane protein type 2A (LAMP-2A).  
LAMP2A is present in a monomeric form at the surface of the lysosome, 
but in association proteins such as the substrate-chaperone complex, it 
results in the formation of a multimeric protein complex that is required for 
substrate translocation in step 3 (Cuervo, 1996). The binding of the 
chaperone-substrate complex to LAMP2A, at the surface of the lysosome 
(see Figure 1.12b), takes places while the substrate is still in an unfolded 
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state, however, it requires unfolding processes in order to cross the 
lysosomal membrane. Translocation also requires the presence of hsc70 
which is normally found in the lysosomes. The last step of CMA is the 
degradation of the substrate by disassembling the multimeric LAMP-2A 
complex into monomers that can be reused in further CMA pathways 
(Figure 1.12).  
 
 
Figure 1.12 Chaperone-mediated autophagy. Chaperone-mediate 
autophagy steps describing the recognition of the substrate in the cytosol, 
with the help of chaperones, followed by formation of a complex substrate-
chaperone, which will migrate to the cell surface where the substrate will 
be translocated, through a transmembrane protein, into the cell to be 
degraded. 
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As previously mentioned, CMA rate is regulated by the rate of assembly 
and disassembly of the translocation complex (Cuervo, 1996). CMA rate is 
also dependent on the LAMP2A present in the lysosomal membrane. 
According to Kaushik, LAMP2A is exclusively associated with CMA, 
although hsc70 chaperones are involved in both CMA and 
microautophagy (Kaushik, 2009). While LAMP2A is a widely used marker 
of CMA, measuring the rate of substrate translocation in the lysosome in 
order to be degraded, the other different isoform of this protein, LAMP2B, 
has been described to be a potential marker exclusively in 
macroautophagy pathway measuring the rate of autolysosome formation 
(Nishino, 2000). 
Similar to macroautophagy, CMA is measured by looking at the levels of 
CMA markers either by immunohistochemical studies, by 
immunofluorescence or by immunoblotting. The most commonly used 
markers of CMA are LAMP2A (the only isoform associated with CMA), 
which measures the translocation rate of the  abnormal or defective 
proteins to be degraded, through the lysosomal membrane and Hsp70 
which indicates the rate of recognition of KFERQ motif on the protein that 
is cleared and the rate of binding to it.  Under hypoxic and ischemic stress, 
dysfunction of CMA, has been shown to result in accumulation of 
abnormal proteins in the brain therefore exploration of CMA impairments is 
crucial in AD (Koga, 2011; Cuervo, 2014). A decrease in both lysosomal 
LAM2A and hsc70 indicate a reduced CMA rate, while increased levels of 
LAMP2A would suggest overexpression of LAMP2A (Patel, 2015), 
however, if LAMP2A production is upregulated but lys-Hsc70 is 
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insufficient, substrate uptake would become limited, resulting in CMA 
defects (Cuervo, 1995; Cuervo, 2000).  
 
1.3.3 Microautophagy 
 
The third type of autophagy, called microautophagy differs as it involves a 
direct engulfment of the protein to be degraded into the lysosome. This 
action takes place by a process called invagination and involves the 
inward budding of the lysosomal membrane (figure 1.9) (Lee, 2012).  
Similarly to macroautophagy, microautophagy role is important in cell 
survival during oxygen starvation and nutrient scarcity. Microautophagy is 
activated by stress conditions such as short-term starvation or prolonged 
starvation but also by glucagon and cyclic AMP administration, cortisone 
acetate treatment and albumin injection (Mijaljica, 2011). Microautophagy 
does not respond to most commonly used autophagy enhancers (Cuervo, 
2004).  
The major limitations of microautophagy investigation are the incomplete 
understanding of its physiological roles and its contribution to specific 
diseases along with the methods of detection such as the electron 
microscopy. Microautophagy investigation is represented by the 
morphological analysis of the lysosomes with the electron microscope 
which is expensive and yields minimal information regarding lysosomal 
content.  Previous studies which investigated abnormalities seen in the 
lysosomal morphology of the microautophagy have reported that these 
changes are associated to the final steps of the pathway however the 
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initiation steps of microautophagy were unclear (Dice, 2000). 
Microautophagy research is not as popular as MA and CMA research due 
to high costs of electron microscopy facilities and due to its biochemical 
and molecular events that take place at a much lower scale than the other 
autophagy pathways.  
 
1.4 Autophagy in neurodegenerative disorders 
 
Over the last decade, there has been emerging evidence linking 
impairments of autophagy pathway to neurodegenerative disorders such 
as AD, resulting in failure of abnormal proteins clearance (Nixon, 2005; 
Nikon, 2007; Pickford, 2008; Son, 2012). Generally, autophagy cannot 
complete digestion unless functional and dynamic communications 
between all stages of the autophagic pathways work. Studies have shown 
that when these particular interactions are disrupted, neuronal cells are 
prone to become vulnerable, especially with age (Cuervo, 2008; Martinez-
Lopez, 2015).  
The substantial dependency of neurons on autophagy is demonstrated by 
brain studies in lysosomal disorders and studies of autophagy-related 
gene mutations (Platt, 2012). Neurons are atypical cells in the body as 
they have dendrites and axonal cytoplasm and as a result these cells meet 
a higher degree of difficulty in eliminating accumulations of dysfunctional 
organelles and protein aggregates (Misgeld, 2017). Young neurons 
manage to efficiently clear all damaged components, despite the 
significant distances that the many vacuoles, containing organelles and 
proteins, generated in axons must travel to reach lysosomes (Carmona-
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Gutierrez, 2016). Nevertheless, studies suggest that lysosomal-based 
autophagy pathways including macroautophagy and CMA are involved in 
the clearance of both AD deposits: Aβ and tau suggesting that both protein 
degradation pathways could be important in neurodegeneration (Wang, 
2009; Wang, 2012; Lee, 2013).  
Over two decades ago, electron microscopy studies on AD brain revealed 
a possible link between neurodegeneration and impaired macroautophagy 
(Nixon et al., 2005). A significant increased level of autophagic vacuoles 
was observed within the lysosome of AD neurons, after it fused with the 
autophagosomes, suggesting an accumulation of immature vacuoles 
leading to incompletion of macroautophagy in AD. Also, the damaged 
neurons, containing neurofibrillary tangles, showed high autophagic levels 
in the cell bodies, measured by immunoblotting and immunofluorescent 
labelling (Yu et al, 2005). Impaired macroautophagy was suggested due to 
incomplete development of macroautophagic vacuoles by immunolabeling, 
affecting their transport to the lysosomes. Surprisingly, immature vacuoles 
were discovered to be a considerable Aβ-containing site while APP 
molecules (either complete or cleaved), γ–secretase complex and 
presenilin-1 were found abundantly in autophagic vacuoles, suggesting 
that macroautophagy is linked to AD pathology however, it failed to clear 
Aβ molecules, resulting in impaired macroautophagy (Yu et al., 2005). 
Based on this study, we could hypothesize that macroautophagy gets 
impaired in AD at the autophagosome formation step, suggesting a 
possible target for therapeutics.  
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According to Nixon, transport and development of autophagolysosomes is 
impaired in AD, leading to significant accumulation of immature 
autophagic vacuoles in the neuron cell bodies. Upregulation of autophagy 
induction, combined with faulty mechanisms of Aβ clearance was reported 
to result in accumulation of toxic protein aggregates and alteration of 
neuronal cells (Nixon, 2007). Beclin-1 protein is a key regulator of 
macroautophagy pathway initiation. It was shown that this protein 
expression decreases with age, thus reducing the levels of autophagy in 
the human brain (Pickford et al., 2008). AD transgenic mouse model 
experiments revealed that deletion of Beclin-1 gene causes decline in 
neuronal autophagy leading to neurodegeneration pathology (Pickford et 
al., 2008). In addition, beclin-1 depletion in age brain causes damage to 
the autophagosome and lysosome degradation, altering APP metabolism, 
too. It is still unclear how Beclin-1 levels relate to protein accumulation in 
individual neurons. Considering the beclin-1 findings, its increase may play 
a role in therapeutic potential in Alzheimer’s disease (Jaeger et al., 2010).  
Age-related diseases such as AD and PD have been shown to 
demonstrate a decline in the well-functioning of the lysosome and a 
decline in lysosomal lifespan, resulting in compromised efficient clearance 
of abnormal accumulations in the ageing neurons, however the cause of 
lysosomal malfunction is unclear (Carmona-Gutierrez, 2016). 
Neuronal cells become vulnerable to decline in the proteolytic clearance of 
lysosomal material. If autophagy fails to function, ubiquitinated protein 
aggregates accumulate within neurons and they start to degenerate, 
losing vital functions and integrity (Nixon, 2013). 
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Substantial evidence suggests that impaired CMA leads to pathogenesis 
and one example is neurodegeneration by failure of proteolytic systems to 
remove abnormal aggregates that cause toxicity (Koga, 2011). Impaired 
CMA levels are associated with AD, as studies in mouse neuroblastoma 
N2a cell model suggest that tau protein contains the CMA recognizing 
motif, interacting with Hsc70 facilitating mutant tau to translocate to the 
lysosomes, therefore being degraded by CMA (Wang, 2009). Other 
studies have reported APP to contain the KFERQ motif, meaning that 
Hsc70 could target it and degrade beta-amyloid aggregated via CMA 
(Koga, 2011). Considering this, there is sufficient evidence to warrant 
further investigation of CMA in AD since enhancing this pathway could be 
a viable therapeutic target.  
In addition, autophagy-mediated mTOR kinase complex has been 
proposed to contribute to neurodegeneration in AD (Talboom, 2015). Post-
mortem brain studies revealed mTOR signalling hyperactivity and 
dysregulation, was associated with the presence of soluble Aβ and 
hyperphosphorylated tau proteins (Rosner, 2008). Therefore, another 
therapeutic target is mTOR complex, by inhibiting its signalling pathways. 
A regulator of cell metabolism and survival, mTOR emerges as a novel 
therapeutic target for Parkinson’s disease (PD), which is explained, in 
more detail, in the following section. The mTOR complex was shown to 
modulate cognitive functions including memory and learning (Lan, 2017).  
Some studies on rat models suggest that activation of autophagy involving 
autophagy-related proteins such as Beclin-1 and mTOR are involved in 
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the pathology of vascular dementia leading to impaired cognition and 
learning functions (Liu, 2014; Guo, 2016). 
Rapamycin treatment on mice models aimed to inhibit mTOR signalling 
and as a result, this pharmacological approach improved some 
neurodegenerative symptoms and reduced senile plaque pathology 
(Caccamo et al., 2010). Regarding all these findings, mTOR signalling 
inhibition plays an important role of amelioration in cognitive impairment 
and confirms that the result of increased autophagy is directly linked to Aβ 
reduction. Previous studies have suggested that in AD there is an 
impairment of MA in the pathway initiation, autophagosome formation and 
maturation, as well as a CMA impairment associated to reduced levels of 
LAMP2A and Hsc70 (Nixon, 2005; Yu, et al 2005; Koga, 2011; Cuervo, 
2014). However, it is unclear at what stage in disease this occurs, how the 
impairments relate to AD protein aggregation and if alterations vary 
between brain regions. 
Macroautophagy and CMA are also implicated in the clearance of other 
neurodegenerative diseases associated with aggregated proteins such as 
Lewy bodies (Vogiatzi et al., 2008; Tanik, 2013). Formation of Lewy 
bodies is the main pathological feature of PD, inclusions which are 
composed of ubiquitin and α-synuclein (Spillatini, 1998).  
Initially, brain studies on PD patients revealed increased apoptosis and 
decreased autophagy in the substantia nigra neurons, primarily affected in 
PD (Anglade et al., 1997).  This was shown by inhibitory experiments of 
the two pathways, showing that CMA and macroautophagy inhibition 
results in accumulation of α-synuclein species (Vogiatzi et al., 2008). 
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Over a decade ago, links between PD and autophagy pathways were 
established by finding that α-synuclein is degraded by macroautophagy 
and CMA (Cuervo et al., 2004). More recent studies suggest that PD 
abnormal protein aggregates fail to degrade resulting in impairment of the 
autophagy pathways (Lynch-Day, 2012; Giacoppo, 2017; Karabiyik, 2017). 
There is a study on parkinsonian Sprague-Dawley rat models suggesting 
that there is decreased tyrosine hydroxylase, an important enzyme for 
dopamine synthesis, and increased LAMP2A and Hsp90, in the PD rats, 
suggesting a link of CMA activation and neurodegeneration (Marin, 2011).  
Other studies have shown that CMA impairment is associated with 
neurodegeneration in familial and sporadic Parkinson’s disease cases. 
Experiments using mouse models, which included lysosome extraction, 
neuronal-differentiated induced pluripotent stem cells and cell culture 
based models, suggested lysosomal degradation of specific PD proteins 
such as alpha-synuclein (Wang, 2009). While Beclin-1, which regulates 
macroautophagy pathway, was shown to be important in AD, experimental 
studies, on transgenic mice, proved the same for PD. This was 
accomplished by injecting Beclin-1 expressing lentivirus into the mice 
brain and the results suggested reduced α-synuclein abnormal deposition 
(Spencer et al., 2009).  
Studies in PD post-mortem brain sections showed that Lewy bodies 
contained autophagy-related proteins and decreased levels of LAMP2A 
and Hsc70 in the dopaminergic neurons of human PD brains when 
compared to control brain samples, suggesting a reduced CMA activity in 
PD (Alvarez-Erviti, 2010).  
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Although, the majority of the PD cases are sporadic, in familial cases, 
studies revealed that mutant variants of the α-synuclein gene, such as 
A53T and A30P have inhibitory effects on CMA with mutant A53T and 
A30P α-synuclein being shown to bind with high affinity to LAMP2A (Sala, 
2016). Several studies on post-mortem PD brains with genetic mutations, 
have proved an important role of macroautophagy mechanism which 
contributes to dopaminergic neuronal cell death. For instance, Anglade’s 
paper reported active cell death in the final stages of the disease, in 
substantia nigra of PD patients. Oxidative stress was reported to induce 
toxicity of dopamine, resulting in an increase of autophagic vacuoles. 
(Anglade et al., 1997). In PD, oxidative stress is a common pathogenic 
mechanism and neuroprotective protein Oxi‐α is shown to be reduced in 
dopaminergic neurons (Yoo, 2004). Researcher found that Oxi‐α protein 
can protect dopamine neurons by activating mTOR kinase involved in 
autophagy. Therefore, downregulation of this protein inhibits mTOR kinase 
and activated oxidative stress responses in the brain. Moreover, the same 
study demonstrated that treatment with Rapamycin, an autophagy 
enhancer, aggravated cell death due to enhanced oxidative stress 
whereas treatment with 3-methyladenine, an autophagy inhibitor, showed 
neuroprotective properties on the neurons (Choi et al, 2010). 
Other studies using ALS transgenic mouse models (SOD1G93A) have 
suggested that after treatment with Rapamycin, the neuropathology and 
the symptoms worsened (Zhang, 2011). This suggests that switching on 
the whole autophagy machinery may, in some cases, have irreversible, 
damaging effects so the most suitable therapeutic intervention would be a 
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highly specific drug that could target the defected step within the different 
protein degradation pathways. 
 
 
1.5 Models of Alzheimer’s disease 
 
The mechanisms that lead to AD pathogenesis and irreversible brain 
damage have been described extensively, providing potential tools of 
generating AD models including invertebrate, rodent and cell models. Yet, 
the biggest challenge is to produce a disease model that includes all 
pathological aspects of AD (Saraceno, 2013). 
 
1.5.1 Drosophila and C. elegans 
 
Drosophila and C. elegans have been used in many studies as they have 
conserved AD proteins enabling researchers to understand the molecular 
functions of their genes and the associated proteins. Examples are Apl-1 
protein, equivalent to human APP protein, expressed in the cortical region 
of nervous system (Hornsten et al., 2007), kuzbanian gene in Drosophila, 
ortholog of human α-secretase (Tan et al., 2017) or sup17 and adm-4 
genes in C. elegans, equivalent to human α-secretase (Ewald, 2010).  
Presenilin 1 and 2 are also conserved in the two species, along with tau 
protein (Iijima-Ando, 2010; Prüßing, 2013). 
These models pose some limitations, despite contributing with knowledge to 
the AD field. One example is that Apl-1, the APP drosophila ortholog, lacks 
the human Aβ42 domain, making this key protein difficult to study (Figure 
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1.13) (Prüßing, 2013). Similarly, in C. elegans, Apl-1 does not contain the 
Aβ domain (Figure 1.13), although the Apl-1 extracellular domain is 
approximately 50% similar to the human APP extracellular domain, while 
the transmembrane and the cytosolic domains share 71% sequence 
similarity to human APP (Alexander, 2014).  
 
1.5.2 Zebrafish models 
 
Zebrafish (Danio rerio) have become a potent model in the research of AD 
exhibiting neuropathological and behavioural phenotypes that are 
quantifiable in experimental studies (Newman, 2011). Zebrafish have 
numerous advantageous, offering physiological complexity, high rates of 
reproduction and longer lifespan than rodent models enable zebrafish to 
model neurodegeneration (Santana, 2012; Leitner, 2014). Investigating 
neurodegeneration by exploring molecular and genetic mechanisms on 
zebrafish are costly effective and less time consuming compared to other 
models (Leitner, 2014). Zebrafish models have a fully characterized 
genome (Barbazuk, 2000), with physiological homology to humans with a 
high conservation of the basic brain organization including the 
hypothalamus, the olfactory bulb and the lateral pallium, which is thought to 
be the homologous of the mammalian hippocampus (Mueller, 2004). 
Moreover, zebrafish have been shown to produce neurotransmitters crucial 
for the glutaminergic and GABAergic systems, including GABA, dopamine, 
acetylcholine, glutamate, serotonin, histamine and others (Panula, 2006; 
Rico, 2011). 
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Studies reported that zebrafish express presenilin genes and others 
orthologous to the human genes in familial AD (Newman, 2014). Other 
studies suggest that zebrafish models could be used in studying the 
underlying mechanisms of tauopathies (Bai, 2011). Two genes equivalent to 
human MAPT have been indentified as mapta and maptb, however they 
need further investigation (Chen, 2009).  Twenty years ago, scientists 
started to describe the presence of AD major genes in zebrafish, such as 
APP, PSEN1, PSEN2, APOE (Babin, 1997; Leimer, 1999; Musa, 2001; 
Groth, 2002), which are crucial in understanding the molecular biology of 
AD. More recent studies on APP gene in zebrafish (homologous appa and 
appb), demonstrated that APP transgenic models exhibit appb protein in the 
brain, spinal cord, thalamus and cerebellum (Lee, 2007) and that knocking 
down the appa and appb genes results in body structural deformities, 
movement impairment and mild synophtalmia, with no Aβ plaques present 
(Joshi et al, 2009). 
Limitations in zebrafish models include a need for developing more effective 
transgenic zebrafish AD models, for a better understanding of the key 
genes and their corresponding proteins as well as the need to develop 
APOE zebrafish transgenic models (Figure 1.13) (Saraceno, 2013). Another 
limitation is that studies of neurodegenerative diseases on zebrafish have 
limited understanding in the neuronal cell death, process crucial in human 
neurodegeneration (Fontana, 2013). Moreover, scientists describe 
pharmacological limitation of using zebrafish models in neuroscience 
research, as drug manipulation is simply performed by administering 
chemical compounds to the aqueous environment (Tran, 2015), however 
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there is no fully controlled drug dose absorption as it quickly passes through 
the skin (Rubinstein, 2006). Despite the limitations, zebrafish models are 
still a good model for investigating genetic, molecular and pharmacological 
aspects of neurodegeneration (Kalueff, 2013; Norton, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.3 Mouse models 
 
One of the most popular animal model used in the study of 
neurodegenerative disorders including AD is the transgenic mouse (Platt, 
2013). Unfortunately, a mouse model to capture all AD aspects has not yet 
Figure 1.13 Advantages and disadvantages of the use of the invertebrate (left) and vertebrate 
(right) models used in the study of AD. 
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been produced, however each mouse model allows researchers to explore 
certain genes, proteins or pathways by wither genetic of drug manipulation, 
reducing the ethical and other limitations in human cells or brain tissue 
(Saraceno, 2013). Transgenic mouse models have widely been used, being 
generated by using the APP gene mutations which have been identified, 
with Swedish double mutation K670N/M671L being present in almost half of 
the APP transgenic mice (Sasaguri, 2017). Over time, knockout mice 
models including widely used APP23Tg, Tg2576, APP/PS1, 3xTg-AD, 
PS19, Htau, rTg4510 as well as double transgenic mice allowed 
understanding of mechanisms that lead to AD pathogenesis, the disease 
progression and potential therapeutic treatments (Arnim, 2006; Sterniczuk, 
2010; Iba, 2015; Song, 2015). Tg2576 transgenic mouse model has been 
one of the most commonly used rodent model, presenting the Swedish 
mutation at APP695 and expressing amyloid protein in the spinal cord and 
the forebrain regions (Hsiao, 1995). Staining with thioflavin-s have showed 
that these mice exhibit pathology and express amyloid plaques starting at 
the age of 10 months, as well as producing oligomeric beta-amyloid, which 
is known to be more toxic than aggregated beta-amyloid in the plaques 
(Lesne, 2006). Despite plaque deposition, this mouse model failed to 
demonstrate neuronal loss which is commonly observed in AD brains 
(Irizarry, 1997), however later on, studies on Tg2576 mice demonstrated a 
significant loss in synapses in the hippocampal entorhinal cortex at the age 
of 15 months (Dong, 2007). APP23 mouse model has successfully showed 
that besides expression of tau and beta-amyloid, key AD hallmarks, seen in 
transgenic mice, there is also glial cell activation, seen around the plaques, 
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which is known to play an important role in the neuroinflammatory 
responses, seen in human AD (Sturchler-Pierrat, 1997; Stalder, 1999; 
Bornemann, 2001). This model has also successfully demonstrated 
extensive neuronal loss in CA1, of the APP23 mice hippocampi (Calhoun, 
1998).   
Along with APP mutated mice, transgenic models expressing human 
wildtype tau have also been generated in laboratories in order to investigate 
pathological changes in neurodegeneration (Kitazawa, 2012; Platt, 2013). 
One of the first transgenic mouse model, expressing tau 40, either 1N4R or 
0N3R isoform, demonstrated PHF-1 positive phopsho-tau in the cell bodies 
and the dendrites of neurons, however neurofibrillary tangles were absent 
(Götz, 1995; Brion, 1999). At that time, these studies provided useful insight 
on neuropathology, as transgenic mice showed evidence that intracellular 
tangles can aggregate in the absence of amyloid plaques, however more 
recent studies suggest that Aβ fibrils and plaques can enhance the 
formation of tangle pathology in mutant tau mice such as P301L, 
rTg3696AB and APPKOTg30 mice (Götz, 2001; Götz, 2004; Paulson, 2008; 
Vandes Dries, 2017).  
For a better and complete understanding of the neuropathological changes 
in AD, scientists have created transgenic models to express both amyloid 
plaques and tau tangles as single mutations in the rodent models, as 
described above, are insufficient to generate all the specific pathological 
changes observed in the human AD brains (Kitazawa, 2012). 
Lewis and collegues have developed the first dual mutated mouse model, 
by crossing JNPL3 with Tg2576 transgenic lines (Lewis et al, 2001). The 
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key findings of their study were that amyloid plaque formation is generated 
similarly as seen in the parental Tg2576 mice, however NFT deposition, 
seen in the entorhinal cortex, amygdala and the subiculum of these mice, 
was accelerated, when compared to JNPL3 line suggesting that the amyloid 
pathology enhances formation of tau tangles in the double transgenic mice 
models (Lewis et al, 2001) 
Despite all advantages of using mouse models in AD studies, there are also 
papers that debate this using these models, suggesting that human studies 
are still very limited in comparison to mice studies and that key findings in 
transgenic mice studies fail to successfully translate and apply into human 
clinical trials that could find a cure for AD (Franco, 2014). One of the most 
important aspects to be considered regarding the discrepancies between 
research and clinical practise is that the extensive neuronal loss reported in 
the brains of AD patients is not always present in the AD mouse models 
(Cuadrado-Tejedor, 2014). Moreover, when patients are diagnosed with 
moderate and severe AD, they already have substantial synaptic and 
neuronal loss with cognitive impairment (Serrano-Pozo, 2011).  
Most of the research that uses transgenic mice focused on mutations that 
result in plaque and tangle pathology, however patients with AD have been 
described to have more pathologies than just plaques and tangles 
(Scheinder, 2007; Scheinder, 2009). Mouse models represent the pathology 
of AD, exclusively, therefore potential therapies on these mice may not 
prove total efficacy (Kitazawa, 2012).  
Besides AD pathology, the complexity of the disease arises from numerous 
processes such as neuroinflammation, neurotoxicity, mitochondrial and 
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oxidative stress. Thus, no transgenic line is able to cover all aspects of the 
disease, suggesting that the mouse models fail to fully reproduce the 
human disease mechanisms that can take decades to develop specific 
pathology resulting in symptoms that are primarily involved in the higher 
cognitive function (Gama, 2012). 
 
1.5.4 Cell models 
 
Another important AD model, based on growing amount of evidence, 
suggests that studies using cell models such as embryonic stem cells, 
human induced pluripotent stem cells (iPSC) and neuronal cells are 
important in revealing normal (control) and pathological conditions in the 
research of AD through a different approach (Saraceno, 2013). A study 
from 2011, explained the use of familial AD fibroblasts with mutations in the 
PSEN 1 and PSEN2 genes, which were differentiated into iPSC leading to 
neurons that revealed increased Aβ accumulation, illustrating the specific 
pathological characteristics of familial AD (Yagi et al., 2011). This study 
demonstrated the potential of familial AD-iPSC-derived neurons in the 
research of AD to identify novel therapeutic strategies. In the following year, 
another study which explored iPSC in both familial AD and sporadic AD, 
revealed that in some of the sporadic cases, the cells showed increased Aβ 
generation and tau hyperphosphorylation (Israel et al., 2012). The same 
study also emphasized the importance of studying AD pathology only in 
these iPSC-derived neurons as the initial fibroblast cells did not exhibit the 
same AD pathology features (Israel et al., 2012).  These two studies as well 
as other numerous studies demonstrate the potential of iPSC-derived 
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neurons as a good AD model to explore the disease progression and to 
guide the drug development in the hope of finding the cure (Zhang, 2014; 
Nieweg, 2015; Ortiz-Virumbrales, 2017).  
Nevertheless, researchers also consider the limitations of this model as 
growing certain iPSC cell lines could not be time or cost effective due to 
prolonged time required for developing the cells until they reach adult 
phenotype (D’Antonio, 2017; Wray, 2017). Moreover, there is a recent 
paper suggesting that the cell culture models may not represent the variety 
of tau isoforms seen in the adult brain and the necessity of this to the 
development of tau pathology is not known (Arber, 2017).  
Considering the above discussed advantages and disadvantages of AD 
models which allow mimicking AD specific phenotypes at different stages of 
the disease progression, they represent an important tool of investigating 
AD, however a constant need for more accurate potent models is required 
to overcome all challenges of finding the best AD model. 
 
 
1.5.5 Skin-derived fibroblasts 
 
As previously mentioned in Section 1.1.7, a new high throughout model is 
needed to study abnormal Aβ and tau deposits from the brains of AD 
patients. Although altered autophagy pathway, in animal models and human 
autopsy tissue, has been described, it is still unclear whether pathogenic 
alterations extend to peripheral cells such as skin-derived fibroblasts. The 
idea of using fibroblasts as a potential resource came after many of the 
neuronal changes that take place in AD brains, such as toxic protein 
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accumulation, increased oxidative stress and mitochondrial abnormalities 
have also been reported in fibroblasts derived from AD patients (Citron et 
al., 1994, Magini et al., 2010, Ramamoorthy et al., 2012; Mocali, 2014). In 
vitro culture cell models using human skin-derived fibroblasts could explore 
whether AD deposits extend to peripheral cells such as the skin fibroblasts 
based on the previous studies on AD patients fibroblasts. 
Peripheral fibroblasts, obtained from AD patients, are a potentially useful 
tool to investigate the progression of molecular events throughout various 
stages of AD. These cells have many advantages, from which they are 
commercially available and avoid many of the ethical and methodological 
issues associated with the use of animal or human post-mortem tissue. 
Also, there are several cell banks worldwide from which they can be 
ordered and cultured in vitro, fed with suitable medium, stored (at -80° or in 
liquid nitrogen) and recovered when needed for experiments (Connolly, 
1998). 
Once, research will identify specific targets within the autophagy machinery, 
novel strategies to prevent and treat AD could revolutionize the 
neurodegeneration research. Thus, these cells could prove invaluable in 
identifying and assessing new therapeutic approaches, as well as for the 
identification of new diagnostic biomarkers, which are scarce at the 
moment. 
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1.6 Aims and objectives 
 
There are numerous studies on animal models investigating autophagy 
impairment in demented brains however human studies are minimal and 
there are still gaps to the research.  
This study will aim to characterize macroautophagy and CMA deficits in 
post-mortem human brain tissue across different subregions of three brain 
regions and at different AD stages (as defined by Braak stage). This 
investigation also aims to understand macroautophagy and CMA deficits in 
relationship to each other and identify which steps in these complex 
pathways seem to be most significantly impacted in disease. This study 
also aims to test skin-derived fibroblasts and explore the autophagy levels 
that are found within these cells. Another aim is to explore whether there 
are variations in autophagy marker expression across the three brain 
regions differentially affected in AD, the hippocampus, the frontal cortex and 
the occipital cortex. The study also aimed to compare the levels of 
autophagy markers to pathological tau and beta-amyloid in the three brain 
regions to understand how the two pathways relate to significant 
pathological protein aggregates.  
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1.7 Hypotheses 
 
We propose that MA and CMA pathways become impaired with advancing 
AD and that autophagy markers distribution vary between subregions of 
brain areas. We hypothesize that with excessive accumulation of 
pathological proteins such as tau, there will be a decrease in autophagy 
markers found within the brain regions. We also propose that MA and CMA 
become defective at a cellular level, in skin-derived fibroblasts from patients 
with AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MA and CMA markers decrease 
AD pathology increases 
Moderate stage of AD Severe stage of AD 
HUMAN BRAIN 
SKIN FIBROBLASTS 
Cellular alteration Healthy cell 
Early stage of AD 
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Chapter 2 MATERIALS AND METHODS 
 
 
2.1 Human brain tissue 
 
2.1.1 Post-mortem human brain tissue 
The human brain tissue used for this studies was supplied by the 
Manchester Brain Bank. The Newcastle & North Tyneside 1 Research 
Ethics Committee approved the collection, storage and distribution of this 
brain tissue on 29th of June, 2009 (REC reference 09/H0906/52). Under 
conditions agreed with the REC, The Manchester Brain Bank supplied 
tissue or data to the researchers, without requirement for researchers to 
apply individually to the REC for approval. This work was also approved by 
the University of Salford Ethics Committee.     
A total of 45 cases were used from formalin-fixed, wax embedded brain 
tissue sections (6μm) were provided from the Manchester Brain Bank. 
Tissue from three different brain regions including those demonstrating an 
early pathological involvement (hippocampus and temporal cortex) and 
regions that become involved with advancing disease progression (frontal 
and occipital lobe) for each case were provided. The 45 cases consist of 17 
cases of Braak stage 0-II (minimal pathology, highly unlikely Alzheimer’s 
disease), 15 cases Braak stage III-IV (probable AD, moderate pathology 
and 13 cases Braak stage V-VI (highly likely AD). Braak staging had been 
previously performed by the Brain Bank pathologists and data was supplied 
regarding this. 
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2.1.2 Patient demographics 
 
 Data associated with gender, age at death, main clinical feature, principal 
pathology and Braak stage was provided (Table 1). 
 
 Table 2.1 Patients demographic 
 
Brain pH data was only available from a subset of more recent samples that 
were collected fresh and therefore, amenable to pH testing. Thus, minimal 
pH data was available on a few cases (n=11) used in this study: four Braak 
0-II cases had average brain pH 5.63–6.27, four Braak III-IV cases had pH 
6.08–6.63 and three Braak V-VI cases had Ph 5.41–6.27. Post-mortem 
delay (PMD) data was also collected for all cases (n=44; data missing for 
one case) and reported in hours: Braak 0-II, 12–144; Braak III-IV, 6–134; 
and Braak V-VI, 25–176. All 45 cases manifested as sporadic AD; dementia 
status was considered based on the patients’ clinical diagnosis and it was 
recorded for 41 cases (data missing for four cases). In Braak 0-II group, a 
total of 15 patients had available dementia status and were considered: 
cognitively normal (n=11), diagnosed with vascular dementia (n=2) or found 
with a history of stroke (n=2). In Braak III-IV, a total of 11 patients were: 
cognitively normal (n=3), diagnosed with AD (n=2), diagnosed with vascular 
dementia (n=2) or other type of dementia (n=4). In Braak V-VI, 12 patients 
 Braak 0-II Braak III-IV Braak V-VI 
Mean age at death 87 86.2 79.5 
% females 47 73 69 
% males 53 27 31 
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were diagnosed with: AD (n=10), vascular dementia (n=1) and other type of 
dementia (n=1). 
 
 
2.1.3 Tissue processing 
 
The tissue was obtained post-mortem at the Manchester Brain Bank and 
tissue was formalin fixed and wax-embedded to preserve it’s the cellular 
and molecular contents for further analysis. Tissue was then sectioned at 
6μm, attached to glass slides for further analysis. Tissue processing was 
performed by staff at the Manchester Brain Bank. 
 
2.2 Immunohistochemistry 
 
The experiments in this study use methods to investigate alterations in 
autophagy related to neurodegeneration and to explore the correlation 
between autophagy biomarkers and AD pathological hallmarks. Methods 
include immunohistochemistry, microscopy, image analysis, staining 
scoring and stats analysis.  
 
2.2.1 Antibodies  
 
The optimal staining dilution and conditions were achieved for all the 
antibodies (see table 2.1.4). These conditions were used for all 45 sections 
including the positive and the negative controls for each antibody.  
Polyclonal anti-human LAMP2A antibody, purchased from Abcam is a 
lysosome associated membrane protein, present at the surface of the cell 
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and plays a crucial role in the chaperone mediated autophagy pathway, 
being highly selective on the cargo that enters the cell. This antibody is 
used as a biomarker to assess impaired chaperone mediated autophagy in 
the 45 cases of temporal cortex and hippocampal neurodegeneration 
(Cuervo, 2014).  
Polyclonal anti-human LC3 antibody, purchased from the MBL (Medical and 
Biological Laboratories), is an autophagosome biomarker, associated with 
the levels of formation of a double-layered membrane which engulfs the 
cargo that needs to be degraded. LC3 antibody was used to assess 
macroautophagy pathway in the 45 cases of temporal cortex and 
hippocampal neurodegeneration.  
Monoclonal anti-human Beclin-1 antibody, purchased from Abcam, is a key 
regulator in macroautophagy, involved in nucleation of the phagophore and 
the formation of the autophagosome and it is often used in studies to 
assess macroautophagy.  
Monoclonal anti-human Hsp70 antibody, purchased from Santa Cruz 
Biotechnology, is a protein with many functions such as being a chaperone 
to facilitate the assembly of multi-protein complexes and aiding in the 
transport of polypeptides across cell membranes or to reach the nucleus. 
Hsp70 was used to assess chaperone mediated autophagy being the 
biomarker  
Monoclonal anti-human AT8 antibody, purchased from Pierce, stains tau 
protein which a microtubule-associated protein that gets 
hyperphosphorylated and results in the pathological neurofibrillary tangles 
that are found in AD brains. 
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Monoclonal anti-human beta-amyloid (clone 6F/3D), purchased from Dako, 
stains deposits of beta-amyloid, found in plaques specific to AD brains. The 
antibody was manufactured to label human beta-amyloid containing the N-
terminal epitope. 
 
Table 2.2 Antibodies for immunohistochemistry. Table of optimal 
antibody dilutions and staining conditions for each antibody 
 
2.2.2 Immunohistochemistry 
 
Using two separate histoclear (National Diagnostics) pots, the brain 
sections were dewaxed, for 5 mins incubation in each solution. The tissue 
followed sequential rehydration in 100%, 100%, 95% and 75% ethanol, for 
5 mins each. Many types of tissue, in particular the brain tissue contains 
endogenous peroxidase. This may result in high, non-specific background 
Primary 
Antibody 
Host 
species 
Cat no Brand Dilution Pre-treatment 
LAMP2A Rabbit Ab18528 Abcam 1:500 H202 in methanol 
LC3 Rabbit PM036 MBL 1:5000 H202 in methanol 
Beclin-1 Mouse Ab114071 Abcam 1:2000 H202 in methanol 
Hsp70/ 
Hsc70 
Mouse W27/sc-24 SantaCruz 
Biotechnology 
1:4000 H202 in methanol 
AT8 Mouse MN1020 Thermo 
Fisher 
1:750 H202 in methanol 
Aβ Mouse M0872 Dako 1:100 H202 in methanol 
and formic acid 
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staining which can be reduced by adding a pre-treatment step. In order to 
block the endogenous peroxidase activity, LAMP2A, AT8 and Aβ sections 
were incubated in 3% H202 (Sigma-Aldrich) in methanol, for 20 mins 
whereas LC3, Hsp70 and Beclin-1 slides which required 1 hour incubation 
in 3% H202 in methanol. Formalin-fixed tissue sections required an antigen 
retrieval step before immunohistochemical staining was performed. The 
reason for this is the formation of methylene bridges during fixation, which 
cross-link proteins and therefore mask antigenic sites. One method of 
antigen retrieval is heat-mediated or heat-induced epitope retrieval. Thus, 
LAMP2A sections were microwaved for 10 minutes, set at 800W, in 0.01M 
Tri-sodium citrate buffer (pH 6.5). LC3, Beclin-1, Hsp70, AT8 and Aβ 
sections required pre-treatment in the Lab Vision™ PT Module (Thermo 
Scientific) which involved a cycle of heating the slides for 20min in 0.01M 
Tri-sodium citrate at 98°C (Scientific Laboratory Supplies) buffer (pH 6.5). 
Aβ required a 4 hour incubation, in 99% formic acid (Scientific Laboratory 
Supplies) to enhance antigen unmasking after heat induced epitope 
retrieval. The incubation was done before the endogenous peroxidase was 
blocked. 
The following step involved blocking non-specific sites on LAMP2A and LC3 
sections by using 1.5% goat normal blocking serum (diluted in Tris-buffered 
saline/TBS), contained in the Vectastain ABC kit (Elite Vectastain rabbit 
ABC kit (Avidin-biotinylated enzyme complex; Elite PK-6102 Rabbit IgG, 
Vector Laboratories), for 30min incubation (LAMP2A) and 1h (LC3) at room 
temperature. Beclin-1, Hsp70, AT8 and Aβ sections were blocked by using 
1.5% (150μl in 10ml) horse normal blocking serum from the Vectastain ABC 
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kit, for 30min (AT8 and Aβ) and 1h (Beclin-1 and Hsp70) at room 
temperature. 
LAMP2A and LC3 antibodies were diluted in 1.5% goat normal blocking 
serum (1:500 antibody dilution and 1:5000, respectively) and incubated for 
1h at room temperature. AT8 and beta-amyloid antibodies were diluted in 
1.5% horse normal blocking serum (1:750 and 1:100, respectively) for 1 
hour at room temperature. Beclin-1 and Hsp70 required overnight primary 
antibody incubation in 1.5% (150μl in 10ml) horse normal blocking serum 
(1:2000 and 1:4000, respectively) at 4°C, in a humid box to avoid 
evaporation. 
After the incubations, sections were washed with TBS-T (Tris-buffered 
saline + 0.1% Tween 20).  A biotinylated anti-rabbit IgG secondary antibody 
(Elite Vectastain ABC rabbit kit) was made up as per manufacturer 
instructions, then applied to the LAMP2A and LC3 sections for 30 mins at 
room temperature. For Beclin-1, Hsp70, AT8 and Aβ, a biotinylated anti-
mouse IgG secondary antibody (Elite Vectastain ABC mouse kit) was 
prepared as per manufacturer instructions, then applied to the sections for 
30 mins at room temperature. Sections were again washed with TBS-T and 
incubated with ABC (Elite Vectastain ABC kit, Avidin-Biotin complex, made 
up as per manufacturer instructions) for 30 mins at room temperature.  
Peroxidase activity was developed for 1 min (LAMP2A, Beclin-1, Hsp70); 4 
mins (LC3); 5 mins (AT8); 6 mins (Aβ) at room temperature with 3,3-
diaminobenzidine (DAB) kit and the reaction was stopped by washing slides 
in tap water for 5 mins.  
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The DAB (3,3-diaminobenzidine DAB ImmPACT™ peroxidase substrate kit 
from Vector Laboratories and DAB tablets from Sigma-Aldrich) developing 
times were decided after the positive controls for each staining were 
monitored under the light microscope to observe the positive staining 
(brown colouration) and when there was sufficient staining (to avoid 
overexposure) , the reaction was stopped, leading to the optimal chosen 
time for each antibody. Haematoxylin (Vector Laboratories) counterstain 
was applied for 2-3 seconds with the being excess rinsed off with tap water 
for 2-3 mins. Lastly, sections were dehydrated in 75%, 95%, 100% and 
100% ethanol, 5 mins each, followed by 5 mins incubation in a clearing 
histoclear. Sections were mounted in DPX mounting media (Sigma-Aldrich) 
to be further analysed under the light microscope. 
 
2.2.3 Microscopy analysis 
 
Leica AirLab software was used from a tablet connected to a Leica ICC50W 
Wi-Fi Camera attached to Leica Microscope DM500. 100x and 400x 
magnifications were used to capture the autophagy markers staining and 
the AD pathological features in all sections. 
All sections were scored, based on the region with most intense staining 
(one field within the region of interest), on a semi-quantitative scale, for 
positive staining in both grey and white matter, using 0-3 scale and + 
scoring system as previously described (Lace et al, 2009). Stained sections 
were scored according to the number of cells stained positive (0=no cells 
stained; 1=<20% cells stained; 2=21-69% cells stained; 3=70-100% cells 
stained). Also, the cells were scored according to the intensity of the 
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staining (0=no staining present; +=mild/pale brown colour; ++=moderate 
brown colour; +++=severe, intense colour) (Figure 2.1). Positive controls for 
AT8 and Aβ antibodies were chosen based on high Braak. Other positive 
controls for LAMP2A, LC3, Beclin-1 and Hsp70 antibodies were chosen 
based on low Braak stage since these should demonstrate minimal 
disruption to autophagy pathways and previous studies have suggested that 
these markers are present in a normal brain. All negative controls involved 
implementing the immunohistochemistry staining protocols described above 
in absence of the primary antibody incubations. 
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Sections within the hippocampus region of 4 cases which were scored 
according to the number of the cells stained: 0=no staining (A); +=mild (B); 
++ moderate (C); +++ severe (D); Magnification: 100x (A) and 400x (B-D); 
Scale bars 50μm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Scoring scheme of immunohistochemistry 
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Figure 2.2 Immunohistochemical scores areas. Diagram illustrating 
the areas of choice by which the scoring was targeted A) in the 
hippocampus and B) in the frontal/occipital cortices (Layers I-VI).  
WM=white matter; CA=cornu ammonis; DG=dentate gyrus; 
S=subiculum; MEC=medial entorhinal cortex; LEC=lateral entorhinal 
cortex.  
 
A 
B 
73 
 
In the hippocampus, the scored areas comprised chosen fields of view with 
the highest staining levels (most intense staining) for each subregion 
including DG, CA4, CA3, CA2, CA1 and the subiculum as indicated in 
Figure 2.2. LEC (lateral entorhinal cortex) and MEC (medial entorhinal 
cortex) layers were also scored, along with the temporal cortex (TC) and the 
white matter (WM) regions (figure 2.2). The chosen regions are known to 
have different pathological involvement in AD with disease progression 
mentioned in section 1.2. A separate region, the CA1/Subiculum border was 
scored independently, due to slightly different pathology as previously 
described (Lace et al., 2009). Also, the subpial region within the entorhinal 
cortex was take into consideration for astrocytic positivity, being given 
scores of 0 (negative staining) and 1 (positive staining). 
Glial cells morphologies were identified in the AT8 stained sections (Figure 
2.3). Various morphologies of astrocytes were seen in the hippocampus 
sections, including thorn-shaped astrocytes, fuzzy astrocytes with fine 
granular processes, ramified astrocytes, stellate astrocytes and globular 
astroglial inclusions. Microglia and coiled bodies were also seen in the brain 
sections (Figure 2.3). An in-depth analysis of various AT8 lesions 
(Supplementary figures 1–4) and autophagy markers could be explored in 
the future. 
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Figure 2.3 Glial cells morphologies stained by AT8 antibody. 
Tufted astrocyte in the TC (A); thorn-shaped astrocyte in TC (B); 
fuzzy astrocyte with fine granular processes in TC (C); ramified 
astrocyte in MEC (D); stellate astrocyte in CA1 (E); globular 
astroglial inclusion (F); microglial cell in CA4 (G) and coiled body in 
the hippocampal WM (H); Magnification 100X; Scale bars 50μm. 
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For further analysis, all scores of 0, 1, 2 and 3 were dichotomized into two 
groups: significant pathology (all scores of 2-moderate and 3-severe) and 
minor pathology (all scores of 0-none and 1-mild).  
All 45 cases were scored, for each key biomarker. A random selection of 
10% of the cases were scored by an independent scorer (Dr Gemma Lace-
Costigan) in order to check reliability. Inter-rater agreement was tested 
using Cohen’s kappa to compare the scores in the three brain regions–for 
each marker used for staining–from the two observers. A high level of 
agreement was found (kappa=0.94), with respect to all six antibodies used 
for the staining. 
 
 
2.3 Double labelling immunofluorescence staining 
 
Similarly to the conventional immunohistochemistry, the brain sections were 
firstly dewaxed by immersion into histoclear pots for 10 mins, followed by 
sequencial rehydration in 100%, 100%, 95% and 75% ethanol, for 5 mins 
each. Then, the brain sections required antigen retrieval by heat in the PT 
module (Thermo Scientific), for a 20 mins cycle at 98°C. After this step, 
three washes of 10 mins each with 100mM glycine buffer were introduced 
to reduce the non-specific staining due to autofluorescence of the brain 
tissue. For amplified results and a better signal of the staining, an avidin-
biotin complex was selected. The avidin-biotin complex (ABC) is a highly 
sensitive method for immunohistochemical detection with biotinylated 
secondary antibodies. Avidin is a 65kDa protein, found in the egg whites of 
birds, reptiles and amphibians which shows strong affinity for biotin, a water 
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soluble vitamin (vitamin B7 or vitamin H) having four biotin binding sites 
which makes the interaction ideal for detection of antibodies. The avidin-
biotin complex is one of the strongest non-covalent interaction between a 
protein and a ligand as they bind really quickly to each other and do not 
seem to get affected by changes in temperature or pH or by other organic 
solvents. 
Prior to the avidin and biotin incubations, several extra steps were required 
including a 15 mins incubation with egg white (containing casein) in ddH20, 
followed by a 15mins incubation in 2% skimmed milk in PBS buffer, both 
steps at RT. The avidin and biotin blocking steps were included to saturate 
any available avidin and biotin binding sites, exposed and potentially being 
able to generate false positive results. All sections were blocked, using 
1.5% horse normal blocking serum from the Vectastain ABC kit, for 30min 
at room temperature. The sections were then incubated with primary rabbit 
antibodies against LAMP2A (1:500) and LC3 (1:1000) for 1 hour at RT 
followed by washes with PBS buffer. Biotinylated secondary antibody from 
the rabbit Vectastain ABC kit was used to incubate the sections for 30mins 
at RT. After three washes with PBS buffer, avidin-Red Texas dye conjugate 
(Sigma,-Aldrich) was applied to all the sections in the dark, for 30mins at RT 
followed by an additional blocking step with horse serum for 30mins at RT. 
The second primary antibody, mouse monoclonal AT8, was then applied on 
the sections (1:750) for 1h at RT, followed by a 30mins incubation with 
biotinylated secondary antibody from the mouse Vectastain ABC kit. 
Sections were then incubated with avidin-green dye conjugate (Thermo 
Scientific) for 30mins at RT, away from the sunlight. An additional step for 
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further non-specific staining reduction due to autofluorescence was 
required, thus 0.1% Sudan Black B reagent (Abcam) diluted in 70% ethanol 
was used to incubate all the sections for 30 minutes, which were then 
washed with PBS and mounted with aqueous ProLong Antifade mounting 
media (Thermo Fisher) (no dehydration required).  
Zeiss Zen Software in correlation with a multi-headed Carl Zeiss 
microscope allowed computer controlled image capturing for the double 
labelling studies. Magnifications used included 200x and 400x.   
Five cases from each Braak group (Braak 0-II, n=5; Braak III-IV, n=5; and 
Braak V-VI, n=5) were randomly selected and double-stained for each 
marker LC3 (n=15) and LAMP2A (n=15). Therefore, a total of 15 sections 
were stained against LAMP2A and a total of 15 sections were stained 
against LC3. Images were captured in each CA4 and CA1 subregions for 
each individual case. After capturing, the red and the green channel images 
(of each region/case) were merged in order to assess the protein 
expression of the autophagy markers and the co-localisation with AD 
related tau protein. Five random fields of view from the chosen regions CA4 
and CA1 were selected and mean values for autophagy marker vs AD 
protein were obtained. Individual cells within the selected fields of view were 
then analysed to explore the MA and CMA markers levels (red channel) and 
the tau protein levels across all three Braak stage groups and the same cell 
area was kept for the two channels to reduce variability among the results. 
For accuracy, five selections of background with no fluorescence were 
selected around each cell that was analysed to give final corrected total cell 
fluorescence (CTCF) values. LAMP2A, LC3 and AT8 positive cells, in both 
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subregions CA4 and CA1, were then quantified, in all cases, in order to 
assess the co-localisation of the two autophagy markers and tau protein. 
The degree of co-localisation was then explored with increasing Braak 
staging to assess its variation with disease progression. 
 
2.4 Statistical analysis 
 
Statistical analysis was initially performed on GraphPad software (Inc., San 
Diego, CA, USA) or on SPSS 22/24 software. Chi-square test was 
performed to evaluate the variation in MA and CMA markers across Braak 
stage groups and the regional variation of LAMP2A, LC3, Beclin-1, Hsp70, 
AT8 and beta-amyloid across all hippocampal subregions.  This test was 
also used to assess the relationship between the autophagy positively 
stained astrocytes and oligodendrocytes across the different Braak stages 
in order to explore glial autophagy changes at different stages of disease.  
CA4 and CA1 were chosen as regions of interest as CA4 is associated with 
tau/beta-amyloid in late stages of AD and CA1 is associated with tau/beta-
amyloid in early stages of AD. Chi-square test explored if different 
autophagy markers varied across various pathologies including astrocytes 
and NTh. Chi-square test also assessed autophagy markers positively 
stained lesions such as the axons, neurophil threads, vacuoles and 
intracellular inclusions across Braak stages. Chi-square tests were also 
used to assess the co-localisation of the two autophagy markers with AT8 
marker with Braak staging and to evaluate the variation between CA4 and 
CA1 staining of LAMP2A and LC3 as well as AT8 in individual neurons of 
the hippocampal subregions.  
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2.5 Human skin-derived fibroblasts 
 
 
2.5.1 Cells 
 
Commercially available fibroblasts were purchased from NHCDR and 
Coriell Cell Biorepositories. The cells purchased from Coriell were found 
within NIA (National Institute of Aging) Aging Cell Culture repository 
catalogue and all details can be found at https://www.coriell.org/. Skin-
derived fibroblasts were collected from arm/calf from patients with sporadic 
AD (no known family history) and familial AD (FAD) with PSEN mutations 
and age-matched controls. Skin-derived fibroblasts were cultured and 
characterized by Coriell before shipping. Cells from nine individual cases: 
three from sporadic AD cases, three from familial AD cases and three age-
matched controls, were used in this study.  
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Table 2.3 Skin-derived fibroblasts used in this study 
 Coriell catalog ID Age Gender 
Controls ND35044 77 male 
 ND36320 71 female 
 ND29178 66 male 
Sporadic AD AG09019 76 female 
 AG07375B 71 male 
 AG08517 66 female 
Familial AD AG08711 34 female 
 AG06840 56 male 
 AG06848 56 female 
 
 
2.5.2 Growth conditions in vitro 
 
The fibroblasts were grown in until passage 14 in T75 flasks, at 37°C, 5% 
CO2 and 21% O2 and fed with MEM w/ Earle’s Salts media (Labtech), 
supplemented with penicillin/streptomycin (Labtech), 200mM L-glutamine 
(Thermo Fisher), 20% foetal bovine serum (Scientific Laboratory Supplies), 
10% non-essential amino acids and 10% vitamins (Scientific Laboratory 
Supplies). Media changes were performed every 2-3 days until cells 
reached 70-80% confluency (Figure 2.8).  
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2.5.3 Cell trypsinization 
 
Once the cells reached 70-80% confluency (Figure 2.4), they were 
subcultured by trypsinization, using 0.25% trypsin/EDTA (Scientific 
Laboratory Supplies), for 2-3 mins at 37°C. Trypsinization was stopped by 
addition of 3-4 fold volume of FBS containing media, followed by 
centrifugation for 4 mins at 400xg to obtain a pellet of the cells. The pellet 
was washed twice in sterile PBS before being resuspended in fresh media 
for passaging at a ratio of 1:3. Alternatively trypsinized cell may have been 
harvested for freezing by resuspending the collected pellet in sterile 
freezing buffer (10 % DMSO in FBS-Pierce) and rapid transfer to a Mr 
Frosty (Thermo Scientific) in a -80 freezer for 24-48hrs. Cells were then 
transferred to liquid nitrogen for long term storage.  
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Fibroblasts confluency. Fibroblasts confluent at 
approximately 30-40% in the flask (left) and at over 70%, being ready 
to be split (right). Magnification 400x. Scale bar 100 μm 
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2.5.4 Protein extraction 
 
Cells were grown until passage 14 and experiments were performed on cell 
lysates from passages 10–12. Protein extraction was performed at each 
passage for all control and AD cells, by trypsinization (as previously 
described in 2.5.3), followed by centrifugation for 4 mins at 400xg to obtain 
a pellet and lastly, additional washes of the pellet with sterile PBS, to wash 
away the media (as previously described in 2.5.3). Once the pellet was 
clean, 150µl radioimmunoprecipitation assay buffer (RIPA) (Thermo 
Scientific), supplemented with Halt™ Protease and Phosphatase Inhibitor 
Cocktail (Thermo Scientific) was added to lyse the cells, while gently 
pipetting up and down, on ice. This allowed cell membranes lysis and 
exposure of the cellular content, which protected proteins from degradation 
during the extraction process.   
 
2.6 Western blotting 
 
2.6.1 Bradford assay 
 
Known concentrations of bovine serum albumin (BSA, Thermo Scientific) 
were used to generate a standard curve to determine unknown protein 
concentration in the cell homogenates by Bradford assay. This assay is a 
commonly used method, a colorimetric protein method of determining the 
concentration in a solution using the Commassie blue absorbance 
properties. Under acidic conditions, the initial form of Commassie blue 
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which is red/brown becomes blue by binding to the proteins that are being 
assaye (Butt, 2013). 
For each cell lysate sample, 2.5µl of protein lysate of unknown 
concentration (section 2.5.4) was mixed with 997.5µl dH20 to make up an 
end volume of 1000µl. 100µl from each sample was added to a 96 well 
plate with equal volumes of Commassie blue reagent (Thermo Scientific).  
MultiSkan FC plate reader was used to read the absorbance values of the 
Bradford samples, at 595nm wavelength, giving values for both unknown 
samples and known concentration standards, which were then used to plot 
a standard curve. The linear equation y=ax+b of the standard curve was 
used to establish the concentration of unknown protein samples and the 
results were adjusted depending on the dilution factors used. 
 
2.6.2 Homogenates preparation 
 
Prior to running the proteins through the gel, the homogenates were treated 
with active sample buffer (SB) which was prepared by adding 200µl 
dithiothreitol (DTT, Scientific Laboratory Supplies) to 800µl 2xSample buffer 
(100mM Tris-HCl pH 6.8, 4% SDS, 0.02% bromophenol blue (purchased 
from Scientific Laboratory Supplies), 20% glycerol (Scientific Laboratory 
Supplies). DTT is a denaturing agent and its role is to break down the 
disulphide bonds between protein-protein. SDS is a denaturing anionic 
detergent that converts the folded form of proteins into linear chains of 
amino acids, giving them a negative charge. This is because the linearized 
proteins need an even charge as they have to separate based on their size 
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only, migrating from the negative electrode to the positive electrode. The 
glycerol gives enough density to the samples so they sink, while 
bromophenol blue is a tracking dye enabling the sample loading in the wells 
as well as checking how far the proteins have travelled through the gel, 
before the electric current is stopped.  
Samples were then boiled in equal volumes of active 2x sample buffer for 5 
mins to help further unfolding of the proteins and bring them to their primary 
structure. Samples were centrifuged for 15s in a bench top microcentrifuge 
and stored at -20°C until ready to use for Western blotting. 
 
2.6.3 SDS polyacrylamide gel electrophoresis 
 
The first experiments aimed to optimise LC3 (Novus), LAMP2A (Abcam), 
Beclin-1 (Abcam) and Hsp70/Hsc70 (Santa Cruz Biotechnology) antibodies 
using the cell homogenates from the skin-derived fibroblasts. A 12% SDS 
optimal gel was chosen for LC3 antibody (Table 2.4) as LC3 protein’s 
molecular weight is 15-17kDa, being found in two forms: 15kDa cytosolic 
(LC3I) and 17kDa membrane bound (LC3II). This means, the LC3 bands 
would be captured 3/4 down the gel to avoid it being ‘pushed’ off the end of 
the gel during electrophoresis.  The resolving gel was firstly made, which is 
2/3 of the total length gel, by adding distilled water, 30% polyacrylamide, 
1.5M Tris pH 8.8, 10% SDS, 10% ammonium persulfate (APS-purchased 
from National Diagnostics) and TEMED.  Gel polymerization is initiated by 
APS and TEMED, forming cross-links between acrylamide molecules that 
result in pores of specific size, depending on the acrylamide amount used. 
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Then, the stacking gel was made by adding distilled water, 30% 
polyacrylamide (Sigma), 0.5M Tris pH 6.8, 10% SDS, 10% APS and 
TEMED (Sigma). The SDS-PAGE gel uses two types of layers which have 
different functions. The stacking gel is more acidic and has a pH of 6.6, 
packing and concentrating the proteins together in one band and being 
ready to move towards the positive electrode. Then, the migration of the 
proteins continues in the resolving gel, which has a higher pH of 8.6, where 
pores get smaller, therefore proteins in the samples are able to separate 
according to their size into bands of specific molecular weights. Similarly to 
12% gel for LC3 antibody, a 7.5% gel was used to optimise LAMP2A 
(105kDa), Beclin-1 (60kDa) and Hsp70 (70kDa) antibodies (Table 2.4) as 
these proteins have higher molecular weights, thus their size is bigger 
needing a lower polyacrylamide % of the gel. 
SDS gel electrophoresis and protein transfer were performed using mini-
PROTEAN Tetra Cell System attached to a PowerPac HC Power supply by 
Bio-Rad. The nine samples (3 controls and 6 AD samples) were loaded in 
lanes 2-10 of the gel at 0.2A per gel and constant 150V, with 10µl of the 
hyperladder (molecular weight marker, Thermo Scientific) loaded in lane 1. 
All wells were balanced with 1x SB to ensure equal volumes. 10X 
electrolyte buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) was used to fill 
up the electrophoresis tank which was placed on a tray filled with ice to 
keep the temperature low. The gel was then run for 1h 30 mins (LAMP2A, 
Hsp70 and Beclin-1) and for 1h 45min (LC3) to allow differentiation of the 
two LC3 bands (Table 2.4). Once the running finished, the gel was washed 
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in cold (4°C) transfer buffer (25 mM Tris base, 192 mM glycine, 20% 
methanol) for 15min on a shaker to remove any excess electrolyte buffer. 
 
 
2.6.4 Wet transfer of the proteins 
 
The proteins in the gel were then transferred to a nitrocellulose membrane 
(Sigma) in cold transfer buffer (4°C). The Biorad Trans-Blot system was 
used for 1h at 100V to perform the transfer. Then, the membrane was 
washed in TBS-T for 3 x 10min to remove the transfer buffer.  
 
2.6.5 Immunostaining of autophagy markers 
 
The membranes were blocked in 1% BSA with 5% (Marvel) skimmed 
powdered milk made up in TBS-T, for 30 min (Hsp70 and Beclin-1) and for 
1h (LAMP2A, LC3) at room temperature, on a rocker (Table 2.4), followed 
by incubation with primary antibody diluted into blocking solution, 1:3000 
(LC3 antibody); 1:1000 (LAMP2A, Beclin-1 and Hsp70) for 1h at room 
temperature (Table 2.4). The membranes were rinsed in TBS-T for 3 x 
10min and blocked for a second time in the same blocking solution for 30 
mins at room temperature, on a rocker. After blocking step, membranes 
were incubated with secondary antibodies. LC3 and LAMP2A membranes 
were incubated with secondary goat anti-mouse HRP conjugated antibody 
(Goat pAb to Rb IgG; Abcam) diluted into blocking solution, 1:5000 for 
30min at room temperature, while Beclin-1 and Hsp70 membranes were 
incubated in goat anti-mouse secondary antibody (Abcam), diluted in 
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blocking solution 1:5000, for 30 mins, at room temperature. Lastly, the 
membranes were washed in TBS-T for 5 x 10min.  
 
2.6.6 Enhanced chemiluminescence 
 
The Thermo Scientific ECL kit (SuperSignal West Femto Maximum 
Sensitivity Substrate; as per manufacturer instructions) was used to 
visualize the proteins in a G: Box Chemi XX6 (Syngene). Software G: Box 
Chemi XX6 GeneSys was used to capture images at exposure times 5 sec 
(LAMP2A), 10 sec (Hsp70), 1 min (Beclin-1) and 3mins (LC3) (Table 2.4). 
 
Table 2.4 Optimal conditions of Western blotting experiments. These 
conditions were chosen for the four antibodies LAMP2A, Hsp70, LC3 and 
Beclin-1 to give the best bands resolution with minimal non-specific staining 
and background. 
 
Experimental condition LAMP2A Hsp70 LC3 Beclin-1 
Protein concentration (μg) 20 10 20 10 
Gel % 7.5 7.5 12 7.5 
Gel running time 1h30min 1h30min 1h45min 1h30min 
Blocking incubation time 1h 30min 1h 30min 
Primary antibody incubation 1:1000 1:1000 1:3000 1:1000 
Exposure time 5 sec 10 sec 3 mins 1 min 
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2.6.7 Stripping and reprobing for beta-actin (loading control) 
 
Membranes were washed 3 x for 10min in TBS-T and incubated in stripping 
buffer (62.5mM Tris HCl, pH 2.2, 0.1% SDS, 1% Tween20) for 10 min at 
room temperature to remove the previously used antibodies from the 
membrane. The membranes were then incubated in blocking solution 1% 
BSA and 5% skimmed milk made up in TBS-T, for 30min at room 
temperature. Primary antibody monoclonal mouse beta-actin (Thermo 
Fisher) was added directly into blocking solution, at a dilution of 1:5000, for 
1h at room temperature, followed by three washes in TBS-T for 3 x 10min 
and blocked again for 30 min. Secondary anti-mouse HRP conjugated 
antibody was added into blocking solution at 1:5000 and incubated for 
30min and washed with TBS-T for 3x 10min. SuperSignal West Femto 
Maximum Sensitivy substrate reagent (Thermo Scientific) were added to the 
membrane to visualise bands as previously described. 
 
2.6.8 Protein quantification and statistical analysis 
 
The protein bands were then quantified by analysis in ImageJ software in 
order to determine a relative protein ratio of each protein of interest 
compared to the loading control beta-actin. Ratios were also corrected to 
the background and for LC3, due to presence of two isoforms, LC3-I and 
LC3-II, each isoform was corrected to beta-actin, then a final ratio LC3-
I/LC3-II was obtained to reflect the autophagic flux rate in the cells.  
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All relative ratios were then plotted on graphs and protein amounts in the 
sporadic AD cells and the mutated AD cells were compared to the protein 
amounts in the control fibroblasts. 
Paired T-test was used to assess the variation of autophagy markers 
expression in the skin-derived fibroblasts between the control cases, 
sporadic cases and PSEN mutated cases. Error bars on graphs represent 
the standard error and statistical significance is denoted by asterisks with p-
values as following: *p<0.05 and **p<0.01. 
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Chapter 3 RESULTS: Autophagy in human brain tissue 
 
 
 
3.1 Immunohistochemistry of human brain tissue 
 
This chapter will explore the variation of staining distribution of autophagy 
markers in the three brain regions – the hippocampus, the frontal cortex and 
the occipital cortex – and will look in-depth at each subregion of these three 
regions to evaluate how autophagy proteins vary across these areas. 
Staining distribution will be assessed based on the number of the cells 
stained positive, as well as based on the immunoreactive intensity at a 
cellular level. These variations will also be investigated in each Braak stage 
group in order to evaluate how they change with disease progression. 
Overall MA and CMA markers staining will then be compared in the three 
brain regions to identify which pathways becomes more susceptible in AD. 
Immunoreactivity of autophagy markers will also be evaluated in axons, 
neuropil threads, intracellular inclusions and glial cells such as 
oligodendrocytes and astrocytes. Overall, in the hippocampus, LAMP2A 
staining levels were found the highest in the subiculum and the entorhinal 
cortex, and the lowest in CA1 and CA3 sugregions. Hsp70 staining levels 
were also found the lowest in CA1 subregions. For MA markers, LC3 and 
Beclin-1, the staining distribution was reduced in DG, CA1 and CA3, and 
was more increased in CA1/S and EC subregions. In the hippocampus, only 
LC3 was found to significantly decrease with advancing AD (p<0.001).  
91 
 
In the frontal cortex, LAMP2A and Hsp70 staining levels were the lowest in 
layers II, IV and VI, and the highest in layers III and V. Very similar results 
were seen for the MA markers, LC3 and Beclin-1. No autophagy marker 
was found to significantly decrease with advancing disease, however, 
Beclin-1 was significantly increased in the high Braak group (p<0.001). 
In the occipital cortex, variation of LAMP2A staining distribution between the 
subcortical layers was less noticeable. Hsp70 staining varied more than 
LAMP2A with increasing levels seen in layer III and decreased levels seen 
in layer IV. Similar distribution of both MA markers were seen in the 
occipital cortex, with layers II and IV having the lowest levels, and layers III 
and IV having the most staining. In this brain region, both Hsp70 and LC3 
were found to significantly decrease with increasing Braak (p=0.02). 
These results were based on both the number of the cells stained and on 
the immunereactive intensity. 
Overall CMA markers were distributed less than MA markers in the 
hippocampus and the occipital cortex, whereas in the frontal cortex, the 
staining levels of CMA markers were more abundant than the MA markers. 
In terms of immunopositivity of autophagy markers in the glial cells, no 
significances were found for CMA proteins, however LC3 positive 
oligodendrocytes were found to significantly increase with advancing AD in 
both the hippocampus and the frontal cortex (p<0.01). On the other hand, 
LC3 positive astroyctes significantly decreased in Braak V-VI (p=0.03). 
Beclin-1 positive oligodendrocytes were also found to increase with 
increasing Braak (p<0.001). 
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Moreover, in the hippocampus, a significant increase with higher Braak 
cases was seen in Beclin-1 positively-stained neurophil threads (p=0.02). In 
the frontal cortex, significant decreases were seen in LAMP2A positively 
stained intracellular inclusions (p=0.002) and in Beclin-1 positively-stained 
axons (p=0.04).  
 
 
3.1.1 Variation of neuronal staining distribution in the hippocampus 
 
The first set of graphs describe the percentage of cases in the cohort with 
any staining (mild, moderate, severe) based on the number of the cells 
stained (0–3 rating scale), for LAMP2A, LC3, Hsp70 and Beclin-1 in each 
hippocampal region (Figure 3.1 and 3.2).  
The majority of cases demonstrated similar degree of staining in the 
hippocampus. Thus, LAMP2A positivity was found in 90% of cases, LC3 in 
80% of cases, Beclin-1 in 94% of cases and Hsp70 positive staining was 
seen in 72% of cases. There was a similar level of positive staining across 
most hippocampal subregions. DG subregion was the only area to present 
less staining for both LC3 and Hsp70 (68% of cases) compared with all 
other hippocampal subregions. 
Beclin-1 staining is the most present in the hippocampus region (Figure 
3.2B, followed by LAMP2A staining (Figure 3.1A), while LC3 (Figure 3.2A) 
and Hsp70 (Figure 3.1B) staining had slightly lower levels of positivity. All 
cases (100%) demonstrated Beclin-1 positivity in the LEC subregion, 
followed by 95% of cases demonstrating staining in CA4, CA1 and CA1/S. 
A total of 93% of cases had Beclin-1 staining in DG, CA3, CA2, S and MEC 
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subregions (Figure 3.2B). LAMP2A positive staining was found in less than 
90% of cases, with CA3 region having the lowest value (84%) (Figure 3.1A).  
LC3 staining levels were found lower compared with LAMP2A and Beclin-1. 
LC3 positivity was found in 68% of cases in DG region, followed by the 
subiculum (72%) (Figure 3.2A). LC3 staining was found in 80% cases in the 
hippocampus, with the most staining found in CA4 (84%) and CA1/S (84%); 
and it was least prevalent in DG (68%). Hsp70 staining was found the 
lowest in the hippocampus (72%) in comparison to other autophagy 
markers.  A mild variation was observed across the hippocampus, when 
looking at Hsp70 staining with 65% cases found positive in LEC, followed 
by 68% in DG (Figure 3.1B). Most subregions had around 70% Hsp70 
positivity, while CA4 and CA2 had the highest prevalence of the marker, 
81% (Figure 3.1B). Overall, DG subregion seemed to have the lowest 
autophagy proteins distribution, followed by CA3. On the other hand, EC 
and CA4 were the areas with the most autophagy marker staining in the 
hippocampal neurons. Based on overall high prevalence of authophagy 
marker staining across the hippocampal regions, it was decided to 
dichotomise the data to allow analysis of cases demonstrating only 
significant staining attaining scores of moderate/severe staining compared 
to minimal/absent staining (both 0–3 and -/+/++/+++ rating scales). 
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Figure 3.1 Chaperone-mediated autophagy markers across the 
hippocampal subregions. LAMP2A (A) and Hsp70 (B) staining, expressed 
in the hippocampal subregions, by the proportion of cases with positive 
staining, according to the number of the cells stained; (0–3 rating scale). 
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The number of cases that demonstrated any staining for the autophagy 
markers did not significantly vary across the cohort, within the hippocampus 
subregions, therefore, for a better understanding of the results, the staining 
scores were dichotomised into two groups: significant staining of autophagy 
markers (scores of 2 and 3) and minimal staining (scores of 0 and 1). 
Graphs were then generated based on the significant scores of autophagy 
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Figure 3.2 Macroautophagy markers across the hippocampal 
subregions. LC3 (A) and Beclin-1 (B) staining, in the hippocampal 
subregions, represented by the proportion of cases with positive staining, 
according to the number of the cells stained; (0–3 rating scale). 
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markers in the hippocampus subregions (2 and 3; ++ and ++), therefore the 
graphs show the percentage of the cases that express each of the four 
autophagy markers (Figure 3.3 and 3.4). Dichotomised data showed a more 
evident variation across the hippocampal subregions when compared with 
the non-dichotomised results (Figure 3.1 and 3.2). Stratification of 
dichotomised results into the three Braak groups demonstrated a degree of 
regional variation in LAMP2A staining, seen in Braak V-VI (Figure 3.3A). 
Staining levels of LAMP2A were found the lowest in CA3 (53%) compared 
with the highest amounts of staining in LEC (92%) and the subiculum 
(100%) (Figure 3.3A). Dichotomised results show that Hsp70 positive 
staining was the lowest in CA1, across all three Braak groups (38%, 40% 
and 23%, respectively); the lowest value was seen in Braak V-VI (Figure 
3.3B). The highest levels of Hsp70 staining were found in MEC (75%) and 
LEC (75%) in Braak 0-II, in CA2 and CA1/S (60%) in Braak III-IV and lastly, 
in CA2-4 (61%) and MEC (61%) in Braak V-VI (Figure 3.3B). 
For the MA markers, the most evident regional variation was observed for 
LC3 staining, in Braak III-IV, with the lowest staining seen in DG (33%), 
followed by the subiculum (40%) compared with the highest staining 
presence in CA2 (80%) (Figure 3.4A). In Braak 0-II, similar levels of staining 
were seen across most hippocampal regions, except DG which scored the 
lowest value of 56% (Figure 3.4A). DG was also found with the lowest level 
of LC3 staining (53%) in Braak V-VI, while CA1/S region had 84% positively 
stained cases (Figure 3.4A).  
Beclin-1 staining demonstrated similar levels of staining across most 
hippocampal regions, with minimal regional variation (Figure 3.4B). 
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Differences were only observed in Braak 0-II as DG had the lowest staining 
levels (63%), compared with LEC (100%); Braak V-VI showing CA1 with the 
lowest Beclin-1 staining (69%), compared to MEC,LEC (92%) (Figure 3.4B).  
These results demonstrated a regional variation of Hsp70 (CMA) and LC3 
(MA) staining across the hippocampal subregions, mostly associated with 
Braak III-IV and Braak V-VI.  
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Figure 3.3 Chaperone-mediated autophagy markers in the hippocampal 
subregions across Braak stages (Braak 0-II, Braak III-IV, Braaak V-VI). 
LAMP2A (A) and Hsp70 (B) significant staining, expressed across the 
hippocampal subregions, represented by the total percentage of all cases 
with dichotomised scores of 1 (significant staining), based on the number of 
the cells stained; (0–3 rating scale). 
A B 
0-II 
III-IV 
V-VI 
0
20
40
60
80
P
er
ce
n
ta
ge
 o
f 
ca
se
s 
w
it
h
 p
o
si
ti
ve
 c
el
ls
 (
%
)
0
20
40
60
80
100
P
er
ce
n
ta
ge
 o
f 
ca
se
s 
w
it
h
 p
o
si
ti
ve
 c
el
ls
 (
%
)
0
20
40
60
80
100
P
er
ce
n
ta
ge
 o
f 
ca
se
s
w
it
h
 p
o
si
ti
ve
 c
el
ls
 (
%
)
0
20
40
60
80
P
er
ce
n
ta
ge
 o
f 
ca
se
s 
w
it
h
 p
o
si
ti
ve
 c
el
ls
(%
)
99 
 
0
20
40
60
80
100
P
er
ce
n
ta
ge
 o
f 
ca
se
s 
w
it
h
 p
o
si
ti
ve
 c
el
ls
 (
%
)
 
 
0
20
40
60
80
100
P
er
ce
n
tg
e 
o
f 
ca
se
s 
w
it
h
 
p
o
si
ti
ve
 c
el
ls
 (
%
)
0-II 
III-IV 
V-VI 
A B 
Figure 3.4 Macroautophagy markers in the hippocampal subregions 
across Braak stages (Braak 0-II, Braak III-IV, Braaak V-VI). LC3 (A) and 
Beclin-1 (B) significant staining, expressed across the hippocampal 
subregions, represented by the total percentage of all cases with 
dichotomised scores of 1 (significant staining), based on the number of the 
cells stained; (0–3 rating scale). 
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Following assessment of the number of the cells stained, consideration of 
intensity of staining (-/+/++/+++ rating scale) was performed as described in 
section 2.2.3. All autophagy markers had similar staining across all 
hippocampal regions with no noticeable differences (Figure 3.5 and 3.6). DG 
had the lowest staining levels, seen in Hsp70 (CMA) and LC3 (MA) staining 
present in 68% cases (Figure 3.5B and 3.6A). However, most subregions 
demonstrated positive staining in above 70% of cases. The intensity graphs 
did not depict significant regional variation in the autophagy markers and as a 
result, the staining scores were dichotomised into two groups as previously 
described (-/+ scores in the not significant group and ++/+++ in the significant 
group).   
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Figure 3.5 Chaperone-mediated autophagy markers across the 
hippocampal subregions. LAMP2A (A) and Hsp70 (B) staining, 
expressed in the hippocampal subregions, by the proportion of cases 
with positive staining, based on the cells intensity; (-/+/++/+++ rating 
scale). 
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Figure 3.6 Macroautophagy markers across the hippocampal 
subregions. LC3 (A) and Beclin-1 (B) staining, expressed in the 
hippocampal subregions, by the proportion of cases with positive 
staining, based on the cells intensity; (-/+/++/+++ rating scale). 
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After dichotomisation, based on the staining intensity, a more evident 
regional variation was observed across all hippocampal regions in the 
autophagy markers levels (Figure 3.7 and 3.8). Hsp70 staining variation 
was higher than LAMP2A staining variation across all three Braak groups 
(Figure 3.7 and 3.8). Nevertheless, LAMP2A staining was found the lowest 
in CA3 and CA2 (33%), compared with the highest in CA1/S (73%), 
followed by the subiculum and MEC (66%) in Braak 0-II (Figure 3.7A). In 
Braak III-IV, the same subregion, CA2, had the lowest LAMP2A staining 
(60%), whereas all cases demonstrated significant LAMP2A staining 
(100%) (Figure 3.7A). Levels of LAMP2A decreased in CA2, from Braak III-
IV to Braak V-VI (46%), with CA2 being the region with the lowest staining 
levels across all Braak groups (Figure 3.7A). Very low levels of Hsp70 
staining were seen in CA1 subregion in Braak 0-II (6%) and Braak V-VI 
(15%) (Figure 3.7B). Higher levels of Hsp70 staining were observed in the 
subiculum (50%) in Braak 0-II and in CA4 and CA2 (54%) in Braak V-VI 
(Figure 3.7B).  In Braak III-IV, Hsp70 staining was found the lowest in CA3 
(13%), compared with the highest staining in CA2 (53%) (Figure 3.7B). 
There was also a regional variation in both MA markers across all Braak 
groups (Figure 3.8). LC3 staining was found the lowest in CA3 (26%), 
compared with CA1/S (80%) in Braak 0-II (Figure 3.8A). In Braak III-IV, LC3 
positive staining was only found in 13% of cases in the subiculum and CA1 
compared with 46% in CA1/S, whereas in high Braak, LC3 staining was the 
lowest in LEC (23%) and the highest in CA2 (61%) (Figure 3.8A). Beclin-1 
staining was found very low in DG (6%), compared with CA1/S (60%) in 
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Braak 0-II (Figure 3.8B). In Braak III-IV, Beclin-1 staining was present in 
26% in LEC compared with 73% in CA4, whereas in high Braak, LC3 
staining was the lowest in CA1 (30%) and the highest in CA1/S (77%) 
(Figure 3.8B). These results demonstrated a regional variation of all 
autophagy markers staining across the hippocampal subregions, in all 
Braak groups. 
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Figure 3.7 Chaperone mediated autophagy markers in the hippocampal 
subregions across Braak stages (Braak 0-II, Braak III-IV, Braaak V-VI). 
LAMP2A (A) and Hsp70 (B) significant staining, expressed across the 
hippocampal subregions, represented by the total percentage of all cases with 
dichotomised scores of 1 (significant staining), based on the cells intensity; 
(-/+/++/+++ rating scale). 
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Figure 3.8 Macroautophagy autophagy markers in the hippocampal 
subregions across Braak stages (Braak 0-II, Braak III-IV, Braaak V-VI). 
LC3 (A) and Beclin-1 (B) significant staining, expressed across the 
hippocampal subregions, represented by the total percentage of all cases 
with dichotomised scores of 1 (significant staining), based on the cells 
intensity; (-/+/++/+++). 
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Next, we looked at the overall moderate/severe staining of MA and CMA 
autophagy markers in the hippocampus to explore how the markers 
distribution change with disease progression (scores of 2 and 3 considered; 
0-3 rating scale). LC3 staining levels were found to decrease significantly in 
Braak III-IV cases (Figure 3.9).  
Hippocampal cells stained by LC3 were present in 78% of the cases in 
Braak 0-II, dropping to 53% in Braak III-IV and an increase in high Braak 
(68%) (Chi square test, p<0.001) (Figure 3.9 and 3.10). Hsp70 
hippocampus levels showed a slower decline rate, with no statistical 
significance, from 63% in low Braak, to 51% and 53%, respectively, in late 
stages of the disease (Chi square test, p=0.09) (Figure 3.9 and 3.10). 
Beclin-1 and LAMP2A staining was similar across the Braak stages, being 
present in the majority of the cases (Chi square test, p=0.7 and p=0.13, 
respectively) (Figure 3.9).  
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Figure 3.9 Autophagy markers staining across all Braak stages in 
the hippocampus. Scores were based on the number of the cells 
stained; (0–3 rating scale); *p<0.05  
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Figure 3.10 Immunohistochemical representation of all autophagy 
markers distribution across all Braak stages in the hippocampus. 
Hsp70 and LC3 markers demonstrated a decrease of staining in Braak 
III-IV and Braak V-VI, whereas LAMP2A and Beclin-1 were abundant 
across all Braak groups. Magnification 100x; Scale bars represent μm.  
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3.1.2 Variation of neuronal staining distribution in the frontal cortex 
 
Next, the study aimed to explore if autophagy marker distribution varied in 
the different cells of the frontal cortex, an area of the brain that gets affected 
in later stages of disease (Scahill, 2002). Therefore, positive intracellular 
staining of the four autophagy markers was scored and assessed. 
A high number of cases were stained by LAMP2A (83%), LC3 (67%), 
Hsp70 (90%) and Beclin-1 (82%). Similar levels of staining were reported 
across all subcortical layers of the frontal cortex with no significant variation 
(Figure 3.11).  As previously described, based on the high prevalence of 
staining across the layers in the frontal cortex, the data was dichotomised to 
allow analysis of cases demonstrating significant staining attaining scores of 
moderate/severe staining (2/3 in the 0-3 rating scale; ++/+++ in the -
/+/++/+++ rating scale) compared with minimal or absent staining (0/1 in the 
0-3 rating scale; -/+ in the -/+/++/++ rating scale ). 
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Figure 3.11 MA and CMA markers staining across the frontal 
cortex layers. LAMP2A (A), Hsp70 (B), LC3 (C) and Beclin-1 (D) 
staining across the frontal cortex subcortical layers. Bar charts 
represent the proportion of cases based on the number of the cells 
stained; (0–3 rating scale). 
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Moderate/severe scores (2/3 in the 0-3 rating scale; ++/+++ in the -/+/++/+++ 
rating scale) were used to illustrate the variation in the distribution of autophagy 
markers across different subcortical layers of the frontal cortex.  
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Overall, there was a minimal variation of CMA markers across the frontal cortex 
layers, with similar staining levels in each layer. Layers II and IV had slightly 
lower staining than layers III and V, which have the highest staining levels 
(Figure 3.12). In Braak 0-II, LAMP2A distribution was found the lowest in layer 
IV (70%), compared with the highest in layer V (94%). Hsp70 staining varied 
less across the layers, presenting the lowest staining seen in layer II (70%) 
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Figure 3.12A). In both Braak III-IV and Braak V-VI groups, LAMP2A was found 
the lowest in layer IV and II (60%) and the highest in layer III and V (84% and 
86%, respectively) (Figure 3.12A). A more evident variation of Hsp70 positive 
staining was seen with increasing Braak staging, therefore the lowest staining, 
in Braak III-IV, was found in 66% cases (layer IV) compared with 93% cases 
(layers III and V) (Figure 3.12B). Similarly, Hsp70 staining was reported the 
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lowest in 46% cases (layer VI) compared with 77% cases (layer III) (Figure 
3.12B).  Neuronal staining varied more for the MA markers, across all Braak 
stages. Beclin-1 staining levels were found quite similar across all layers, in 
Braak 0-II (Figure 3.13B). However, in Braak 0-III, LC3 staining was found the 
lowest in layer IV (23%) and the highest in layer V (58%) (Figure 3.13A). 
Distribution of LC3 decreased with increasing Braak, resulting in only 13% 
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cases with positive staining (Braak III-IV) (Layers II, IV and VI), compared with 
46% cases in Layer III (Figure 3.13A). Interestingly, Beclin-1 exhibited a higher 
degree of variation in Braak III-IV, with the lowest staining level in layer IV 
(13%) and the highest in layer III (73%) (Figure3.13B). In high Braak, Beclin-1 
staining was reported the lowest staining in layer IV (53%) and the highest in 
layer III, with all cases demonstrating Beclin-1 positivity (100%) (Figure 3.13B). 
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Figure 3.12 Chaperone-mediated autophagy markers in the frontal cortex 
subcortical layers across Braak stages (Braak 0-II, Braak III-IV, Braaak V-
VI). LAMP2A (A) and Hsp70 (B) significant staining, expressed across the 
layers. Bar charts represent the total percentage of all cases with 
dichotomised scores of 1 (significant staining), based on the number of the 
cells stained; (0–3 rating scale). 
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These results demonstrated a regional variation in MA markers staining, as well 
as Hsp70 (in mid and high Braak groups) across the frontal cortex cellular 
layers. 
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Figure 3.13 Macroautophagy markers in the frontal cortex subcortical 
layers across Braak stages (Braak 0-II, Braak III-IV, Braaak V-VI). LC3 
(A) and Beclin-1 (B) significant staining, expressed across the layers. Bar 
charts represent the total percentage of all cases with dichotomised scores 
of 1 (significant staining), based on the number of the cells stained; (0–3 
rating scale). 
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Following assessment of the number of the cells stained (0-3 rating scale), 
intensity of staining was assesed in the frontal cortex, as described in section 
2.2.3. Significant staining (++/+++) of CMA markers across Braak stages 
demonstrated minimal variation across the layers in this brain region (Figure 
3.14). The only variance seen in LAMP2A staining was found in Braak V-VI, as 
the CMA marker was present in 38% cases (layer II) when compared to 54% 
cases (layers III-VI) (Figure 3.14A). Variation of Hsp70 staining across the 
subcortical layers increased with increasing Braak staging. The variation was 
the most noticeable in Braak V-VI, with the lowest staining in layer VI (46%) and 
the highest in layer III (84%) (Fogure 3.14B). The frontal cortex layers 
demonstrated an evident variation in LC3 staining across all Braak stages 
(Figure 3.15A). In Braak 0-II, LC3 staining was found the lowest in layer IV 
(23%) and the highest in layer V (58%), whereas in Braak III-IV, LC3 distribution 
dropped to 13% in layers II, IV and VI and to 46% in layer III (Figure 3.15A). 
Very similar to Braak 0-II, LC3 staining in Braak V-VI was seen in 23% cases in 
layer IV and in 54% in layer III (Figure 3.15A). Beclin-1 staining demonstrated 
some variation between layers II (53%) and layer III (41%) when compared with 
the rest of the layers (above 80%), with minimal variation in Braak III-IV (Figure 
3.13B). Interestingly, in Braak V-VI, Beclin-1 staining was seen in only 30% 
cases in layer III and in all cases (100%) in layer VI (Figure 3.15B). 
These results demonstrate that, although the degree of variation is not as high 
as seen in the hippocampus, MA markers in the frontal cortex were found in 
various amounts across the subcortical layers layers of this brain regions. Also, 
LAMP2A, LC3 and Beclin-1 markers staining decreased with increasing Braak. 
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Figure 3.14 Chaperone-mediated autophagy markers in the frontal 
cortex subcortical layers across Braak stages (Braak 0-II, Braak III-IV, 
Braaak V-VI). LAMP2A (A) and Hsp70 (B) significant staining, expressed 
across the layers. Bar charts represent the total percentage of all cases with 
dichotomised scores of 1 (significant staining), based on the intensity of the 
cells stained; (-/+/++/+++ rating scale). 
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Figure 3.15 Macroautophagy markers in the frontal cortex subcortical 
layers across Braak stages (Braak 0-II, Braak III-IV, Braaak V-VI). LC3 (A) 
and Beclin-1 (B) significant staining, expressed across the layers. Bar charts 
represent the total percentage of all cases with dichotomised scores of 1 
(significant staining), based on the intensity of the cells stained; (-/+/++/+++ 
rating scale). 
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We, then, investigated the overall moderate/severe (scores of 2/3; 0-3 rating 
scale) staining of MA and CMA autophagy markers in the frontal cortex to 
explore how the markers distribution change with disease progression. Beclin-
1 staining was found to increase significantly between the three Braak groups 
(Figure 3.16).  
LAMP2A staining was reported in 48% cases in Braak 0-II, decreasing to 42% 
in both Braak III-IV and Braak V-VI with no statistical significance (Chi square 
test, p=0.48) (Figure 3.16). Also, Hsp70 staining demonstrated a decline from 
Braak 0-II (50%) to Braak III-IV (47%) and to Braak V-VI (41%) with no 
statistical significance (Chi square test, p=0.35) (Figure 3.16). Both LC3 and 
Beclin-1 markers distribution decreased from Braak 0-II (25% and 36%) to 
Braak III-IV (13%, and 25%), however the staining was found to increase 
significantly in Braak V-VI to 18% (LC3) and 56%, respectively (Chi square 
test, p=0.05 and p<0.001) (Figure 3.16).  
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Figure 3.16 Autophagy markers staining across all Braak stages in 
the frontal cortex. Scores were based on the number of the cells stained; 
(0–3 rating scale); ***p<0.001 
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Figure 3.17 Immunohistochemical representation of all autophagy 
markers distribution across all Braak stages in the frontal cortex. 
LAMP2A, Hsp70 and LC3 demonstrated a decrease of staining in the 
frontal cortex layers across the Braak stages whereas Beclin-1 
increased from Braak 0–II to Braak V-VI. Magnification 100x; Scale 
bars represent 100 μm. 
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3.1.3 Variation of staining distribution in the occipital cortex 
 
The next aim was to explore if there was variation in autophagy marker 
distribution across the cell layers of the occipital cortex. This brain region did not 
exhibit a high degree of regional variation in LAMP2A, Hsp70 and Beclin-1 
staining across all subcortical layers, however there was some variation for LC3 
marker (Figure 3.18). Therefore, positive intracellular staining of the four 
autophagy markers was scored and assessed.  
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Figure 3.18 MA and CMA markers staining across the 
occipital cortex layers. LAMP2A (A), Hsp70 (B), LC3 (C) 
and Beclin-1 (D) staining based on the number of the cells 
stained; (0–3 rating scale). 
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As previously described, all occipital cortex scores were also dichotomised into 
significant staining (2/3 in the 0-3 rating scale) and minimal/absent staining (0/1 
in the 0-3 rating scale), based on the number of the cells stained by all 
autophagy markers. Overall, the results suggested a lower amount of 
autophagy markers staining compared with the other brain regions, the 
hippocampus and the frontal cortex. The majority of cases were stained by 
Beclin-1 (91%), also demonstrating similar levels of staining across all 
subcortical layers (Figure 3.18D). LAMP2A (75%) and Hsp70 (56%) had no 
variation across the layers (Figure 3.18A and 3.18B), except LC3 staining (51%) 
which exhibited some variation (Figure 3.18C).  
After data was dichotomised, regional variations were seen in Braak III-IV 
(LAMP2A, Hsp70, LC3 markers staining) and in Braak 0-II (LAMP2A, LC3 
staining) (Figure 3.19 and 3.20). Beclin-1 staining had similar levels of staining 
across all cellular layers, except in Braak V-VI, where the lowest staining was 
found layers II and IV (61%) compared with layer II (84%) (Figure 3.20B). In 
Braak 0-II, LC3 staining varied from 23% (layer II) to 53% (layer V), whereas in 
Braak III-IV, the lowest staining was seen in layer IV (33%) and the highest 
staining was seen in layers III and V (53%) (Figure 3.20A). The lowest LAMP2A 
staining in both Braak 0-II and Braak III-IV was reported in layer II (32% and 
35%, respectively) and the highest LAMP2A staining was detected in layer V 
(58% and 53%, respectively) (Figure 3.19A). Hsp70 only varied in Braak III-IV, 
with the highest marker distribution seen in layer III (67%), compared with layer 
IV (33%) (Figure 3.19B). Overall, Hsp70 and LC3 markers were reported to 
significantly decrease with increasing Braak staging.  
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Figure 3.19  Chaperone-mediated autophagy markers in the occipital 
cortex subcortical layers across Braak stages. LAMP2A (A) and Hsp70 (B) 
significant staining, expressed across the layers. Bar charts represent the total 
percentage of all cases with dichotomised scores of 1 (significant staining), 
based on the number of the cells stained; (0–3 rating scale). 
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Figure 3.20 Macroautophagy markers in the occipital cortex subcortical 
layers across Braak stages. LC3 (A) and Beclin-1 (B) significant staining, 
expressed across the layers. Bar charts represent the total percentage of all 
cases with dichotomised scores of 1 (significant staining), based on the number 
of the cells stained; (0–3 rating scale). 
III-IV
 
0-II 
A B 
128 
 
As previously described, the intensity of positive staining was assesed using 
the occipital cortex scores. There was no regional variation of LAMP2A 
staining in the occipital cortex, with similar levels seen across the layers 
(Figure 3.21A). Moderate/severe (++/++ scores) Hsp70 staining was absent in 
all layers in Braak 0-II, Braak III-IV and in layer II in Braak V-VI (Figure 3.21B).  
Despite the very low levels of staining seen in Braak V-VI, there was no 
regional variation across layers III-VI (Figure 3.21B). LC3 staining varied 
across the layers in all Braak groups, with the lowest levels in layers II and IV 
and the highest levels in layers III, V, VI (Figure 3.22A). Similar patterns were 
seen in Beclin-1 staining, with variation in Braak III-IV and Braak V-VI (Figure 
3.22B).  
Overall, these results demonstrate minimal regional variation compared with 
the results associated with the other two brain regions. 
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Figure 3.21 Chaperone-mediated autophagy markers in the occipital 
cortex subcortical layers across Braak stages. LAMP2A (A) and Hsp70 
(B) significant staining, expressed across the layers. No significant Hsp70 
staining seen in Braak 0-II and Braak III-IV groups. Bar charts represent the 
total percentage of all cases with dichotomised scores of 1 (significant 
staining), based on the intensity of the cells stained; (-/+/++/+++ rating 
scale). 
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Figure 3.22 Macroautophagy markers in the occipital cortex subcortical 
layers across Braak stages. LC3 (A) and Beclin-1 (B) significant staining, 
expressed across the layers. Bar charts represent the total percentage of all 
cases with dichotomised scores of 1 (significant staining), based on the 
intensity of the cells stained; (-/+/++/+++ rating scale). 
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We then analysed the overall moderate/severe staining (scores of 2/3; 0-3 
rating scale) of MA and CMA autophagy markers in the occipital cortex. The 
staining levels of LC3 and Hsp70 were found to significantly decrease with 
advancing Braak staging (Figure 3.23).  
In the occipital cortex, LAMP2A staining had a linear increase, being present 
in 27% cases in Braak 0-II and in 40% cases in Braak V-VI (Chi square test, 
p=0.07). All other autophagy markers were found to linearly decrease across 
the three Braak stages (Figure 3.23). Therefore, Beclin-1 declined from 54% in 
early stages by 45% in mid and late stages with no statistical significance (Chi 
square test, p=0.05), while both Hsp70 and LC3 followed similar decreasing 
trends, from approximately 25% in Braak 0-II and Braak III-IV to around 10% 
in late stages (Chi square test, p=0.02) (Figure 3.23).  
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Figure 3.23 Autophagy markers staining across all Braak stages in the 
occipital cortex. Scores were based on the number of the cells stained; 
(0–3 rating scale); *p<0.05 
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Figure 3.24 Immunohistochemical representation of all autophagy 
markers distribution across all Braak stages in the occipital cortex. 
Hsp70, LC3 and Beclin-1 markers were found to decrease with increasing 
Braak stage whereas LAMP2A was found to increase in Braak V-VI. 
Magnification 100x; Scale bars in A-F represent 100 μm. 
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3.1.4 Comparison of MA and CMA 
 
Next, we segregated the overall autophagy scores into MA and CMA staining 
to allow comparison of MA and CMA preference in each brain region 
assessed. In the hippocampus, the total CMA marker levels (moderate/severe 
staining of both LAMP2A and Hsp70 proteins) were 11% lower than the total 
MA marker levels (moderate/severe staining of both LC3 and Beclin-1 
proteins) (Figure 3.25). In the frontal cortex, CMA overall staining was reported 
to be 41% higher when compared with MA expression (Figure 3.25). Similar to 
the hippocampus, in the occipital cortex, the total CMA expression levels were 
22% lower than the total MA levels (Figure 3.25).  
Therefore, these results suggest that the hippocampus had a similar 
distribution of MA and CMA markers (77% and 70%, respectively) whereas in 
the frontal cortex, CMA staining (68%) was more predominant when compared 
with MA staining (40%) and in the occipital cortex, MA staining (51%) was 
higher than CMA staining(40%) (Figure 3.25).  
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3.1.5 Regional comparison of autophagy marker distribution across all Braak 
groups 
 
A generalised regional comparison of autophagy markers distribution between 
all three brain regions: the hippocampus, the frontal and the occipital cortex 
was generated by collecting all moderate/severe scores in each Braak group. 
There is a noticeable variation in the overall autophagy markers staining 
between the three brain regions. Overall, all markers were decreased in the 
frontal and the occipital cortex when compared to the hippocampus in all 
Braak stages (Figure 3.25).    
Hippocampus
MA CMA
LAMP2A 
Hsp70 
LC3 
Occipital cortex
MA CMA
Frontal cortex
MA CMA
Beclin-1 
Figure 3.25 Comparison between MA and CMA. A diagram illustrating 
the proportion of cases with moderate to severe staining of MA proteins 
(LAMP2A and Hsp70) in contrast with CMA proteins (LC3 and Beclin-1) in 
each of the three brain regions. Scores were based on the number of the 
cells stained; (0–3 rating scale). 
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In Braak 0-II, CMA marker levels were similar in the hippocampus and the 
frontal cortex when compared with the occipital cortex (Figure 3.25). 
Therefore, LAMP2A staining was very prevalent in the hippocampus (80%) 
and the frontal cortex (71%), when compared with the lower levels in the 
occipital cortex (40%) (Figure 3.25).  Hsp70 marker had the highest levels in 
the hippocampus (63%) and the frontal cortex (62%) and the lowest in the 
occipital cortex (38%) (Figure 3.25). LC3 distribution pattern between the brain 
regions varied and although the hippocampus identified 93% cases with 
Hsp70, the other two brain regions had a much lower staining of this marker 
(35%) (Figure 3.25). Beclin-1 positivity was reported the highest in the occipital 
cortex (80%), followed by the hippocampus (77%) and the lowest was seen in 
the frontal cortex (50%) (Figure 3.25).  
In Braak III-IV, the occipital cortex was still the brain region with lowest 
LAMP2A and Hsp70 markers staining (43% and 36%, respectively), when 
compared with the other two regions (Figure 3.25). LAMP2A was found in 
higher proportion in the hippocampus (87%) when compared with the frontal 
cortex (63%), whereas Hsp70 staining was more abundant in the frontal cortex 
(71%) rather than the hippocampus (51%) (Figure 3.25). Hippocampal LC3 
staining was found in half of the cases (53%), followed by staining in the 
occipital cell layers (38%) and lastly, the frontal cells presented LC3 staining in 
fewer cases (19%) (Figure 3.25). On the other hand, Beclin-1 stained the 
hippocampal cells in almost all cases (90%), compared to the frontal cortex 
(67%) and the occipital cortex (37%) (Figure 3.25). 
Lastly, in Braak V-VI, the occipital cortex had the lowest staining levels of all 
autophagy markers (Figure 3.25). LAMP2A had similar distribution across both 
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the frontal (61%) and the occipital (59%) cortices, when compared with the 
hippocampus (78%) (Figure 3.25). Hsp70 (19%) and LC3 (14%) marked the 
lowest levels of staining in the occipital cell layers, whereas the other two brain 
regions presented higher proportions (53-87%), suggesting a high degree of 
regional variation between the brain regions (Figure 3.25). Beclin-1 was found 
prevalent in all regions: the hippocampus (87%), the frontal cortex (71%) and 
the occipital cortex (65%) (Figure 3.25). 
Overall, these results suggest that both MA and CMA markers distribution 
exhibit a regional variation between the three brain regions, which get involved 
at different stages of disease. CMA markers, but mostly MA markers were the 
most present in the hippocampus region when compared to the other two 
brain regions. Moreover, the results suggest that the regional variation 
becomes more evident with increasing Braak.  
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Figure 3.26 Comparison of autophagy markers distribution 
across the three brain regions in each Braak group (Braak 0-II, 
Braak III-IV, Braak V-VI). Bar charts represent percentage of 
cases with moderate/severe staining of each autophagy marker 
based on the number of cells stained; (0–3 rating scale).  
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Moreover, to allow a generalised comparison of autophagy markers across the 
Braak groups, each case was given a significant or minimal staining score. This 
meant each case had a single score for each of the three brain regions, 
allowing to understand how each autophagy marker gets involved in each brain 
region across the Braak groups. In other words, each case received either a 
score of 0 (absent/mild staining) or a score of 1 (moderate/severe staining) for 
each autophagy marker in each brain region. Then, the three brain regions 
scores were added up so that each individual case would have either a total 
score of 0 (no brain region significantly stained), a score of 1 (one brain region 
had significant staining), a score of 2 (two brain regions had significant staining) 
or a score of 3 (all three brain regions had significant staining). The total scores 
for regional involvement of each autophagy marker were then represented as 
proportions, suggesting that there was no variation in LAMP2A staining (p=0.9, 
Chi-square test) across Braak stages, whereas variations were seen in the 
other markers staining (Figure 3.27). Hsp70 and LC3 total scores proportion 
showed a decline with increasing Braak groups, suggesting that in mid and late 
stages of disease, the regional involvement of Hsp70 and LC3 in the brain 
regions was reduced. No statistical significance was identified (Figure 3.27) 
(p=0.1 and p=0.5, respectively, Chi-square test). Beclin-1 distribution 
demonstrated a different pattern as the total scores for regional variation 
increased in higher Braak stages, suggesting that Beclin-1 significant brain 
regions in higher Braak groups (p=0.5, Chi-square test) (Figure 3.27).  
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Figure 3.27 Autophagy marker distribution across the Braak groups. 
Bars represent the total score of significant (moderate/severe) staining for 
regional involvement of each marker (A-LAMP2A; B-Hsp70; C-LC3; D-
Beclin-1) across all Braak stages; Scores were based on the number of the 
cells stained; (0–3 rating scale).  
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3.1.6 Axons and neuronal inclusions distribution of autophagy markers 
 
In sections 3.1.1-3.1.5, we described the neuronal staining, which has been the 
main focus when assessing the levels of autophagy marker staining across 
different stages of AD, in the three brain regions. However, other neuronal 
structures within the brain areas were noted to be positively stained by 
LAMP2A, Hsp70, LC3 and Beclin-1 (Figure 3.28). These structures included 
axons, neuropil threads and neuronal inclusions (Figure 3.28). 
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A B 
C D 
Figure 3.28 Distribution of other neuronal structures stained 
by autophagy markers. A- LAMP2A positivity in the choroid 
plexus epithelium; B-axonal staining; C-intracellular inclusions 
within CA4 neurons; D-presence of vacuoles in positively CA4 
pyramidal stained cells; E- Intracellular and extracellular cluster 
of granules in CA1 cells; F-Neuropil threads. Magnification 100x. 
Scale bar 50 μm  
E F 
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Autophagy markers were assessed in axons, neuropil threads and intracellular 
inclusions in each of the three Braak groups to assess variation in distribution 
with disease progression.  
Overall, LC3 protein expression level in these structures was found the most 
abundant, while LAMP2A expression was found the lowest (Figure 3.29A). The 
axons within the grey matter of the hippocampus were stained by LAMP2A in 
56% of the cases in Braak 0-II, decreasing by 10% in Braak V-VI (Chi-square 
test, p=0.85) (Figure 3.29A). Similarly, LC3 positive axons staining decreased 
across the three stages from 86-87% cases in Braak 0-II and Braak III-IV to 
75% in Braak V-VI (Chi-square test, p=0.54) (Figure 3.29C). For Hsp70 and 
Beclin-1 axonal staining, a increase was observed across the AD stages from 
around 44% cases, in Braak 0-II, expressing both Hsp70 and Beclin-1 proteins 
in the axons of the hippocampal areas, to approximately 70% in Braak V-VI 
(Chi-square test, p=0.12 for both Hsp70 and Beclin-1) (Figure 3.29B and 
3.29D). The neurophil threads (NTh) stained by Hsp70 and Beclin-1 proteins 
increased across the Braak stages, from 25% in Braak 0-II, to 47% in Braak III-
IV and 53% (Hsp70), 58% respectively (Beclin-1) in late stages of AD 
demonstrating a statistically significant association with disease progression 
(Chi-square test, *p=0.02, respectively) (Figure 3.29B and 3.29D). The cases 
with LC3 stained NTh decreased in number, from 56% in Braak 0-II to 33% in 
Braak III-IV (Chi-square test, p=0.11) and increased back to 50% in late stages 
(Figure 3.29C). NTh expressing LAMP2A were found the lowest, decreasing 
from 12% in Braak 0-II to only 6% in Braak III-IV (Chi-square test, p=0.52) 
(Figure 3.29A). Similarly to LC3 stained threads, the number of Nth stained by 
LAMP2A increased back to late stages (15%) (Figure 3.29C). Interestingly, 
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hippocampal LC3 positive cells were found to have the highest presence of 
vacuoles, with around 60% in early and late AD stages and a drop in their 
number (46%) in mid AD stages (Chi-square test, p=0.24) (Figure 3.29C). 
Intracellular inclusions within the hippocampal neurons were also stained by the 
autophagy biomarkers for MA and CMA and a decrease in presence was seen 
across the three stages of AD (Figure 3.29) No significant change in any 
autophagy immunoreactive axons with Braak stage. Only positive Beclin-1 NTh 
was found significantly increased as Braak stage increases (Chi-square test, 
p=0.02). However, no statistically significant differences were seen in the 
autophagy markers positively stained inclusions across the Braak groups (Chi-
square test, p=0.67, p=78, p=0.34, p=0.78).  
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Figure 3.29 Distribution of other neuronal structures stained 
by autophagy markers. (A-LAMP2A; B-Hsp70; C-LC3; D-Beclin-
1) in the hippocampus across the Braak stages *p<0.05,  
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The same structures stained by the autophagy markers, which were seen in the 
hippocampus, were also observed in the frontal cortex (Figure 3.30). Overall, 
Hsp70 marker stained more structures, such as threads, axons and inclusions, 
then the other autophagy marker (Figure 3.30B). LC3 positive structures were 
found two-fold less present in the frontal cortex layers compared with the 
hippocampus (Figure 3.30C). LAMP2A and Beclin-1 positivity within these 
structures were found at similar levels (Figure 3.30A and 3.30D).  
The number of immunoreactive axons, stained by all autophagy markers, 
decreased with increasing Braak stage in a linear trend with the most noticeable 
decline seen with Beclin-1 staining decreasing from 44% (Braak 0-II) to 18% 
(Braak V-VI) (Chi-square test, **p=0.04)  (Figure 3.30D).  
In the frontal cortex, neurophil threads (NTh) were stained by LAMP2A, Hsp70 
and LC3 but not by LC3. LAMP2A and Hsp70 stained threads were found to 
increase in a linear pattern across the Braak stages (Figure 3.30A and 3.30B). 
Therefore, in Braak V-VI, cases with Hsp70 associated threads were twice as 
many seen in Braak 0-II group with a strong association with disease 
progression (Chi-square test, p<0.001). There were no NTh found in the LC3 
positive cases across the Braak stages (Figure 3.30C).  
A total of 17% of the early Braak cases demonstrated LAMP2A positive 
cytoplasmic intracellular inclusions (Chi-square test, p=0.002) (Figure 3.30A), 
however there were no inclusions observed in the mid and late-staged cases. 
Similarly, there were intracellular inclusions in only 6% of the LC3 in the 0-II 
Braak group and they were completely absent in later Braak groups (Figure 
3.30C). A decrease in the frequency of cases with Hsp70 positive intracellular 
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inclusions was observed as well with 23% cases in Braak 0-II demonstrating 
this feature and only 8% in the Braak V-VI group (Figure 3.30B).  
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Figure 3.30 Distribution of other neuronal structures stained 
by autophagy markers. (A-LAMP2A; B-Hsp70; C-LC3; D-Beclin-
1) in the frontal cortex across the Braak stages *p<0.05, 
**p<0.001 
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In order to understand the cellular distribution in more detail of autophagy 
markers, neuronal staining was divided into diffuse staining and granular 
staining (Figure 3.31). Diffuse staining was used to describe staining 
characterized by the even spread of positive stain, dispersed across both the 
cytoplasm or/and the nucleus, with no clear punctate-like structures being 
evident. On the other hand, the granular staining was used to describe non-
uniform and granular (small, punctate inclusions) staining (Figure 3.31).  
 
 
 
 
 
 
 
 
 
 
 
 
No significant changewas seen in the granular staining of the hippocampus for 
any of the autophagy markers. No significant change in the diffuse staining in 
the frontal cortex with any of the autophagy markers, except Hsp70, which was 
found to decrease (Figure 3.32).  
Figure 3.31 Diffuse cellular staining (left) by LAMP2A 
antibody and granular cellular staining (right) by LC3 
antibody in the hippocampus. Magnification 100x; Scale bars 
50 μm 
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Figure 3.32 Diffuse and granular staining. Proportion of cases 
with diffuse and granular staining across the Braak stages in the 
hippocampus (A, B) and in the frontal cortex (C, D). *p<0.05; 
**p<0.01 
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3.1.7 Distribution of autophagy markers in glial cells 
 
Autophagy markers positivity was also found in the glial cells (namely the 
astrocytes and oligodendrocytes, Figure 3.33) of the deep white matter of the 
hippocampus and the frontal cortex and in the subpial region of the 
hippocampus.  
 
 
 
 
 
 
 
 
 
Analysis explored the prevalence of any glial cells positivity (either astrocytes 
or oligodendrocytes) in the hippocampus, the frontal cortex and the occipital 
cortex across the Braak groups. Overall, oligodendrocytes stained by the MA 
and CMA markers were mostly seen in Braak 0-II, decreasing by 33% in Braak 
III-IV and increasing by 25% in Braak V-VI (Figure 3.34A). Looking at 
particular autophagy proteins, the most noticeable oligodendrocytes changes, 
related to progression of AD, were the linear decreases of both CMA proteins, 
from 76% and 69% in early disease stages to 54% and 46%, respectively, in 
late stages with no statistically significant differences (Chi-square test, p=0.24, 
  
Figure 3.33 Glial cells (astrocytes-left and oligodendrocytes-right) 
distribution in the hippocampus. Magnification 400x; Scale bars 50 μm 
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p=0.16) (Figure 3.34A). LC3 positive oligodendrocytes dropped by half from 
early to mid Braak stages, and increased back to 58% in Braak V-VI, 
demonstrating a statistically significant difference (Chi-square test, p=0.007). A 
stronger variation was seen in the Beclin-1 oligodendrocytes, which increased 
in number, being found in almost all cases with severe AD (92%) (Chi-square 
test, p<0.001)  (Figure 3.34A).  
Astrocytes distribution in the hippocampus was very similar in all three stages 
of the disease with maximum 8% difference between Braak 0-II and Braak III-
IV variation (Figure 3.40B). Astrocytes recruiting LAMP2A, Hsp70 and Beclin-1 
were all increasing with AD progression, in particular in Braak III-IV with 
LAMP2A astrocytes being present in almost all cases (92%) (Figure 3.34B). 
On the other hand, glial cells stained by LC3 protein decreased from 50% in 
Braak 0-II, to 33% in Braak III-IV and 41% in Braak V-VI (Figure 3.34B). No 
statistically significant differences were observed in the positively stained 
astrocytes with increasing Braak staging. 
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Figure 3.34 Distribution of oligodendrocytes (A) and astrocytes (B) 
across the Braak groups in the hippocampus **p<0.05, ***p<0.001 
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In the frontal cortex, no significant difference in either astrocytes or 
oligodendrocytes expression autophagy markers was found, except a 
significant decrease in LC3 in oligodendrocytes as Braak stage increases. 
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Figure 3.35 Distribution of astrocytes (A) and oligodendrocytes (B) 
across the Braak groups in the frontal cortex *p<0.05 
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In the occipital cortex, no significant difference in either astrocytes or 
oligodendrocytes expression autophagy markers was found, except a 
significant decrease in LC3 in astrocytes as Braak stage increases. 
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Figure 3.36 Distribution of astrocytes (A) and oligodendrocytes 
(B) across the Braak groups in the occipital cortex *p<0.05 
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3.1.8 Autophagy markers vs tau and β-amyloid pathology 
 
 
In the previous sections of Chapter 3, the staining of all four autophagy markers 
has been assessed in relation to variation in the three brain regions assessed, 
in relation to Braak stage, with respect to the type of neuronal staining (diffuse, 
granular) and  its presence in other interesting structures and glial cells. 
In this section, MA and CMA related protein staining will be assessed in relation 
to AT8 positive structures and β-amyloid plaques to allow an exploration of how 
autophagy markers relate to abnormal protein accumulation.  
As previously mentioned in section 3.1.5, each case was given a significant or 
minimal staining score. This meant each case had a single score for each of the 
three brain regions, therefore receiving either a score of 0 (absent/mild staining) 
or a score of 1 (moderate/severe staining) for each autophagy marker in each 
brain region. Similarly, AT8 staining scores were dichotomised into minimal and 
significant staining and each case received a single score of 0 or 1 for each 
brain region. Then, for each brain region, the single score of each autophagy 
marker was compared to the AT8 single score in each individual case.  
First, the hippocampus was assessed and Chi-square tests were done to 
explore the relationship between significant staining of each autophagy marker 
and significant AT8 pathology in each Braak group, allowing the understanding 
of the relationship between the autophagy markers and AT8 pathology and how 
it varies with disease progression. Statistical analysis demonstrated a significant 
negative association of LAMP2A, LC3 and Beclin-1 markers to AT8 pathology in 
Braak 0-II groups (p=0.01, p=0.03, p=0.006, Chi-square test). In the frontal 
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cortex, significant associations were also found in Braak 0-II groups. In this 
brain region, stronger associations were identified between the CMA markers 
LAMP2A and Hsp70 when compared with AT8 marker (p<0.001; p<0.001, Chi-
square test) whereas MA markers LC3 and Beclin-1 demonstrated less strong 
associations with AT8 staining (p=0.02, p=0.01, Chi-square test). All these 
associations between the increased immoreactive profile of the autophagy 
markers and the minimal AD pathology were found negative. Interestingly, LC3 
and AT8 demonstrated a significant positive association in Braak III-IV (p=0.01, 
Chi-square test). In the occipital cortex, the only significant positive association 
seen in Braak 0-II group was found between Beclin-1 and AT8 (p<0.001, Chi-
square test). Braak III-IV positive associations were seen when LAMP2A and 
LC3 significant scores were compared with significant AT8 (p=0.001, p=0.006, 
Chi-square test). The occipital cortex was the only brain region in which 
negative significant associations were found in the Braak V-VI group when 
Hsp70 (p=0.02, Chi-square test) and LC3 (p=0.009, Chi-square test) were 
related to AT8 significant staining.  
Chi-square tests were also performed to assess the relationship between the 
autophagy markers staining and β-amyloid pathology, based on the 
dichotomised scores which were given to each case in each brain region. 
Stronger variations were more predominant in the brain regions when 
autophagy marker staining was related to β-amyloid pathology. In the 
hippocampus, LAMP2A was found to be negatively associated with β-amyloid 
pathology in all Braak groups (p=0.03, p=0.03, p<0.001, Chi-square test) 
whereas Hsp70 negative association to β-amyloid was found significant only in 
Braak 0-II stage (p<0.001, Chi-square test). The relationship between LC3 and 
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β-amyloid staining was also statistically significant in Braak 0-II (p<0.001, Chi-
square test) and Braak III-IV (p=0.03, Chi-square test) and was found negative. 
In the frontal cortex, significant associations were identified in Braak 0-II for all 
autophagy markers LAMP2A, Hsp70, LC3, Beclin-1 (p<0.001, 0<0.001, p=0.02, 
p=0.01, Chi-square test). Lastly, the occipital cortex was the brain region with 
the most predominant variation between the autophagy markers staining and β-
amyloid staining. The relationship of both CMA markers to pathological β-
amyloid demonstrated a statistically significant relationship in Braak 0-II stages 
(p=0.001, p=0.01, Chi-square test), which was found negative. Significance of 
relationship between MA marker LC3 and β-amyloid was identified in Braak 0-II 
(p=0.001, Chi-square test) and Braak V-VI (p=0.02, Chi-square test), whereas 
Beclin-1 significant staining was strongly associated with β-amyloid in Braak 0-II 
(p<0.001, Chi-square test) and in Braak III-IV (p=0.001, Chi-square test). All 
associations were negative. 
These results demonstrate that the majority of the associations between all 
autophagy markers when compared with tau and β-amyloid pathologies are 
negative, meaning that they follow opposite trends. Also, the stronger the 
association, the higher the variation in scores between the autophagy marker 
staining and the AT8 and β-amyloid staining. Also, there were more variations 
between autophagy markers and AT8 pathology in the frontal and the occipital 
cortices, rather than in the hippocampus. In addition, both the relationships of 
autophagy markers staining with AT8 staining and with β-amyloid staining 
varied the most in the occipital cortex. 
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3.2 Immunofluorescence double labelling of human brain tissue 
 
Previous research has demonstrated that CA1 is an early site of abnormal 
protein accumulation in AD, whereas CA4 only becomes affected in late 
stages of disease (Braak et al, 1991; Lace et al, 2009; Serrano-Pozo, 
2011). Therefore, CA4 and CA1 subregions were explored in detail to allow 
investigation of how autophagy markers are dissembled in regions 
differently affected in disease. In section 3.1.1, we showed the regional 
variation of all four autophagy markers staining and found that overall 
staining levels were lower in CA1 compared with CA4 (Figures 3.37 and 
3.38). In this section, we will look at individual neurons within CA4 and CA1, 
to assess the co-localization degree of LC3 and LAMP2A autophagy 
markers with pathological tau protein.   
 
 
  
Beclin-1 LC3 Hsp70 LAMP2A
Q 
CA4 
CA1 
Figure 3.37 Immunohistochemical staining of all autophagy markers in 
hippocampal subregions CA4 and CA1. Magnification 100x. Scale bar 100 
μm 
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In section 3.1.1, we looked at the autophagy markers stained in CA4 and CA1 
(both 0-3 rating scale and -/+/++/+++ rating scale), in relationship to all other 
hippocampal subregions, however, in this section, we only looked at the number 
of the cells stained in CA4 and CA1. An overall decrease in the number of the 
cells stained by Hsp70, LC3 and Beclin-1 was observed in CA1, compared to 
CA4 (Figure 3.38A). Significant Hsp70 staining was found in 69% cases in CA4, 
compared to 38% in CA1 in Braak 0-II and in 50% cases in CA4, compared to 
38% in CA1 in Braak III-IV (Figure 3.38A). In high Braak, half of the cases had 
significant Hsp70 staining (50%) in CA4 and only 19% cases presented staining 
in CA1 region (Figure 3.38A). LC3 staining was also found to differ between the 
two regions with lower levels of staining in CA1 when compared to CA4. The 
variation of LC3 staining, seen in Braak III-IV group, which was found in 63% 
cases (CA4) and 44% cases (CA1), is more evident than the variation seen in 
Braak V-VI, where LC3 is seen in 63% (CA4) and 50% (CA1) (Figure 3.38A). 
Beclin-1 staining varied only in Braak V-VI, being present in 75% cases (CA4) 
and 56% (CA1) (Figure 3.38A). An overall decrease was also found in the 
intensity of cellular staining of all autophagy markers, observed in CA1 when 
compared to CA4 (Figure 3.38B). LC3 staining was found variable between the 
two regions in all three Braak groups, with the most noticeable variation in 
Braak V-VI, present in 44% cases (CA4) and 25% (CA1) (Figure 3.38B). 
LAMP2A and Beclin-1 staining demonstrated a variation between CA4 and CA1 
in both Braak III-IV and Braak V-VI groups, however most significant differences 
were seen in Braak III-IV for both markers. LAMP2 staining was found in a very 
high number of 94% cases in CA4 compared to 63% cases in CA1, whereas 
Beclin-1 was seen in 67% cases in CA4 and 31% cases in CA1 (Figure 3.38B). 
160 
 
Significant variation of Hsp70 was also reported in Braak 0-II and Braak V-VI 
groups with very low levels seen in CA1: 6% respectively 13% cases presenting 
Hsp70 (Figure 3.38B). Therefore, these results suggest a variation between 
CA4 and CA1 hippocampal regions across all Braak groups (Figure 3.38). 
Besides the variation of staining between CA4 and CA1, a decrease in the 
number of the cells stained by all autophagy markers was reported with 
increasing Braak stages in both CA4 and CA1 (Figure 3.38B). Moderate/severe 
LAMP2A and LC3 decreased from being present in 81% cases (Braak (0-II) to 
63% cases (Braak V-VI) in CA4. Also, LC3 staining decreased from 75% to 
50% in CA1 (Figure 3.38). Beclin-1 staining, which was present in almost all 
cases in both subregions, declined to 75% in CA4 and to 56% in CA1 (Figure 
3.38A). 
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Figure 3.38 Autophagy protein levels in CA4 and CA1. Levels of MA and 
CMA markers staining in the hippocampal regions of interest, CA4 and CA1, 
across all Braak groups. Bar charts express percentage of cases with moderate 
and severe staining, based on the number of the cells stained (A) and on the 
cells intensity (B). *p<0.05 
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To assess if autophagy markers co-localize with intracellular accumulation of 
abnormal tau protein, the double-labelling immunofluorescence technique was 
used (Figure 3.39). LAMP2A and LC3 markers were selected for use because 
they demonstrated the least background staining. Aditionally, LC3 was 
previously shown to be largely associated with granular staining in the 
hippocampus (Figure 3.32) whereas LAMP2A was similar across different 
Braak stages. 
For the double-labelling staining, tau protein was chosen rather than beta-
amyloid in order to explore its relationship to autophagy markers in individual 
neurons. In section 3.1, autophagy marker distribution was assessed based on 
cellular staining and tau protein is known to be found intracellularly rather than 
extracellularly like beta-amyloid, which would link tau better to the autophagy 
markers investigation in this study.  There are also studies which explore beta-
amyloid burden in the frontal cortex and one study on AD mice suggests a 
neuronal loss in 10 months old APP/PS1K1 mice compared to 2 month old 
APP/PS1K1 mice, while the amyloid-plaque load in old mice was found low 
(Lemmens, 2011). Therefore, tau pathology is considered to be more relevant 
to the autophagy impairment, hence choosing tau protein for the double-
labelling studies.  
The expression levels of the proteins of interest were analysed in individual 
cells in both CA4 and CA1 hippocampal subregions across all Braak stages, 
since there are areas to be known differentially affected at each stage of 
disease. 
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The images below represent co-localisation of the autophagy markers LAMP2A 
and LC3 with pathological AT8 marker through double-labelling staining AT8 in 
the hippocampal subregions CA4 and CA1 (Figure 3.40-45).  
These images suggest that in Braak 0-II and Braak III-IV, all AT8 positive cells 
were also LAMP2A positive (Figure 3.40 and 3.41), therefore the two markers 
co-localize, whereas in Braak V-VI, many AT8 positive cells were LAMP2A 
negative (Figure 3.42). The images also suggest that in Braak 0-II, all AT8 
positive cells were also LC3 positive and that many LC3 positive cells were AT8 
negative (Figure 3.43). In Braak III-IV and Braak V-VI, all LC3 positive cells 
were also AT8 positive and many AT8 positive cells were observed to be LC3 
negative (Figure 3.44, 3.45). 
Negative ctrl 
Red channel 
Green channel 
Figure 3.39 Optimisation of double-labelling technique A) Negative control 
in the red channel; B) Positive control-red channel (LC3 antibody); C) Negative 
control in the green channel and D) Positive control-green channel (AT8 
antibody). 
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We then looked at all cases stained (LAMP2A, n=15; LC3, n=15) and quantified 
all LAMP2A/LC3 positive cells and all AT8 positive cells in both CA4 and CA1, 
assessed the co-localisation LAMP2A-AT8 and LC3-AT8 (meaning when 
LAMP2A/LC3 co-localized with AT8) and expressed them as percentage 
(LAMP2A/LC3 % to AT8 positive staining) to assess how co-localisation varied 
with disease progression in both CA4 and CA1 (Figure 3.40). The results 
demonstrated that in CA1, co-localisation of LAMP2A with AT8 decreased 
significantly in Braak V-VI (p<0.001, Chi-square test), whereas in CA4, the 
increase, which was seen only in Braak III-IV was not found to be significant 
(p=0.2, Chi-square test). On the other hand, co-localisation of LC3 with AT8, in 
both CA1 and CA4, decreased drastically from being present in almost all cases 
in Braak 0-II to being present in only half of the cases (p<0.001, p<0.001, Chi-
square test).  
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Figure 3.40 Co-localisation of autophagy markers 
LAMP2A/LC3 with AT8 in individual neurons of hippocampal 
subregions CA4 and CA1; **p<0.001 
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Figure 3.42 Double-immunofluorescent labelling of hippocampal CA4 
and CA1 with LAMP2A (red) and AT8 (green) in a Braak III-IV case. These 
images suggest that all AT8 positive cells are also LAMP2A positive (arrow); 
images captured at 400x magnification; scale bar 50μm. 
CA4 
CA1 
CA4 
CA1 
LAMP2A AT8 Merged 
LAMP2A AT8 Merged 
Figure 3.41 Double-immunofluorescent labelling of hippocampal CA4 
and CA1 with LAMP2A (red) and AT8 (green) in a Braak 0-II case. These 
images suggest that all AT8 positive cells are also LAMP2A positive (arrow); 
images captured at 400x magnification; scale bar 50μm. 
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CA4 
CA1 
CA4 
CA1 
LAMP2A AT8 Merged 
LC3 AT8 Merged 
Figure 3.41 Double-immunofluorescent labelling of hippocampal CA4 and 
CA1 with LAMP2A (red) and AT8 (green) in high Braak V-VI. These images 
suggest that many AT8 positive cells are LAMP2A negative (star); images 
captured at 400x magnification; scale bar 50μm. 
Figure 3.42 Double-immunofluorescent labelling of hippocampal CA4 and 
CA1 with LC3 (red) and AT8 (green) in low Braak 0-II. These images suggest 
that all AT8 positive cells are also LC3 positive cells (arrow) and that many LC3 
positive cells are AT8 negative (star); images captured at 400x magnification; 
scale bar 50μm. 
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CA4 
CA1 
LC3 
AT8 
Merged 
Figure 3.44 Double-immunofluorescent labelling of hippocampal CA4 
and CA1 with LC3 (red) and AT8 (green) in Braak V-VI. These images 
suggest that all LC3 positive cells are also AT8 positive cells and that many 
AT8 positive cells are LC3 negative; images captured at 400x magnification; 
scale bar 50μm. 
 
LC3 
AT8 
Merged 
CA4 
CA1 
Figure 3.43  Double-immunofluorescent labelling of hippocampal CA4 
and CA1 with LC3 (red) and AT8 (green) in mid Braak III-IV. These images 
suggest that all LC3 positive cells are also AT8 positive cells (arrow) and that 
some AT8 positive cells are LC3 negative (star); images captured at 400x 
magnification; scale bar 50μm. 
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3.3 Western-blot analysis of skin-derived fibroblasts 
 
 
Studies using skin-derived fibroblasts (as described in section 1.5.2) 
suggest that they may be a potentially useful model of neurodegenerative 
disease, particularly to use in throughput screening assays which are used 
to assess the efficacy of new drug therapies. As described in section 
1.5.5, previous research has reported the genetic and protein expression 
profile in AD skin derived fibroblasts and studies have shown same of the 
cellular changes in brain cells are also evident in AD skin-derived 
fibroblast (Citron et al., 1994, Magini et al., 2010, Ramamoorthy et al., 
2012; Mocali, 2014). However, it is unclear if changes in autophagy 
markers can be detected in these cells.  
In this chapter, MA and CMA biomarker levels were explored in AD skin 
fibroblasts and in comparison to normal skin fibroblasts of individuals of 
same age (age matched controls). After cells have been successfully 
grown in vitro, proteins were extracted and assessed via Western Blotting. 
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3.4 Optimisation 
 
For each antibody, experiments aimed to optimize the gel percentage, 
amount of protein loaded, blocking method, primary antibody dilution and 
optimal temperature (Figure 3.47-53). The optimal gel percentage was 
chosen to capture the bands of interest such as the two LC3 bands. 
(Figure 3.47) 
 
 
 
 
 
 
 
 
For each antibody, a range of protein concentrations were loaded (10μg, 
15μg and 20μg). An example is shown in Figure 3.48, where LAMP2A 
bands demonstrated poor signal when 10μg were loaded on the gel while, 
20μg of protein loaded, showed better results (Figure 3.48). 
 
 
 
C AD 
15kDa- 
10kDa- 
10kDa- 
15kDa- 
AD C MW 
Figure 3.47 Example of optimisation by trying different gel 
percentages: 12% (top) and 15% (bottom) on LC3 antibody. 
MW=molecular weight ladder, C=control fibroblast, AD=disease fibroblast 
LC3 (12%) 
LC3 (15%) 
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Some antibodies (LAMP2A, Hsp70 and LC3) blotting resulted in noisy 
background due to non-specific binding to the membrane (Figure 3.49A) and 
this was resolved by adding 5% non-fat dry milk and 1% BSA to the blocking 
solution (Figure 3.49B). 
 
 
 
 
 
 
 
 
 
 
42kDa- 
70kDa- 
70kDa- 
PSEN
1 
AD  C
  
42kDa- 
105kDa- 
105kDa- 
Figure 3.48 Example of optimisation. Various protein concentrations 
were tested in order to achieve better intensity for optimal bands 
resolution. After loading 10μg of protein, LAMP2A bands showed poor 
signal (top), while 20μg of protein seemed to improve the resolution of the 
bands (bottom). C-control fibroblasts, AD-disease fibroblasts. 
10 μg  
20 μg  
LAMP2A  
LAMP2A  
C
  
AD  
Beta-actin  
Hsp70  
Beta-actin  
Hsp70  
Figure 3.49 Example of optimisation of the 
blocking method. A) Before treatment and B) 
After treatment 
A 
B 
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Also, some antibodies expressed multiple non-specific bands on the 
membrane (Figure 3.50A). One example was LAMP2A optimisation to 
reduce the multiple bands to one single specific band at 105kDa by 
increasing the blocking time from 30min to 1h (Figure 3.50B). 
 
 
 
 
 
 
 
 
Another important step of the optimisation was to choose the optimal 
antibody dilution for each protein of interest, in order to give the best 
staining of the protein with minimum background and after incubation 
with a series of experimental dilutions of the antibodies (1:500, 1:1000) 
(Figure 3.51), the optimal dilution for each antibody was as follows: 
LAMP2A (1:1000), LC3 (1:3000), Beclin-1 (1:1000) and Hsp70 (1:1000).  
 
 
 
 
105kDa- 
105kDa- 
AD  C
  
Figure 3.50 Example of optimisation. A) Presence of multiple non-
specific LAMP2A bands and B) One specific LAMP2A band after 
increased blocking time. 
B 
A 
LAMP2A  
LAMP2A  
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Figure 3.51 Example of antibody dilution optimisation. The image shows 
LAMP2A optimisation: A) 1:500 and B) 1:1000. C-control fibroblasts, AD-
disease fibroblasts, PSEN1-mutated fibroblasts 
 
Due to lab temperature variability during the experimental studies, blotting 
bands demonstrated poor resolution therefore optimisation included 
antibody incubation temperature control. When performing a Western 
blotting, environmental factors are crucial and in this case, a constant 
temperature was kept to give consistent results. Before optimisation, gels 
were run at room temperature which varied each day, giving poorly 
resolved bands, either fuzzy, dispersed or fragmented bands (Figure 
3.52). Therefore, all gels were run at 4°C, in the cold room, followed by the 
transfer of the proteins onto the membrane at the same temperature. 
 
 
 
 
 
 
 
 
42kDa- 
60kDa- 
105kDa- 
AD  C
  
105kDa- 
105kDa- 
PSEN1  AD  C
  
LAMP2A  
LAMP2A  
Figure 3.52 Example of optimisation of temperature control.  
A) Fragmented or fuzzy bands due to variability of room 
temperature and B)   Compact bands due to constant temperature 
LAMP2A  
Beclin-1  
Beta-actin  
A 
B 
B 
A 
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Lastly, the final step for achieving the best staining results was by 
choosing the optimal exposure time, after reading the membranes in the 
G-box. Subsequential exposure times starting from a few seconds up to a 
maximum of 10 mins have been tried on all antibodies and an example is 
seen below (Figure 3.53), where a 5 mins exposure of the LC3 bands 
demonstrated better results (optimal intensity) than a 3 mins exposure. 
 
 
 
 
 
 
 
 
Overall, it was found that the optimal protein concentration was 15μg for 
Hsp70 and Beclin-1 and 20μg for LAMP2A and LC3, respectively (Table 
2.4). Also, the optimal gel percentages were 7.5% (LAMP2A, Hsp70 and 
Beclin-1) and 12% (LC3) (Table 2.4). The blocking solution made of 1% 
BSA and 5% milk in TBS-T required optimal times of 30 mins (Hsp70, 
Beclin-1) and 1h (LAMP2A, LC3) (Table 2.4). The gel running time 
required 1h30 mins (LAMP2A, Hsp70 and Beclin-1) and 1h (LC3) to allow 
differentiation of the two LC3 bands (Table 2.4). The best antibody 
17/15kDa- 
17/15kDa- 
AD  C
  
LC3  
A 
LC3  
B 
Figure 3.53 Different exposure times of LC3 bands: A) 3 mins and 
B) 5 mins  
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dilutions were found to be 1:1000 (LAMP2A, Hsp70 and Beclin-1) and 
1:3000 (LC3). Lastly, the exposure times chosen were 5 sec (LAMP2A), 
10 sec (Hsp70), 1 min (Beclin-1) and 3mins (LC3) (Table 2.4). 
 
 
3.5 Autophagy markers expression in the fibroblasts 
 
 
After numerous and extensive optimisation experiments, optimal results 
were chosen to represent the autophagy marker levels of expression in 
the skin fibroblasts, grown in vitro. 
Semi-quantification of the levels of all proteins of interest were normalised 
against housekeeping beta-actin, which acted as a loading control. This is 
to minimize variations resulting from experimental errors such as 
inconsistent sample preparation, uneven sample loading on the gel, 
incomplete transfer of the proteins. Nine samples from different patients 
were used in this study comprising of 3 sporadic AD cases (AD1-3), 
genetically mutated AD cases having a mutation in the presenilin gene 
(PSEN1-3) and 3 control cases which represent age matched controls or 
healthy ageing subjects.  
LAMP2A expression was found very low in the fibroblasts derived from 
patients with sporadic AD or from the age matched control subjects 
(Figure 3.58). Although LAMP2A cellular levels were found very low, the 
CMA marker expression in the control cells (C) were relatively the same as 
the expression in the sporadic AD cells with no statistical significant 
difference (p=0.47, paired T-test) (Figure 3.58). In the genetically mutated 
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cells (PSEN), LAMP2A was found much higher when compared to the AD 
sporadic cells or the control cells, with a statistically significant difference 
between the control vs PSEN group, respectively the AD group vs the 
mutated cells group (p=0.006, p=0.0006, paired T-test) (Figure 3.58). 
 
 
 
 
 
 
 
 
 
 
 
 
Overall Hsp70 expression in the control cells is higher by 15% than the 
expression in the sporadic AD cells, with a noticeable lowest expression in 
case AD3 (Figure 3.59). There is no statistically difference between control 
and disease expression of the CMA marker (paired T test, p=0.33). Looking 
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Figure 3.54 LAMP2A relative expression in the fibroblasts. 
LAMP2A expression observed in the sporadic AD group (AD) and in 
the presenilin mutated group (PSEN) compared to LAMP2A 
expression levels in the control group (C) *p<0.05 
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at the levels of Hsp70 expression in the presenilin mutated cells, the levels 
are 24% higher compared to the control levels, however no statistically 
significant difference (Figure 3.59) (paired T test, p=0.17). When comparing 
Hsp70 expression in the sporadic AD cases and the genetically mutated AD 
cases, the mutated genes have by 36% more cellular Hsp70 (paired T test, 
p=0.16). 
 
 
 
 
 
 
 
 
 
 
 
 
LC3-I/LC3-II ratio was the highest in the sporadic AD group when compared 
to both the control group and the PSEN group, with no statistically 
significant difference found (p=0.23, p=0.16, paired T test) (Figure 3.60). 
Also, LC3-I/LC3-II ratio found in the control group was slightly higher than in 
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Figure 3.55 Hsp70 relative expression in the fibroblasts. Hsp70 
expression observed in the sporadic AD group (AD) and in the presenilin 
mutated group (PSEN) compared to Hsp70 expression levels in the 
control group (C). ns=not significant 
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the mutated PSEN cells with no significant difference (p=0.27, paired T test) 
(Figure 3.60). 
 
 
 
 
 
 
 
 
 
 
Beclin-1 overall expression was found the highest in the mutated group 
when compared to the control group, demonstrating a statistically significant 
difference (p=0.04, paired T test) (Figure 3.61)  
Also, the MA marker was found to be more expressed in the sporadic AD 
group when compared to the control group (p=0.1, paired T test) (Figure 
3.61). 
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Figure 3.56 LC3 relative expression in the fibroblasts. LC3 expression 
observed in the sporadic AD group (AD) and in the presenilin mutated 
group (PSEN) compared to LC3 expression levels in the control group (C). 
The LC3 ratio represents the autophagic flux rate of MA; ns=not significant 
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Next, we explored the variability of all autophagy marker expression between 
the three cases of each group (C1-C3 control cases, sporadic AD1-AD3 cases 
and genetically mutated PSEN1-PSEN3 cases) to assess the potential use of 
fibroblasts as a diagnostic tool in the disease (Figure 3.62). The results 
demonstrate that the lowest variability of autophagy marker expression was 
seen between the control cases, whereas a higher degree of variability was 
seen between the AD cases and the PSEN cases (Figure 3.62).  
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Figure 3.57 Beclin-1 relative expression in the fibroblasts.  Beclin-1 
expression observed in the sporadic AD group (AD) and in the presenilin 
mutated group (PSEN) compared to Beclin-1 expression levels in the 
control group (C) *p<0.05 
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Figure 3.58 Autophagy markers expression in each case of the 
three groups. Different variabilities of autophagy marker expression 
between cases of control group (C1-C3), sporadic AD group (AD1-
AD3) and genetically mutated group (PSEN1-PSEN3)  
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These results demonstrate that LAMP2A, Hsp70 and Beclin-1 were the highest 
expressed in the genetically mutated fibroblasts however, there is a high 
variation of the autophagy markers expression between these cases. On the 
other hand, LC3 was the highest expressed in the sporadic AD fibroblasts, 
however there was also an evident variation of LC3 expression between the 
three sporadic cases. The control groups showed the least varied expression of 
the autophagy markers between the control cases, with low levels of Hsp70 and 
LC3 and very low levels of LAMP2A and Beclin-1 in the control cells.  
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Chapter 4 Discussion 
 
 
4.1 General discussion 
 
Regional variation 
The aim of this project was to explore variations in autophagy-related 
proteins in AD, with consideration of regional changes, variation with 
respect to different stages of disease and relationship to AD associated 
abnormal proteins such as tau protein. The following section will consider 
and explore the implications of this study results and how this relates to 
the current field of AD research. 
LC3 and Hsp70 markers decreased with increasing Braak, in all brain 
regions, suggesting that there might be evidence of autophagy activity 
declining in the presence of more AD pathology. It is interesting to explore 
if this is potentially a cause or a consequence of build-up of abnormal 
proteins in AD. There is a lot of evidence based on research studies that 
links impairments of autophagy to neurodegenerative disorders such as 
AD, PD or ALS resulting in failure of abnormal proteins clearance and this 
has been previously described in detail in section 1.4 (Nixon, 2005; Nikon, 
2007; Pickford, 2008; Son, 2012).  
We understand that there might be an impairment in the autophagy 
pathways, due to decreased levels of autophagic proteins with increasing 
Braak staging. However, there is minimal evidence in the existing research 
on autophagy variation across different brain regions and subregions. In 
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AD, tau and beta-amyloid pathology is known to have a specific deposition 
pattern according to the region (Braak et al, 1997; Lace et al, 2009; Liu, 
2012; Calignon, 2012, Whittington, 2017).  
The results described in section 3.1 support a regional variation in the 
expression and intensity of staining in the three brain regions. The 
research initially focused on subdivisions of the hippocampus, a brain 
region involved in memory formation and an early site of 
neurodegeneration (Braak et al, 1997).  
A high prevalence of all autophagy markers, in particular LAMP2A and 
Beclin-1, was observed in the hippocampus across most subregions. 
However, a regional variation was noticeable, with respect to both the 
number of cells and the intensity of the staining, but no association with 
Braak stage. The hippocampus demonstrated the most abundant levels of 
staining for all autophagy markers, in comparison to the frontal and 
occipital cortices, showing a decrease in Hsp70 and LC3 markers with 
increasing Braak, except LAMP2A and Beclin-1, which were found similar 
throughout the Braak stages. This is interesting because this region is 
impacted earliest in AD with respect to abnormal protein accumulation and 
cell loss (Dhikav, 2011; Serrano-Pozo, 2011). A recent study used natural 
ageing rat models to investigate autophagy changes in the hippocampus 
in order to determine the ideal age for treating neurodegeneration (Yu et 
al, 2017).  They looked at levels of autophagy-related proteins such as 
LC3II, Beclin-1 and ULK via Western blotting and results showed that 
hippocampal autophagy marker levels were found very high in adult rats (5 
months age) and even higher in old rats (18 months), however, the levels 
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declined considerably in the oldest group of rats (24 months) (Yu et al, 
2017). Other studies on post-mortem human brain tissue, which examined 
autophagy levels in hippocampal CA1 pyramidal cells, suggested that 
autophagy induction and autophagosome formation were upregulated in 
early staged AD subjects (Bordi, 2016), which could explain the 
hippocampal abundant autophagy markers in our findings. They also 
found that the elevated levels of autophagy were maintained with disease 
progression, despite progressive impairment of substrate clearance via 
lysosomes (Bordi, 2016), which might explain our results as LAMP2A and 
Beclin-1 distribution had no variation across the Braak groups and 
remained high. 
Through immunohistochemistry, we showed that in the hippocampus, 
Beclin-1 marker was found abundant in all Braak groups, with a minimal 
decrease in CA1 in Braak V-VI, when compared with CA4, which has been 
previously demonstrated in knockout Beclin-1 mice, leading to apoptotic 
CA1 neuronal death (McKnight, 2014). 
As previously described in section 1.3.1, Beclin-1 is involved in the 
initiation of MA, being of the most important activator marker. As literature 
suggests, increased induction of MA may lead to failure of lysosomal 
substrate clearance in neurodegeneration and increased neuritic 
dystrophy, causing impaired MA that could result in pathogenesis (Liu, 
2014; Bordi, 2016; Guo, 2016). This is supported by studies on impaired 
autophagy which suggested that abundant dystrophic neurites, which are 
a specific AD neuropathological feature, were found to be filled with 
autophagy-related vacuoles containing incomplete digested cellular 
185 
 
components, as well as  β-amyloid and neurofibrillary tangles (Nixon et al, 
2005). 
We found that aAlthough Beclin-1 was high in all Braak groups, LC3 was 
significantly decreased with AD progression. These results could suggest 
that there is an excessive rate of MA initiation in early stages of disease, 
however in later stages, LC3 decreased, therefore the autophagic flux 
decreases causing failure of the MA system. Therefore, we believe that 
these results suggest an impairment in MA pathway. Lower levels of LC3 
in late stages could indicate that after initiation of the pathway through 
Beclin-1, the MA deficit could be associated with LC3 causing incomplete 
formation of autophagosomes, hence accumulation of abnormal clearance 
of AD deposits.  
Based on the number of the cells stained in the hippocampus, Beclin-1 
staining demonstrated minimal variation, which was only seen in DG and 
CA1 subregions, with increasing Braak. LAMP2A marker was also highly 
prevalent with similar levels across all subregions; minimal variation was 
seen in CA2 and CA3 across the Braak groups. The variation of MA 
markers across Braak groups identified a decrease in subregions such as 
DG, CA1, the entorhinal cortex and the subiculum, whereas CMA markers 
across Braak groups described a decrease mainly in CA1, as well as in 
CA2 and CA3. Considering the existing literature, previously described in 
section 1.2, on differential involvement of the hippocampal subregions in 
the disease, we assume that both autophagy pathways might become 
impaired at early stages of tau deposition.  
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Overall, CA1 and DG regions had the lowest level of autophagy markers, 
while EC, CA4 and the subiculum regions had the highest amount of MA 
and CMA markers. This could explain the relationship between autophagy 
impairment and AD progression as tau pathology is deposited differently 
across the hippocampal subregions (Lace et al, 2009; Serrano-Pozo, 
2011). CA1 is known to demonstrate abnormal tau accumulation early in 
AD, therefore LC3 and Hsp70 decreased levels might suggest autophagy 
deficits in this region. CA4 is known to have minimal tau pathology at early 
stages and here, we found that this region was rich in autophagy markers 
staining. On the other hand, other brain subregions known to demonstrate 
tau pathology such as the EC and subiculum (Lace et al, 2009) showed a 
high presence of autophagy proteins. This may suggest that some cell 
populations trigger autophagy marker recruitment in the attempt to clear 
pathological tau.  
Strong regional variation in Hsp70 staining was shown as a result of CA1 
low levels of staining and CA4 high levels of staining Therefore, to further 
investigate if autophagy markers were found in individual cells harbouring 
abnormal tau deposits, double labelling immunofluorescence was 
performed. Our findings, suggest that in Braak 0-II and Braak III-IV groups, 
LAMP2A positive cells within CA1 were also AT8 positive, suggesting their 
co-localization. However, in Braak V-VI, many AT8 positive cells within 
CA1 were LAMP2A negative, suggesting that the rate of co-localization 
declines in late stages of disease. This could indicate an impairment of 
CMA pathway, therefore abnormal intracellular proteins such as tau fail to 
be degraded. Moreover, our results suggest that LC3 and AT8 co-
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localization rate was very high in the Braak 0-II group; In CA4, all AT8 
positive cells were found to be LC3 positive. This suggests the importance 
of MA pathway to stay upregulated in the normal ageing brains to clear 
abnormal protein accumulations. Although LC3 and AT8 were both found 
positive in the same individual cells within both CA4 and CA1, in Braak III-
IV, the co-localization rate dropped when compared withto Braak 0-II, 
which could suggest that MA becomes impaired in moderate stages of AD 
when tau burden increases. Moreover, in Braak V-VI, many AT8 positive 
cells were found LC3 negative with rates of co-localization declining 
significantly by half when compared with Braak 0-II suggesting that in late 
stages of AD, there might be a failure of MA to clear abnormal tau. 
The dual staining results of LC3/LAMP2A vs AT8 confirmed the 
immunohistochemical findings that AT8 increased with increasing Braak 
staging and that LAMP2A, but especially LC3 decreased with increasing 
Braak suggesting an impairment in both MA and CMA. Therefore, 
although there is a degree of co-existence of LAMP2A/LC3 with AT8, it 
varies with Braak staging and this could be due to failure of LAMP2A/LC3 
targeting and degrading tau protein. There was also a variation between 
CA4 and CA1 region, mostly seen in the LC3/AT8 staining suggesting that 
MA is more likely to get impaired due to defective autophagosome 
formation.  
As previously discussed in section 1.4, numerous studies suggest that 
lysosomal-based autophagy pathways including MA and CMA are 
involved in the clearance of AD deposits such as tau and Aβ, suggesting 
that both protein degradation pathways could be important in 
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neurodegeneration (Wang, 2009; Wang, 2012; Lee, 2013). Researchers 
have used various mechanisms to either promote or inhibit autophagy in 
order to assess tau production and relate it to the protein clearance 
pathways. It was shown that using 3-methyladenine, an inhibitor of 
autophagy, supressing autophagosome formation, results in excessive tau 
aggregates (Wang, 2009). In vivo and in vitro studies showed that using 
methylene blue to induce autophagy, promoted tau clearance and reduced 
toxic forms such as insoluble and hyperphosphorylated tau (Congdon, 
2012). Other studies describe that cells expressing the repeat domain of 
tau FTDP-17 mutant ΔK280 or P301S, which were treated with 
disaccharide trehalose, an autophagy enhancer, demonstrated a reduction 
of tau aggregates via immunohistochemistry and western blotting (Kruger, 
2012; Schaeffer, 2012). There are also genetic studies on transgenic mice 
expressing mutant tau which have demonstrated that manipulating mTor 
pathway related genes can reduce the pathological tau (Caccamo, 2013). 
All these studies contribute as evidence of tau being degraded by 
autophagy systems, therefore understanding the relationship of autophagy 
proteins in the process of tau degradation in disease is crucial. Also, this 
could be linked to our findings as in Braak 0-II group, the co-localization of 
LC3 and AT8 markers was seen in almost all cases. 
In section 1.4, we extensively described the link between impaired 
autophagy and neurodegeneration which is believed to result in the build-
up of abnormal tau aggregates. Nixon and collegues, was one of the first 
to observe a significant high number of autophagic vacuoles within the 
lysosome of AD neurons, which were suggested to be an accumulation of 
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immature vacuoles due to incomplete macroautophagy in AD (Nixon et al., 
2005). In another key study, researchers found that the AD-damaged 
neurons, containing neurofibrillary tangles, showed high autophagic levels 
in the cell bodies, measured by immunoblotting and immunofluorescent 
labelling (Yu et al, 2005). Therefore impaired macroautophagy was 
suggested due to incomplete development of macroautophagic vacuoles, 
which affected their transport to the lysosomes, resulting in faulty tau 
degradation. This links with our findings showing that although in Braak 0-
II and Braak III-IV groups, all AT8 positive cells were also LC3 positive, in 
Braak V-VI (late stages of AD), most of the AT8 positive cells were found 
LC3 negative, suggesting a possible impairment in MA and a defective 
clearance of tau in late stages of the disease. This could also indicate that 
impairment of autophagy is a late change that occurs due to the system 
becoming overly stressed, rather than an early disease change which is 
crucial in understanding which stage is the most suitable for therapeutic 
intervention to rescue autophagy.  
When looking at the regional variation of the autophagy markers in CA4 
and CA1 subregions, their distribution was higher in CA4 when compared 
with CA1, with a significant difference seen in Hsp70 marker. Existing 
studies describe the importance of Hsp70, a major component of the 
Hsp70 family, in stabilizing lysosomal function and ensuring cytoprotection 
by inhibiting protein aggregation (Ge, 2008; Zhu, 2012). Cleavage of 
carbonylated Hsp70 by calpain enzyme in CA1 neurons has been shown 
to lead to ischemia and neuronal death through lysosomal rupture in the 
hippocampal CA1, whereas in the motor cortex, Hsp70 expression in the 
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absence of active calpain has neuroprotective properties (Yamashima, 
2012; Zhu, 2012). Calpains are calcium-activated proteases, found in high 
levels in the brain (Liu, 2008) and have been described to play a role in 
neurodegeneration (Vosler, 2008). Studies have shown that once 
activated, calpain levels increase significantly when compared with healthy 
ageing brains and are found in the neurofibrillary tangles of AD and 
tauophathies related brains (Taniguchi et al, 2001; Adamec, 2002; 
Yamashima, 2004). 
Chaperone proteins such as heat-shock proteins are specialized in cellular 
protection from oxidative stress, maintaining homeostasis (Mayer, 2005; 
Hall, 2013). One of the most important of the chaperone protein family and 
is Hsp70 and along with other chaperones (Hsp60, Hsp27, etc) play a 
crucial role in protein misfolding by stopping the abnormal protein 
aggregation seen in AD (Lu, 2014). Research has shown that Hsp70 acts 
as a regulator in neurodegeneration, assisting protein folding and being 
involved in repair mechanisms of faulty proteins  therefore Hsp70 has 
been investigated as a potential therapeutic agent in AD (Franklin, 2005; 
Meriin, 2005; Hoshino, 2011; Doyle, 2013). Studies in transgenic AD 
mouse model have showed that overexpression of Hsp70, after intranasal 
administration of exogenous Hsp70, demonstrated neuroprotection 
properties by reducing Aβ formation and accumulation in these murine 
species (Bobkova, 2014). Exogenous Hsp70 was also shown to have 
similar effects in cell models such as SK-N-SH neuroblastoma cells, 
reducing Aβ42 cytotoxicity (Yurinskaya, 2015). There is also evidence in 
transgenic mice and AD human brains, which demonstrates that Hsp70 
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enhances tau binding to microtubule and promotes tau solubility, therefore 
reducing insoluble and hyperphosphorylated tau which can suppress 
neurofibrillary tangles formation (Dou, 2003).   
Considering all the existing evidence that Hsp70 is neuroprotective in AD 
and that Hsp70 was found to decrease in CA1 with AD progression, we 
could suggest that in this hippocampal subregion, there is compromised 
neuroprotection at late stages of the disease, which could indicate 
animpairment of CMA and tau excessive build-up in CA1 neurons.  
Studies on Hsp70 cleavage by calpain could support our findings 
demonstrating a significant reduction in CA1 Hsp70 levels across all Braak 
groups, when compared with CA4, Hsp70 reduction may lead to lysosomal 
dysfunction, causing a possible CMA impairment and abnormal 
accumulation of phosphorylated tau. Studies could further explore these 
findings by assessing the levels of calpain in the brain sections.  
As previously described, CA4 and CA1 hippocampal regions were chosen 
to explore regional variation in the expression of autophagy markers in 
relation to tau deposition Only LC3 marker decreased with increasing 
Braak in both CA4 and CA1 suggesting a possible impairment of MA .   
Lack of significant Beclin-1 staining variation in Braak III-IV suggests that 
autophagy initiation may not be impacted at moderate stages of AD, 
considering that other proteins (PI3K-III, Atg14, Vps34; see section 1.3.1) 
are also involved in autophagy initiation. Previous studies on rat models, 
showed that induction of AD-related cerebral hypoperfusion in the animals, 
increased Beclin-1 significantly in hippocampal CA1 neurons (Liu, 2015). 
Similarly, another study on vascular dementia rat models, suggests that 
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Beclin-1 was elevated in hippocampal CA1 cells due to neuronal injury 
(Liu, 2014). This evidence suggests that Beclin-1 might not be related to 
impaired MA and abnormal accumulation of tau in CA1, when compared to 
the other autophagy proteins.  
 Hsp70 and LC3 markers were found higher in CA4, whereas in CA1, their 
levels were very low across all Braak groups, in particular in Braak III-IV 
and Braak V-VI. This suggests their poor involvement in the autophagic 
process for the clearance of tau deposits, found in a high numberin CA1. 
These findings offer an insight to understand the regional variation of 
autophagy impairment in specific subregions of the hippocampus, which is 
crucial for developing a highly selective and effective treatment to restore 
autophagy functions.Our results prove a regional variation of LC3 in 
relationship with Braak stages and further studies could explore LC3 
related to tau pathology in the hippocampal CA4 and CA1. 
Our study then focused on investigating variations in autophagy-related 
proteins in the frontal cortex. It is already known that each subcortical 
layer has specific functions within the central nervous system, mediating 
nerve impulses from the cerebral cortex to other regions, having distinct 
connections within the cortex and with other structures (Rubenstein, 
2011). The six layers stratification has been described since over a 
century ago by pioneers Brodmann and Meynert, featuring morphological 
and anatomical distribution in size and shape of pyramidal and granular 
cell bodies within each layer (Brodmann, 1909). Only in the recent years, it 
has become evident that the layer stratification plays a crucial role, not just 
anatomically speaking, but also because functional differences depend on 
193 
 
specific subcortical layers that have particular cell types, based on animal 
model research (Morishima et al, 2011; Oberlaender et al, 
2012; Narayanan et al, 2015). The most recent review on subcortical 
stratification describes these changes important in synapse activity and 
neuronal excitability via neurotransmitters such as adenosine, dopamine 
and acetylcholine (Radnikow, 2018). These neuromodulation chemicals 
can be released from axons of afferent neurons that come from other 
cortex regions (neurons in cortical layers II and III), from the thalamus 
(neurons in cortical layer IV) or from the brain stem (neurons in cortical 
layer V). They can also be released from axons of efferent neurons which 
leave to the thalamus (layer VI), to the brain stem and spinal cord (layer V) 
or other cortical regions (layers II and III) (Thomson, 2010; Mitchell, 2015; 
Miller, 2017).  
A regional variation in the autophagy markers staining was observed 
across the subcortical cellular layers of the frontal cortex. A noticeable 
variation was seen across layer II-VI associated with LAMP2A, LC3 and 
Beclin-1 staining. Layer I or the molecular layer was excluded when 
assessing the regional variation in neurons as it has few cell bodies and 
mainly axons and dendrites of neurons from the deeper layers (Krause 
2005) and the main interest was in the layers rich in pyramidal, granular 
and polymorphic neurons.  
The regional variation seen across the frontal cortex layers was due to 
higher distribution of autophagy markers in layer III and V and lower 
distribution in layers II and IV.  
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Interestingly, these findings could be linked to abnormal tau protein based 
on its preferential deposition in the deeper subcortical layers III-V. There 
are numerous studies demonstrating how tau preferentially deposits within 
the cortical layers and how various layers get more affected in 
neurodegeneration. One recent immunohistochemical study revealed 
reduced cell volume by nearly 40% of large pyramidal cells in layers III 
and V in the frontal cortex in patients with vascular dementia, mixed AD 
and post-stroke patients when compared with non-dementia control 
subjects, suggesting the susceptibility of these two layers in 
neurodegeneration (Foster, 2014). Other studies suggest that, in contrast 
with pThr tau pathology (tau neuronal inclusions) involvement in the 
superficial layers of the hippocampus, the frontal cortex has the most 
prominent pathology including dystrophic neurites in the deeper layers as 
shown in ALS cases (Moszczynski, 2017). Although, tau pathology is 
mainly associated with the limbic regions such as the hippocampus, hence 
higher levels of AT8, pathological tau is seen in the deeper layers of the 
frontal cortex in cases of AD, vascular dementia, ALS, MSA, DLBD, FTLD 
(Moszczynski, 2017). This could explain tau propagation starting from the 
hippocampus and arriving to the layers III, IV and V of anterior cingulate 
cortex through thalamic projections and ultimately propagating to the 
frontal cortex (Moszczynski, 2017). These studies could relate neuritic 
dystrophy and high tau pathology found in deeper layers to our findings 
which suggest that distribution of autophagy markers was the highest in 
layers III, V whereas the lowest was in layer II. This suggest that tau might 
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co-localize with autophagy markers in individual neurons within the cellular 
layers, as a result of autophagy markers tagging tau for degradation.  
Interestingly, the only marker found to vary significantly with increasing 
Braak was Beclin-1. The MA marker distrubtion increased in advanced 
stages of AD. In the frontal cortex, excessive induction has been 
demonstrated to have neurotoxic effects and leads to AD pathology and 
neurodegeneration. Layer IV demonstrated lower levels of staining, in 
particular in the MA markers staining, but studies suggest that deep layer 
IV, along with layers V and VI present tau burden (Calignon, 2012).  
Human studies that used late staged AD brains, in which LC3-II 
expression (isoform actively involved in MA) was significantly decreased in 
the frontal cortex of AD patients, compared to age-matched controls 
suggesting an impairment in MA (Qiu, 2016), however most studies fail to 
demonstrate how these impairment varies according to the cell layer 
stratification.  
There are also studies exploring the beta-amyloid plaque burden and the 
neuronal loss according to the cortical stratification in the frontal cortex 
and one study on AD mice suggests a neuronal loss in deep layers V-VI of 
10 months old APP/PS1K1 mice compare to two month old APP/PS1K1 
mice, while the amyloid-plaque load in old mice was found low in layers V 
and VI (Lemmens, 2011). This could suggest two important things: that the 
deep layers are mainly affected by tau pathology rather than beta-amyloid 
plaques and that the regional variation found in our results could associate 
tau pathology to be more relevant to the autophagy impairment, hence 
choosing tau protein for the double-labelling studies. In addition, 
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autophagy marker distribution, assessed based on cellular staining, and 
tau protein distribution were are found intracellularly rather than 
extracellularly like beta-amyloid  
These findings suggest that despite some degree of variation between the 
frontal cortex subcortical layers, no significant decreases in the autophagy 
markers distribution was asscociated with advancing disease. The only 
significant variation was the upregulated Beclin-1 marker in advanced 
stages of AD. Therefore, the frontal cortex is not thought to be linked to 
impairments in CMA and MA. High distribution of Beclin-1 remains a 
question to whether the MA marker, involved in initiation of the pathway, 
contributes to increasing AD pathology or whether it is highly recruited to 
initiate MA in the attempt to rescue the protein clearance mechanisms. 
As previously described, tau pathology originates in the limbic structures, 
starting with EC, spreading to the entire hippocampal regions, then to the 
temporal cortex and the frontal cortex and lastly, it spreads to the other 
cortices (Braak, 1997; Hu, 2017).  
The research investigating AD pathology deposition across the occipital 
cortical layers is scarce, however a study from 2015 suggests an 
increased number in neuropil thread, neurofibrillary tangle, amyloid 
plaques and dystrophic neurites in layer VI of the primary visual cortex, in 
cases of Braak VI when compared with fewer AD pathology lesions in 
cases of Braak IV or lower (Rahimi, 2015).  
Another paper describes how the occipital cortex has no AD pathology 
until Braak IV stage with evident tau pathology like neurofibrillary tangles 
197 
 
and neurophil threads, in Braak V and VI and this could be supported by 
our findings in the AT8 staining in the occipital cortex (Pikkarainen, 2009). 
In our study, only Hsp70 and LC3 markers were found to significantly 
decrease with increasing Braak. These findings suggest a possible 
impairment of the autophagy pathways in the occipital cortex as levels of 
LC3 and Hsp70 decrease with increasing Braak staging.   
The already existing studies on human brain tissue and transgenic mice 
support some of our results in which MA marker LC3 and CMA marker 
Hsp70 decrease with increasing Braak stages The most significant 
declines were seen in LC3 and Hsp70, in the hippocampus and the 
occipital cortex We know that LC3 and Hsp70 are involved at different 
steps in MA and CMA as described in section 1.3.1 and 1.3.2, which could 
suggest a possible location of the deficits within the two pathways. In other 
words, if LC3 decreases with AD progression, but Beclin-1 maintains 
constant levels in the brain, it might suggest that MA deficiency is located 
at the autophagosome formation step, hence lower LC3, which leads to 
incomplete formation of the vesicles responsible for degradation. Although 
the first steps of MA are functional, hence constant Beclin-1 levels, the 
incomplete formation of the autophagosomes, due to insufficient levels of 
LC3, could lead to faulty degradation that results in abnormal tau 
accumulation. Incomplete autophagosome formation could be supported 
by Yu et al, study in which they discovered numerous immature vacuoles 
to contain abundant APP molecules and presenilin-1, linking AD pathology 
to incomplete and dysfunctional MA (Yu et al., 2005).  
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As previously mentioned, increased induction of MA could result in failure 
of lysosomal substrate clearance in neurodegeneration and increased 
neuritic dystrophy, causing impaired MA that could result in pathogenesis 
(Liu, 2014; Bordi, 2016; Guo, 2016). On the other hand, Beclin-1 
upregulation, despite decreased levels of LC3, could indicate a 
compensatory mechanism as a response to the system becoming faulty. 
This could be supported by previous studies suggesting that upregulation 
of autophagy induction is believed to be a compensatory attempt to 
increase autophagic flux and cope with abnormal protein build-up since 
autophagosome maturation is defective in AD neurons (Orr, 2013).  
This could explain our results seen in Braak V-VI group, where both 
Beclin-1 and tau were found very high, despite other autophagy proteins 
being decreased (Hsp70, LC3). On the other hand, high Beclin-1 in late 
stages could be explained by its involvement in tau protein clearance, 
however Beclin-1 is only involved in MA initiation, thus, without normal 
levels of LC3, MA would not successfully degrade the abnormal deposits. 
Considering that LC3 was found to decrease in the hippocampus and the 
occipital cortex, in Braak V-VI, we are inclined to believe that increased 
Beclin-1 contributes to pathology. 
As described in detail in section 1.3.2, Hsp70 is responsible for recognition 
and binding of the substrate that requires degradation, before it reaches 
the lysosome therefore. A deficit of Hsp70, due to low levels seen in the 
occipital cortex, could lead to an accumulation of abnormal proteins in the 
cytosol, including pathological tau. This cytosolic accumulation of tau 
could precede the formation of neurofibrillary tangles (Brion, 1998). We 
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mentioned before that Hsp70 has been extensively described to have 
neuroprotection roles by inhibiting protein aggregations and help refolding 
misfolded proteins, by stabilizing the functioning of the lysosome and by 
reducing the oxidative stress (Ge, 2008; Zhu, 2012; Leak, 2015: Morozov, 
2017). Considering these, we could link decreasing Hsp70 levels with 
disease progression, in the occipital cortex to be a factor in CMA 
impairment that leads to excessive accumulation of abnormal proteins. 
We suggest that MA and CMA pathways become impaired as autophagy 
proteins, Hsp70 and LC3, decrease with increasing Braak and we found a 
regional variation of autophagy markers distribution within each brain 
region. We conclude that in the hippocampus, the autophagy markers 
were found the lowest in CA1, a region associated with early deposition of 
tau (Lace et al, 2009; Serrano-Pozo, 2011) and the level of these markers 
decreased in CA1 with advancing disease. On the other hand, the 
autophagy markers distribution was higher in CA4, a region associated 
with late tau deposition (Lace et al, 2009; Serrano-Pozo, 2011). In the 
frontal and the occipital cortices, layers II and IV were associated with the 
lowest rates of staining, whereas autophagy markers were more 
predominant in deeper layers III, V, VI, which have been previously 
associated with tau deposition (Moszczynski, 2017). These findings are 
crucial as they give an insight of the relationship between autophagy 
proteins and pathological tau which could be essential in developing in a 
highly specific therapeutic target.  
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Overall, we could speculate that both autophagy pathways are impaired as 
rates of LC3 and Hsp70, key markers in MA and CMA, were reduced with 
advancing AD.  
 
Summary of MA and CMA impairment 
 
 In conclusion, we understand that both MA and CMA might get impaired.  
LC3 decreased levels were found in both the hippocampus and the 
occipital cortex, with increasing Braak staging, therefore we speculate that 
defective MA might be related to insufficient levels of LC3, while defective 
CMA might get impaired due to Hsp70 deficits in the occipital cortex. LC3 
is responsible for autophagosome formation and maturation, therefore a 
deficit at this step might indicate that the impairment is related to immature 
autophagosome accumulation and incomplete degradation of abnormal 
proteins, resulting in abnormal deposits in the AD neurons. Hsp70 deficits 
could suggest that there is insufficient chaperone proteins in the cytosol 
that specifically recognize and bind the subtrates for degradation, hence 
accumulation of abnormal tau in the neurons (section 1.3.2) 
Currently, there are potential AD therapeutic drugs that alter different 
stages of the autophagy mechanism (Zhang, 2011), but in order for them 
to work, it is essential to target the right pathways and deficits at the right 
stage of disease. Switching on macroautophagy has been shown to 
increase the neuropathology in transgenic mice brains in SOD1G93A 
mouse models, worsening symptoms and accelerating neurodegeneration 
(see section 1.1.7) (Zhang, 2011).  
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As mentioned before, AD pathology originates in the limbic structures, 
starting with EC, spreading to the entire hippocampal regions, then to the 
temporal cortex and the frontal cortex and lastly to all other cortices (Hu, 
2017). When comparing the results of our autophagy protein levels across 
all three brain regions, the hippocampus, followed by the frontal cortex had  
the highest amounts of staining, which could suggest one important thing. 
This could be a result of these regions being largely associated with tau 
and beta-amyloid pathology when compared with the occipital cortex 
(Serrano-Pozo, 2011). Since these regions are known to be largely 
impacted in AD pathogenesis, cells in these regions have been shown to 
have oxidative stress, inflammation, disruption of Ca2+ channels, 
egeneration of xcess reactive oxygen speacies (Di, Bona, 2010; Tan, 
2012; Manoharan, 2016), which is known to initiate autophagy (Essick, 
2010). The generally higher levels of autophagy markers may reflect the 
need for a functioning waste disposal system.  
The two pathways of autophagy were compared in each brain region 
showing that MA marker levels were higher than CMA in the hippocampus 
and in the occipital cortex, while the CMA marker levels were higher in the 
frontal cortex. Results have also revealed that when comparing the overall 
levels of MA with CMA across the Braak stages, CMA rates were lower in 
the hippocampus, compared with the frontal cortex, in all Braak groups, 
whereas in the frontal cortex, MA is much lower than CMA, in both Braak 
0-II and Braak III-IV groups. However, a change was seen in Braak V-VI, 
where MA and CMA levels become similar in the frontal cortex. These 
patterns suggest that in this brain region, the two pathways might work 
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together via compensatory mechanisms in late stages of disease in the 
attempt to rescue the imbalances.  
These findings are important for the future research in order to identify 
which autophagy pathway should be therapeutically targeted at different 
stages. Also, differences between the levels of MA and CMA activity in 
each brain region, could suggest that they exhibit compensatory 
mechanisms. In other words, if MA becomes defective, CMA 
compensatory mechanisms will try and rescue the protein degradation 
system in order to antagonize the adverse effects caused by the MA 
impairment the other way around. Studies have shown that both lysosomal 
pathways compensate each other to promote cell survival in hepatocytes 
after cell injury (Wang, 2010; Chava, 2017). It was shown that CMA is 
upregulated in rat cell line RALA255-10G in order to compensate impaired 
MA after hepatocyte injury and cirrhotic liver (Wang, 2010; Chava, 2017). 
Moreover, studies in cancer have showed that genetically suppression of 
MA upregulates CMA levels in order to degrade aberrant p53 tumour 
suppressor (Vakifahmetoglu-Norberg, 2013). 
Studies in neurodegeneration have also shown that there is a functional 
relationship between the two pathways and disruption of one of them 
leads to upregulation of the other one (Massey, 2006; Cuervo, 2014).  
More specifically, cell model studies, including mouse fibroblasts, have 
showed that CMA can compensate for MA, but not the opposite, 
suggesting that highly selective mechanisms of CMA are essential in 
stress responses (Massey, 2006). There is also a review paper which 
describes how the two machineries interact with each other in the 
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mammalians systems and how they counteract at a molecular level (Wu, 
2015).  These could relate to our findings as we observed that in the 
frontal cortex, in the Braak V-VI group, overall MA levels increased and 
became similar to the CMA levels, suggesting that CMA might have 
compensated to rescue impaired MA in this brain region, at late stages of 
disease.  
These findings suggest that according to the brain regions affected in the 
disease, therapeutic targets should focus on specific pathways. In other 
words, therapeutics for rescuing autophagy, should target CMA 
impairment in the hippocampus across all stages of disease as our 
findings suggest that CMA levels were decreased in this brain region when 
compared with the MA levels. Regarding the frontal cortex, therapeutics 
should aim to target MA impairment in early and moderate stages (Braak 
0-II and Braak III-IV) as our results indicated lower MA levels in these 
stages. Considering the existing literature which describes that it is easier 
for MA to compensate CMA activity, rather than the opposite, we tend to 
believe that targeting the hippocampus would be ideal for therapeutics. 
This means drugs could aim to enhance CMA activity in this brain region 
at any stage of disease. However, it would be ideal to target CMA 
impairments at the earliest stages, considering that our findings indicated 
lower levels of CMA compared to MA in Braak 0-II.  
Studies on neurodegenerative mouse models have already tested MA 
activator drugs such as rapamycin, spermidine, carbamazepine and 
tamoxifen which have showed therapeutic potential, improving behaviour, 
enhancing learning and memory and slowing down the loss of motor 
204 
 
function (Wang, 2012). Other studies have showed that rapamycin had 
neuroprotective properties, facilitating the clearance of aberrant proteins 
and reducing tau and beta-amyloid in the AD brains (Cai, 2013). There are 
also studies which contradict these findings, suggesting that treatment 
with rapamycin on ALS mouse models, can increase neuropathology in 
the brain and worsen the symptoms (Zhang, 2011). More recent studies 
on neuronal cell lines suggest the therapeutic potential of spermidine 
which is shown to be neuroprotective by suppressing caspase 3 protease 
to cleave Beclin-1, essential in the well-functioning of MA (Yang, 2017). 
Moreover, Choi et al, showed that spermidine had anti-inflammatory 
effects on lipopolysaccharide treated murine microglia, therefore inhibiting 
inflammation (Choi et al, 2012). Despite these studies, there are also 
controversial researchers which contradicts the potential therapeutic of 
this drug in preventing or delaying the progression of AD as Lewandowski 
et al, showed a link between spermidine pathway and α-synuclein toxicity 
in the pathogenesis of PD by using a yeast model expressing α-synuclein 
(Lewandowski, 2010). Trehalose, an mTOR activator of autophagy was 
also tested on human mutant P301S tau transgenic mouse models 
however, the treatment failed to activate autophagy in the mice spinal cord 
and had no improvement effects on these mice motor impairments 
(Schaeffer, 2012). A more recent study on Tg2576 transgenic AD mouse 
model showed that oral administration of trehalose had no effect on MA, 
due to no variation of LC3I/II ratio western blotting results and had no 
cognitive improvement on the mice (Portbury, 2017). Considering all 
studies investigating the beneficial points of autophagy activation by using 
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enhancers, we tend to believe that these drugs offer therapeutic potential 
in rescuing autophagy in AD, however we also need to consider the 
amount of studies which fail to prove efficacy of these drugs in some of the 
AD modelsThus, this field requires a better understanding of how these 
drugs would successfully promote protein clearance in the AD brains. 
Moreover, most studies on therapeutic intervention to rescue autophagy 
focus on MA, and there is a gap in research, regarding the drugs that 
would successfully target impaired CMA.  
 
Glial cells 
 
The white matter, which largely consists of myelinated axons of the 
neurons and the glial cells, stained positively for all autophagy markers in 
the three brain regions, We considered the glial cells stained by the 
autophagy markers as the white matter is directly linked to cognition, 
distribution of action potentials, and information exchange between 
different brain regions, which are all affected in AD (Fields, 2008; Zhang, 
2009).  Immunohistochemistry and imaging studies suggest that white 
matter abnormalities seen in AD are due to impaired myelin and 
oligodendrocytes, which result in demyelination causing pathology and 
impaired cognition (Nasrabady, 2018).   
Glial cells are very important components of the nervous system as they 
perform various functions from sustaining neurons by maintaining 
homeostasis, providing nutrients and oxygen to the cells and protecting 
against threats, pathogens and oxidative stress (Greener, 2015; Jäkel, 
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2017). Different types of astrocytes are known to exist (Sun, 2012), though 
short, thick protoplasmic star-shaped astrocytes were found to be very 
abundant in the subpial regions, in most of the cases.  
Autophagy is described to be impaired not only in neurons but also in glial 
cells, however the role of autophagy in glial cells and the role of glia in 
defective MA in AD is not very well understood (Nikoletopoulou, 2015). 
There are studies that link glial cells and autophagy pathways and one 
example is a study on a parkinsonian mouse model that suggests that 
Gaucher disease (lysosomal storage disorder) specific mutation leads to 
impaired autophagy and activation of astrocytes in the AD brains 
(Osellame, 2013). Another in vivo study linking defective lysosomal 
function to glial cells explains that deletion of sulphatase modifying factor 1 
(SUMF1) gene in both neurons and glial cells caused severe lysosomal 
dysfunction, impaired autophagy, neuronal loss and inflammation 
suggesting that astrocytes play a very important part in the disease 
progression (Di Malta, 2012).  
Mutations of the lipid phosphatase FIG4 that regulates PI (3,5)P2, a 
signalling lipid, have been associated with ALS, spongiform degeneration 
of the brain and Charcot-Marie-Tooth disease (Chow, 2009). Studies on 
transgenic mouse models reported that mutations in PI (3,5)P2 cause 
accumulations of excessive LC3II, LAMP2 and p62 proteins in the murine 
neurons and astrocytes (Ferguson, 2009). Double-labelling studies 
identified astrocytes to be abundant in p62 protein, suggesting a link of 
glial cells and MA as p62 is involved in recognition and binding to 
substrate for degradation (Ferguson, 2009). Other studies, showed that 
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exposure to toxic compounds (trimethyltin) induces MA not just in neurons 
but also in glia cells, supressing the autophagic flux and overexpressing 
LC3 and p62  (Fabrizi, 2015).  
 There is a study reviewing how microglia and astrocytes surface receptors 
mediate degradation of beta-amyloid through phagocytosis (Ries, 2016). 
The same review explains that although there are some studies in which 
glial cells activation may have damaging effects on the neurons in AD, 
there is plenty of evidence that supports their neuroprotective function and 
removal of beta-amyloid (Ries, 2016). 
Therefore, there is a lot of evidence that links glial cells and autophagy 
which is why we considered the glial cells stained by autophagy markers. 
Glial cells have been extensively linked to neurodegeneration and studies 
suggest that while neurons die in the presence of toxic protein 
accumulations in late stages, glial cells including astrocytes and microglia 
are resistant to toxicity and moreover, they become highly activated in the 
attempt to destroy neurons harbouring tau (Jana, 2010).  There is a lot of 
research that describes glial cells contribution to neurodegeneration 
through neuroinflammatory mechanisms which are commonly seen in AD 
brains (Sofroniew, 2010; Kahlson, 2015; Leyns, 2017). Glial cells secretion 
of proinflammatory cytokines such as interleukins and tumour necrosis 
factor alpha exacerbate tau pathology facilitating neurodegeneration 
(Leyns, 2017). It has been suggested that suppressing excessive 
inflammation by inhibiting active glial cells in AD may reduce the 
production of proinflammatory factors which could reduce neurotoxicity, 
therefore, there are numerous clinical trials using glial cells as therapeutic 
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targets to develop drugs that could prevent or slow AD (Lopategui, 2014). 
On the other hand, there is a recent study which suggests that glial cells 
showed rescuing effects in a Drosophila model of AD expressing toxic 
beta-amyloid, which resulted in engulfment of Aβ peptides by the glial cells 
(Ray, 2017). Some researchers still debate whether glia are good, acting 
as immune cells of the nervous system and degrading abnormal proteins 
and pathogens, or whether glial cells contribute to neurotoxicity and 
pathogenesis in neurodegeneration (Mena, 2008; Jana, 2010; Tejera and 
Heneka, 2015). For example, a review paper describing the role of glial 
cells in PD, suggests that astrocytes have neuroprotective properties as 
they remove toxic deposits and free radicals in the brain, whereas 
microglia, release proinflammatory cytokines and protein complements, 
promoting inflammation in the brain (Mena, 2008). On the other hand, 
Verkhratsky et al, suggests that astrocytes are also a contributor to 
neuroinflammation, therefore promoting neurodegeneration, however, 
astrocytes become highly activated in late staged of AD (Verkhratsky, 
2010). Early stages of AD changes are associated with deterioration of 
astroglia, which disrupts the connection between the synapses, thus the 
neurons, cause an imbalance in the neurotransmitter homeostasis and as 
a result it leads to neuronal death due to high toxicity. Later on, astrocyte 
in advanced stages, become highly activated and contribute to the 
neuroinflammatory part of neurodegeneration (Verkhratsky, 2010). The 
astrocytes can also cause damage inhibiting the axon regeneration with 
nitric oxide TNF-α leading to no recovery and exacerbation of the clinical 
pathology (Verkhratsky, 2010).   
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For a long time, astrocytes were primarily considered to protect the 
neurons, clearing beta-amyloid peptides, yet more and more research has 
shaped their role into inflammation and  neurodegeneration in AD which is 
thought to be due to release of neurotoxins and inflammatory factors, as 
well their initial functional loss (Birch, 2014; Rodríguez-Arellano, 2016).  
Considering that studies suggest glial cells, specifically astrocytes, play a 
role in clearance and degradation of beta-amyloid, we could potentially link 
the role of glia in autophagy in the attempt to clear tau and beta-amyloid.  
In our study, positively stained astrocytes and oligodendrocytes, located in 
the white matter and in the subpial region, were reported in a high number 
across the Braak groups, suggesting possible involvement of glia in MA 
and CMA 
Our results suggest prevalent autophagy markers in glia cells, however, 
there was no difference in autophagy markers in astrocytes, with 
increasing Braak staging, in the hippocampus and the frontal cortex. The 
only difference observed was with astrocytes expression of LC3 
decreasing in the occipital cortex as the disease advances. Moreover, 
there was no difference in expression associated with oligodendrocytes 
across Braak stages in the frontal cortex and the occipital cortex, but a 
difference was seen with LC3 and Beclin-1 positive oligodendrocytes, 
which decreased in Braak III-IV and then increased in the hippocampus at 
Braak V-VI.  
There are studies that demonstrate a substantial damage to the white 
matter of the AD brains, causing a decrease of oligodendrocytes as the 
disease advances and leading to cognitive impairment (Braak et al., 
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2000). According to Roth, cell culture experiments on neonatal rat 
oligodendrocytes show that malfunctioning of oligodendrocytes is due to 
the toxic effect of Aβ in advanced staged of AD (Roth, 2005). They tested 
fibrilogenic Aβ in vitro resulting in a substantial reduction of the 
oligodendrocytes. On the other hand, they have also tested pro-
inflammatory molecules such as lipopolysaccharide and IFNγ cytokine, 
along with active astrocytes presence and noted that these reduced the 
damage caused by Aβ (Roth, 2005). This might support our findings 
suggesting that Aβ might have a direct negative effect on the presence of 
oligodendrocytes, as they decrease with increasing Braak stages in the in 
the frontal cortex (LC3 staining), while astrocytes could become activated 
to compensate the AD neurotoxicity and reduce the damage on the 
neurons. There is also evidence demonstrating a link of autophagy and 
oligodendrocytes suggesting that oligodendroglial precursor cells, NG2 
can degrade beta-amyloid in transgenic AD mice model and in NG2 rat 
cell lines via double-labelling and western blotting studies (Li, 2013). 
It is still not clear why glia recruit autophagic markers and it would be 
interesting to develop an in vitro cell model to see if glia can degrade tau 
and beta-amyloid in MA and CMA. Research on MA and CMA in glial cells 
and their role in AD is very scarce, however there is some research on 
ubiquitin proteasome system which describes the involvement of glia in 
neurodegeneration, suggesting that the ubiquitin proteasome system is 
more effective in removing abnormal proteins in glia (Jansen, 2014). If glia 
pathology will be demonstrated to relate to impaired autophagy, it could 
impact the novel therapeutic strategies and the approaches to a beneficial 
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treatment, directly targeting the glial cells.The benefits of glia inflammation 
are that astrocytes, in a high number, can release neuroprotective factors, 
preventing oxidative stress, apoptosis and excitotoxic damage (Choudhury 
and Ding, 2015). A high number of astrocytes can also contribute to the 
environment maintenance, restricting free radicals release and reducing 
excitotoxicity via glutamate intake (Zhang, 2010). MA and CMA activities 
have been shown to decline with age as the lysosome function is affected 
by the ageing process (Cuervo, 2008; Martinez-Lopez, 2015; Carmona-
Gutierrez, 2016), resulting in accumulation of oxidised proteins and free 
radicals, normally seen in brain tissue of old organisms (Pajares, 2018), 
therefore these products could contribute to decreases of astrocytes in 
late stages of disease. 
Oligodendrocytes are involved in axon sheath myelination and are 
extremely important as the myelin layer which covers the axons of the 
neurons allow quick and efficient transmission of signals through the 
nervous system which become defective in AD (Mitew, 2010; Carmeli, 
2013). Compared with astroglia, oligodendrocytes have lower rates of 
reaction to stress however they can both be activated at the same time 
(Bradl, 2010). These two types of glia might be related as studies suggest 
that active astrocytes induce activation of oligodendrocytes, which are 
recruited in a high number in the attempt to produce new myelin for the 
damaged neurons in order to restore signal transmission (Bradl, 2010). As 
previously described, glial cells have been linked to autophagy and 
although this field of research is very novel, glia are believed to get 
activated in AD brains via compensatory mechanisms, as autophagy 
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pathways become defective and fail to clear abnormal proteins. Our 
findings suggest that Beclin-1 and LAMP2A positive glia were very 
abundant in the brain regions Beclin-1 positive glia significantly increase in 
Braak V-VI, suggesting the potential role of glia in autophagy. Therefore, 
in Braak V-VI, the glial cell numbers was increased in despite the neuronal 
autophagy markers decreasing in the presence of abundant tau/beta-
amyloid. This might suggest that although MA and CMA in neuronal cells 
gets defective and fails to clear the abnormal proteins,  glia, which are 
more resistant to stress conditions such as neurotoxicity and 
neurodegeneration, become activated to rescue autophagy and promote 
degradation via endocytosis.   
 
 Axons and neuronal inclusions distribution of autophagy markers 
 
Axonal staining was found relatively high in all brain regions, however it 
was found to significantly decrease across the Braak stages for Beclin-1 
only. Autophagy role in axonal related pathologies is still unclear. A study 
from 2006 used GFP–LC3 transgenic mice (C57BL/6J) to produce LC3 
tagged with a protein that emitted green fluorescence (GFP) to show that 
autophagy is switched on in axonal dystrophies. Numerous 
autophagosomes of macroautophagy pathway tagged with LC3 bound 
GFP started accumulating in the axons (Wang, 2006), which might explain 
our findings of very high LC3 positive axonal staining seen in the 
hippocampus. Also, the same study investigated microtubule-associated 
protein 1B (MAP1B) which is known to interact with LC3, on a high scale, 
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within the central nervous system. It bounds to both forms of LC3, free 
cytosolic LCI and membrane-bound LC3II at a significant level in the 
axonal swelling that are specific to axonal dystrophy, resulting in high 
prevalence of LC3 related autophagosomes in the axon terminals (Wang, 
2006).  
There is an interesting paper describing how axonal transport is disrupted 
in degradative organelles such as lysosome which causes an Alzheimer’s 
like-axonal dystrophy (Lee, 2012). Neuritic dystrophy, specific in AD, is 
characterized by accumulation of autophagic vacuoles that contain 
incomplete digested proteins and these accumulate in the swelled axons, 
explaining a possible link between defective protein degradation and 
disrupted axonal transport (Lee, 2012). We only found Beclin-1 axonal 
staining to significantly decrease, which could suggest a disruption of the 
axonal transportation in the lysosomes, which are crucial for the well-
functioning of autophagy and this disruption is associated with late stages 
of AD which may lead to impaired autophagy and lysosomal dysfunction in 
AD. In other words, the misallocation of autophaghic components and 
vacuoles could be associated with disease change and that the cellular 
distribution of autophagy markers changes with disease progression which 
may suggest axonal transport deficits.  
Surprisingly, the choroid plexus was positively stained by both LC3 and 
LAMP2A, mostly in Braak V-VI. The epithelium of the choroid plexus, 
found in the four brain ventricles has numerous functions, being at the 
interface of the brain blood and the cerebrospinal fluid, which is being 
produced by the epithelial cells (Strazielle, 2000). The choroid plexus is 
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known to be involved in inflammation responses when various proteins 
such as lipocalin 2 are produced by the choroid plexus epithelial cells 
(Marques et al., 2008). Released proteins might also interact to autophagy 
markers which might upregulate autophagy and explain the LAMP2A and 
LC3 levels of expression in the epithelial cells of the choroid plexus 
(Toyonaga, 2016).  
The intracellular inclusions that were found within the neurons, mostly 
associated with hippocampal LC3 staining, are known to be abnormal 
ubiquitin related protein aggregates that require well-functioning 
autophagy clearance (Yue, 2009). Our results showed that intracellular 
inclusion stained by LAMP2A, decreased with Braak staging, in the frontal 
cortex. It has been previously described in a study that deletion of 
macroautophagy regulatory proteins Atg 5 and Atg7 in mice Purkinje cells 
block the neuronal autophagy resulting in cytoplasmic imbalance, 
abnormal protein accumulations and inclusion bodies formations (Yue, 
2009). Moreover, transgenic mouse models express axonal dystrophies 
which could be directly related to the blocking of macroautophagy due to 
lack of Atg 5 or Atg7 (Nishiyama, 2007).  
In the hippocampus, the presence of the granular staining was mostly 
found in the LC3 positive cells which was shown to be associated with the 
presence of the autophagy markers in the axon, however, no association 
was seen in regards to the LC3 positive intracellular inclusions. Our results 
could relate to studies suggesting that the granules and the cluster of 
grains might be stress granules derived from the endoplasmic reticulum, 
representing unfolded protein mechanisms due to their responsive state to 
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stress kinases (Thakur et al., 2007). Other studies suggest that these 
granules, which positively stain for ubiquitin and other autophagy markers 
(LC3, p62, LAMP1), indicate their involvement in MA and ubiquitin 
proteasome system and an increased granule accumulation can suggest 
incomplete formation of the autolysosome, hence failure of degradation 
systems (Funk et al., 2011).  
One of the major limitations of human pathological studies is that data 
provides just a ‘snapshot’ of protein expression and pathogenesis. 
Therefore, it is difficult to establish the sequence of pathogenic events or 
changes in autophagy staining. However, a general overview of pathology 
in the sections was based on the different tau and beta-amyloid deposition 
in the Braak III-IV and Braak V-VI groups, which was mainly used to relate 
it to the changes seen in the autophagy markers across the groups. 
However, the staining may give an indication of the molecular events that 
may be going on inside the cell at the time of death.   
The limitations of this study include the subjectivity of 
immunohistochemical scoring interpretation.This scoring approach is 
highly subjective and might mask potential differences in expression, 
therefore, a quantitative approace such as assessing the percentage area 
of staining with size exclusion to assess neuronal staining might be more 
useful for future studies.  
Variable activity of antibodies staining is thought to be mainly influenced 
by environmental factors such as pH or laboratory temperatures. Antibody 
specificity is always an issue and the question is whether the antibodies 
are detecting the appropriate proteins of interest. The antibodies of these 
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study have been well described in the chapter 2 and have been previously 
used in other studies and were recommended by staff at the Manchester 
Brain Bank. We could have also used isotype and absorption controls, 
however the tissue available was limited and the antibodies which were 
used are all well-published (see section 2).Another limitation of this study 
could be that the autophagy markers chosen are not exclusively indicators 
of MA and CMA activity although they are gold standard markers in the 
staining of autophagy as described in numerous studies (Yu et al, 2005; 
Jaeger, 2010; Kaushik, 2012; Son, 2012 Cuervo, 2013). Moreover, 
immunohistochemistry, when compared with Western blotting, delivers an 
overall staining of both isoforms of LC3, limiting LC3 ratio findings which 
could be crucial in investigating macroautophagix flux. It would be useful 
to assess the human tissue via Western blotting to explore the LC3 ratio 
for a better overview of the autophagic flux and this is explained, later on, 
in the ‘Future work’ section.  
Another limitation of the study was the small sample size of the brain 
sections (n=17 Braak 0-II; n=15 Braak III-IV; n=13 Braak V-VI. This could 
improve considerably if we could extend the sample size for a better 
understanding of autophagy impairment in AD.  
 
 
Autophagy in skin-derived fibroblasts 
 
For the past decade, alterations in autophagy pathways, in numerous 
animal models and human autopsy tissue havea been described 
extensively for (Nixon, 2005; Nikon, 2007; Pickford, 2008; Son, 2012). 
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Nevertheless, as described in section 1.5, there are still many 
disadvantages of using animal models. New accurate potent models for 
impaired autophagy in AD are required to overcome all challenges that the 
research is currently facing. Of particular interest is a cell-based model 
such as skin fibroblasts that would allow the rapid testing of new drug 
compounds on patients living with AD. This model would allow periodic 
sample collection through biopsy followed by investigation of how different 
drug-based therapies might interact with protein degradation systems. 
Extraction of AD fibroblasts might be crucial for early detection and 
diagnosis of the disease through assessing dysfunctional protein 
mechanisms (Mocali, 2014.) 
It is still unclear whether pathogenic autophagy alterations extend to 
peripheral cells such as skin-derived fibroblasts but the idea of using 
fibroblasts as a potential resource came after many of the neuronal 
pathological modifications that are seen in AD brains, such as toxic protein 
accumulation, increased oxidative stress and mitochondrial abnormalities, 
have also been reported in fibroblasts derived from AD patients (Citron et 
al., 1994, Magini et al., 2010, Ramamoorthy et al., 2012; Mocali, 2014). If 
autophagy deficits are seen in these cells, they could prove invaluable in 
identifying and assessing new therapeutic approaches, as well as for the 
identification of new diagnostic biomarkers, which are scarce at the 
moment.  
In this pilot study, we found variability of MA markers, LC3 and Beclin-1, 
between the control group and the sporadic group suggesting a possible 
impairment of MA. We also identified a variation of LAMP2A, Hsp70 and 
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Beclin-1 autophagy markers in the control group when compared with the 
presenilin mutated group. Increased expression in the presenilin group 
might be due to the lower age of this group, however age-matched 
controls with very similar age was challenging to find in the Coriell 
Biorepository cell bank. Studies in mouse embryonic fibroblasts show that 
mutations of presenilin in familial AD worsen lysosomal pathology, 
supporting a peripheral demonstration of deficit. They demonstrated that 
presenilin gene mutation leads to abnormal build-up of dysfunctional 
autophagosomes, an indicator of autophagy failure and that knock down 
mice exhibit increased LC3-II and decreased mTOR and LAMP2A (Neely, 
2011). Moreover, studies in blastocysts show that lysosomal degradation 
systems such as MA depend on presenilin-1 protein and become defective 
as a mutation occurs in the PSEN gene (Lee, 2010), suggesting that in 
PSEN fibroblasts, we would expect impaired MA. This could link our 
findings that Beclin-1, involved in MA, significantly varies in the presenilin 
group when compared to the control group. If MA depends on presenilin-1, 
which is mutated in this cells, it might suggest that the pathway becomes 
defective by overexpressing Beclin-1 in the attempt to initiate MA which 
could explain our findings that show high levels of Beclin-1 in the 
presenilin group when compared to lower levels in the control group. 
Studies showed that in presenilin knockout mouse model, LC3 and p62 
levels were abnormally high when compared to the control group as 
shown by immunhistochemical studies (Lee, 2010). Then, they treated the 
cells with rapamycin to induce MA and LC3 levels were found to increase 
in both the control cells and the mutated cells, however 6h after they 
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stopped the treatment, LC3 levels returned to normal in the control cells 
whereas in the presenilin mutated cells, they remained elevated (Lee, 
2010).  All of these suggest that impairments in MA are linked to the 
presenilin mutation and AD fibroblasts with mutation in the presenilin gene 
could become a potential tool in investigating MA defects in AD.  
Nixon et al, reviews the role of presenilin mutations (the main cause of 
early onset familial AD) leading to failure of protein degradation systems 
(Nixon, 2011). Presenilin is known to be involved in the APP molecule 
cleavage by γ-secretase enzyme, however, it also plays an important part 
in lysosomal acidification, essential for activation of lysosomal enzymes 
specific to autophagy (Pasternak, 2003; Lee, 2015), therefore using 
presenilin mutated fibroblasts could be a good indicator of lysosomal 
malfunction, hence impaired autophagy.  Existing studies on mice, in 
which presenilin gene was deleted, indicates an abnormally increased 
accumulation of autophagy substrates in the mice neurons and 
blastocytes, therefore presenilin mutations, seen in familial AD, can cause 
a dysfunction in lysosomal acidification, causing failure in substrate 
degradation and accumulation of autophagic vacuoles (Esselens et al, 
2004; Wilson et al, 2004). Besides the mice studies, there is also evidence 
on familial AD fibroblasts showing that presenilin mutations demonstrate 
defective lysosomal acidification and incomplete autolysosome 
maturations (Lee, 2010). These studies could link lysosomal defects in 
presenilin mutated cells to dysfunctional removal of tau and beta-amyloid 
aggregates, accelerating neuronal death and leading to 
neurodegeneration. Induced pluripotent (Arber, 2017). 
220 
 
As previously discussed in section 1.5.4, induced pluripotent stem cells 
are a good source of generating limitless AD models for in vitro studies 
and iPSC-derived fibroblasts would allow exploring the autophagy 
pathways in relation to pathological changes in AD (Arber, 2017). Also, 
studies on iPSC-derived neurons suggest that stem cells with a genetic 
background could offer a source of neurons that express physiological 
levels of mutated genes, therefore they could be key in exploring 
autophagy proteins and how they relate to disease mechanisms (Wray, 
2017).  
A study from 2011, explained the use of familial AD fibroblasts with 
mutations in the PSEN 1 and PSEN2 genes, which were differentiated into 
iPSC leading to neurons that revealed increased Aβ accumulation, 
illustrating the specific pathological characteristics of familial AD (Yagi et 
al., 2011). This study demonstrated the potential of familial AD-iPSC-
derived neurons in the research of AD to identify novel therapeutic 
strategies. In the following year, another study which explored iPSC in 
both familial AD and sporadic AD, revealed that in some of the sporadic 
cases, the cells showed increased Aβ generation and tau 
hyperphosphorylation (Israel et al., 2012). The same study also 
emphasized the importance of studying AD pathology only in these iPSC-
derived neurons as the initial fibroblast cells did not exhibit the same AD 
pathology features (Israel et al., 2012).  These two studies as well as other 
numerous studies demonstrate the potential of iPSC-derived neurons as a 
good AD model to explore the disease progression and to guide the drug 
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development in the hope of finding the cure (Zhang, 2014; Nieweg, 2015; 
Ortiz-Virumbrales, 2017).  
The fibroblast pilot study could improve considerably as we have to 
consider the very small sample size of the fibroblasts (n=3 cells lines for 
each group) giving insufficient understanding of autophagy markers 
expression in the peripheral AD cells. Also, the 3 cases of presenilin 
mutated cells were the only ones commercially available at the start of this 
project. It was also challenging, considering that we aimed to find 
genetically mutated cells from individuals that were age-matched to 
controls. Moreover, there was high variability of all autophagy markers, in 
particular in LC3 and LAMP2A, observed between the three sporadic AD 
cases as well as large variability seen between the three presenilin 
mutated group, which suggests that the study will require more individual 
cases in order assess the potential of the fibroblasts as a suitable model 
for exploring autophagy deficits in AD.  
One of the major weaknesses of using in vitro cell culture is that the cells 
environment is simulated and sometimes conditions may differ from the in 
vivo cell interactions with other types of cells and chemical compounds. 
Autophagy pathways are highly conserved and complex mechanisms in 
eukaryotic species that depending on signalling pathways, cellular stress 
responses, nutrient deprivation and pathogens (He, 2009) and interact 
with numerous other pathways such as the ubiquitin proteasome system 
(Park, 2013), therefore one of the limitations of this pilot study is that 
results might not be an accurate representation of the autophagy changes 
in disease, requiring drug of genetic manipulation in the future work.  
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4.2 Future work 
 
 
Future work would aim to validate the immunohistochemical results by 
using fresh homogenates from the three brain regions of the same 45 
cases and explore the autophagy proteins levels through Western blotting. 
This studies would give a full insight of all autophagy markers chosen in 
this study and see how they change with disease progression, but most 
importantly, it will give an insight on LC3 ratio in the AD brains, which will 
allow the identification of both LCI and LC3II isoforms in the brain 
sections. 
Double labelling would further explore the co-localisation of not just 
LAMP2A and LC3 but all autophagy markers chosen in this study, related 
to both tau and beta amyloid. The relationship of MA and CMA would be 
further explored via dual staining of one marker of MA and one marker of 
CMA to identify the degree of co-localisation and establish potential 
compensatory mechanisms when one pathway becomes impaired.  
The fibroblasts study would further extend to cells from more individuals to 
evaluate the changes in autophagy levels in these cells. Also, drug 
manipulation via autophagy enhancers/inhibitors could manipulate 
autophagy expression in order to identify which protein becomes defective 
in the protein degradation systems.Ideally, age-matched controls for the 
PSEN fibroblast samples would be necessary to depict autophagy marker 
levels in aged individuals. 
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More studies on glia cells and their role in autophagy would be useful to 
offer an insight of the role of astrocytes and oligodendrocytes when protein 
disposal systems fail to clear abnormal deposit in AD.   
 
4.3 Conclusions 
 
 
In this study, results demonstrated that MA marker LC3 and CMA marker 
Hsp70 decreased with increasing Braak staging, in the hippocampus and 
the occipital cortex, suggesting a possible impairment of both pathways. 
We also relate them to AD pathological protein tau. In early stages of AD, 
autophagy markers levels are found high, despite minimal tau pathology. 
In higher Braak groups, LC3 and Hsp70 autophagy markers declined as 
pathological tau significantly increased, suggesting that MA and CMA may 
fail to degrade abnormal proteins in AD. Moreover, hippocampal 
subregions CA4 and CA1, which have been previously described to 
become affected in AD, at different stages, show variation in the 
autophagy marker levels. We showed that in CA1–a hippocampal 
subregion associated with early deposition of tau/beta-amyloid– 
autophagy markers, LC3 and Hsp70, were considerably decreased with 
increasing Braak stages. In CA4 – a hippocampal subregion, associated 
with later tau/beta-amyloid deposition– autophagy levels were not much 
affected across the Braak groups. This emphasizes the significance of 
regional variation in autophagy changes with disease progression. 
Moreover, double-labelling studies investigated LC3 and LAMP2A in 
relation to tau protein in individual cells of both CA4 and CA1 subregions.  
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The main findings suggest that LAMP2A was present in cells harbouring 
tau and this co-localization decreased in CA1 neurons, in Braak V-VI, 
suggesting that CMA becomes impaired and fail to clear the abnormal tau 
deposits. Moreover, our results suggest that LC3 and AT8 co-localization 
rate was very high in the Braak 0-II group as in CA4, all AT8 positive cells 
were found to be LC3 positive, as well. This suggests the importance of 
MA pathway to stay upregulated in the normal ageing brains in order to 
clear abnormal protein accumulations. In Braak III-IV, the co-localization 
rates declined, which could suggest that MA becomes impaired in 
moderate stages of AD as tau burden increases, whereas in Braak V-VI, 
co-localization declined significantly suggesting that in late stages of AD, 
there is an evident failure of MA well-functioning. The importance of 
regional variation in autophagy marker staining is emphasized not only in 
the hippocampus subregions, but also across the subcortical layers of the 
frontal and the occipital cortices. Autophagy markers were mostly 
predominant in the deeper layers which were also associated with tau 
deposition, suggesting the involvement of autophagy proteins in the 
attempt to clear these deposits.  
MA impairment in late stages of disease might be associated to insufficient 
LC3 levels, causing incomplete autophagosome formation and protein 
degradation, leading to abnormal tau accumulations. CMA impairment in 
late stages of disease could be associated to insufficient Hsp70 to 
recognize and bind tau for degradation, therefore this might result in 
cytosolic accumulation of tau aggregates. We also found that in the 
hippocampus, MA levels were higher than CMA levels across all Braak 
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groups, suggesting that deficits in the hippocampus could be associated to 
CMA pathway. On the other hand, in the frontal cortex, CMA levels were 
found higher than MA levels, in Braak 0-II and Braak III-IV however, in 
Braak V-VI, both MA and CMA were found to have similar levels which 
could emphasize activation of compensatory mechanisms by CMA in order 
to rescue defective MA, in the frontal cortex, in late stages of AD.  
Our study also investigated autophagy marker stained glial cells and found 
that astrocytes and oligodendrocytes were highly activated and their 
number increased in higher Braak stages, suggesting that although 
neuronal autophagy markers dropped in late stages of disease, glia might 
be more resistant, becoming highly activated in order to degrade abnormal 
tau and beta-amyloid peptides, hence the positive staining of autophagy 
markers in the glial cells.  
The fibroblast pilot study main findings suggested that there is a variation 
of LAMP2A, Hsp70 AND Beclin-1 expression between the control group 
and the genetically mutated group, as well as a variation of MA markers 
between the control group and the sporadic AD group. This suggests an 
impairment of MA and CMA in AD, however further research will validate if 
the fibroblasts could potentially become a suitable diagnostic tool in AD. 
According to specific deficit locations, lysosomal and autophagic functions, 
which become impaired in AD neurons, can be restored by treatment with 
autophagy enhancers in order to promote the clearance of AD specific 
pathology.  
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Supplementary figures: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1. Astrocytes identified in different regions 
stained by AT8 antibody. Subpial region within LEC (A); in the white 
matter (B) and in the grey matter (C); Magnification 10X (A) and 100X (B, 
C); Scale bars 100μm (A) and 50μm (B, C). 
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Supplemetary figure 0. Tau lesions stained by AT8 antibody. Axonal 
staining in CA4 (A); high background of NTh in CA1 (B) with numerous 
severely stained grains in CA2 (C). Many NP were observed (D); 
Magnification 400X; Scale bar 200μm. 
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Supplementary figure 3. NFT morphologies stained by AT8 antibody. 
Granular NFT in CA4 (A); flame-shaped NFT in CA2 (B), ballooned 
achromatic neuron in CA1 (C) and globose NFT in CA1 (D) *presence of 
NTh; Magnification 100X; Scale bar 50μm. 
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Supplementary figure 4. Aβ plaques and other morphologies stained 
by Aβ antibody. All types of plaques *diffuse **cored ***compact 
****patchy/powdery (A) Numerous patchy/powdery plaques (B) and 
compact, diffuse plaques in MEC, with severe pathology in the subpial 
region (C). A cored plaque with the ring-like structure becoming fade while 
the central compact cored remains intact (D). Very large diffuse plaques 
with fibrillary edges (E). Advanced CAA in the collateral sulcus between 
LEC and TC (F); Magnification 10X; Scale bars 100μm. 
 
